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Summary of findings {#CD009593-sec1-0001}
===================

Summary of findings 1Xpert MTB/RIF and Xpert Ultra for detection of pulmonary tuberculosis**Review question:** What is the diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for detection of pulmonary tuberculosis (PTB)?\
**Patients/population:** Adults with presumptive PTB. Participants were 'unselected\', meaning they were not enrolled in a study based on microscopy smear results or past history of tuberculosis\
**Role:** An initial test\
**Index tests:** Xpert MTB/RIF and Xpert Ultra\
**Threshold for index tests:** An automated result is provided\
**Reference standards:** Solid or liquid culture\
**Studies:** Cross‐sectional and cohort studies\
**Setting:** Primary care facilities and local hospitals**Index testEffect (95% Crl)Number of participants (studies)Test resultNumber of results per 1000 patients tested (95% CrI)^1^Certainty of the evidence (GRADE)Prevalence 1%Prevalence 10%Prevalence 30%**Xpert MTB/RIF in unselected participantsPooled sensitivity 85% (82 to 88)10,409 (70 studies)True positives9 (8 to 9)85 (82 to 88)255 (246 to 264)⊕⊕⊕⊕\
High^a,b,c^False negatives1 (1 to 2)15 (12 to 18)45 (36 to 54)Pooled specificity 98% (97 to 98)26,828 (70 studies)True negatives970 (960 to 970)882 (873 to 882)686 (679 to 686)⊕⊕⊕⊕\
High^a^False positives20 (20 to 30)18 (18 to 27)14 (14 to 21)Xpert UltraSensitivity 88% (85 to 91)462 (1 study)True positives9 (9 to 9)88 (85 to 91)264 (255 to 273)⊕⊕⊕⊝\
Moderate^d,e^False negatives1 (1 to 1)12 (9 to 15)36 (27 to 45)Specificity 96% (94 to 97)977 (1 study)True negatives950 (931 to 960)864 (846 to 873)672 (658 to 679)⊕⊕⊕⊝\
Moderate^d,e^False positives40 (30 to 59)36 (27 to 54)28 (21 to 42)[^2]

Summary of findings 2Xpert MTB/RIF and Xpert Ultra for detection of rifampicin resistance**Review question:** What is the diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for detection of rifampicin resistance?\
**Patients/population:** Adults with confirmed PTB\
**Role:** An initial test\
**Index tests:** Xpert MTB/RIF and Xpert Ultra\
**Threshold for index tests:** An automated result is provided\
**Reference standards:** Phenotypic culture‐based DST and MTBDR*plus*\
**Studies:** Cross‐sectional and cohort studies\
**Setting:** Primary care facilities and local hospitals**Index testEffect (95% Crl)Number of participants (studies)Test resultNumber of results per 1000 patients tested (95% CrI)Certainty of the evidence (GRADE)Prevalence 5%Prevalence 10%Prevalence 15%**Xpert MTB/RIFPooled sensitivity 96% (94 to 97)1775 (48 studies)True positives48 (47 to 49)96 (94 to 97)144 (141 to 146)⊕⊕⊕⊕\
High^a^False negatives2 (1 to 3)4 (3 to 6)6 (4 to 9)Pooled specificity 98% (98 to 99)6245 (48 studies)True negatives931 (931 to 941)882 (882 to 891)833 (833 to 842)⊕⊕⊕⊕\
High^a^False positives19 (9 to 19)18 (9 to 18)17 (8 to 17)Xpert UltraSensitivity 95% (90 to 98)175 (1 study)True positives48 (45 to 49)95 (90 to 98)143 (135 to 147)⊕⊕⊕⊝\
Moderate^b,c^False negatives2 (1 to 5)5 (2 to 10)7 (3 to 15)Specificity 98% (97 to 99)376 (1 study)True negatives931 (922 to 941)882 (873 to 891)833 (825 to 842)⊕⊕⊕⊝\
Moderate^b,c^False positives19 (9 to 28)18 (9 to 27)17 (8 to 25)[^3]

Background {#CD009593-sec1-0002}
==========

Tuberculosis is the world's leading cause of infectious disease‐related death and is one of the top 10 causes of death worldwide ([@CD009593-bbs2-0387]). In 2017, 10 million people developed tuberculosis disease, equivalent to 133 cases per 100,000 population ([@CD009593-bbs2-0387]). Of the 10 million tuberculosis cases, approximately 9% occurred among people living with HIV. Worldwide, for all forms of tuberculosis, a substantial percentage (˜ 36%) of patients were not reported to national treatment programmes ([@CD009593-bbs2-0387]). When tuberculosis is detected early and is effectively treated, the disease is largely curable. However, in 2017, 1.6 million people died of tuberculosis, including 300,000 deaths among people living with HIV ([@CD009593-bbs2-0387]). Ending the tuberculosis epidemic by 2030 is among the health targets of the Sustainable Development Goals.

Drug‐resistant tuberculosis is a serious threat to global health ([@CD009593-bbs2-0398]). Three groupings for tuberculosis drug resistance are used for the purpose of surveillance and treatment: rifampicin‐resistant tuberculosis, multidrug‐resistant tuberculosis (MDR‐TB), and extensively drug‐resistant tuberculosis (XDR‐TB). MDR‐TB is defined as resistance to at least isoniazid and rifampicin, the two most important first‐line anti‐tuberculosis drugs. XDR‐TB is defined as MDR‐TB plus resistance to at least one drug in the following two classes of medicines used in treatment of MDR‐TB: fluoroquinolones and second‐line injectable agents ([@CD009593-bbs2-0387]). In 2017, approximately 558,000 people developed MDR‐TB/rifampicin‐resistant tuberculosis. Regarding XDR‐TB, 10,800 cases were reported by 77 countries ([@CD009593-bbs2-0387]). In 2017, 30% of new and previously‐treated people with tuberculosis were tested for rifampicin resistance; while this is a significant improvement over recent rates, considerable gaps remain.

Accurate and rapid detection of tuberculosis, including smear‐negative tuberculosis and drug resistant‐tuberculosis, is critical for improving patient outcomes (increased cure and decreased mortality, and prevention of additional drug resistance, treatment failure, and relapse), and decreasing tuberculosis transmission. Mycobacterial culture is generally considered the best available reference standard for tuberculosis diagnosis and is a key step in detecting drug resistance. However, culture is a relatively complex and slow procedure. Solid culture typically takes between four to eight weeks for results and liquid culture, although more sensitive and rapid than solid culture, requires weeks and is more prone to contamination ([@CD009593-bbs2-0391]). In addition, culture requires specialized laboratories and highly skilled staff. In 2010, the World Health Organization (WHO) recommended the use of a novel, rapid, automated, cartridge‐based, nucleic acid amplification (NAA) test, Xpert MTB/RIF (Cepheid, Sunnyvale, USA) (hereafter referred to as Xpert MTB/RIF), that can simultaneously detect tuberculosis and rifampicin resistance ([@CD009593-bbs2-0393]).

Target condition being diagnosed {#CD009593-sec2-0001}
--------------------------------

### Tuberculosis {#CD009593-sec3-0001}

Tuberculosis is caused by the bacterium *Mycobacterium tuberculosis (M tuberculosis)* and is spread from person to person through the air. Tuberculosis most commonly affects the lungs (pulmonary tuberculosis (PTB)), but may affect any organ or tissue outside of the lungs (extrapulmonary tuberculosis). Signs and symptoms of PTB include cough, fever, chills, night sweats, weight loss, haemoptysis (coughing up blood), and fatigue. Signs and symptoms of extrapulmonary tuberculosis depend on the site of disease. Tuberculosis treatment regimens must contain multiple drugs to which the organisms are sensitive to cure tuberculosis and avoid selection for drug resistance. The treatment of MDR‐TB is complex, historically requiring two years or more of therapy, although the WHO conditionally recommended a nine‐ to 12‐month regimen in 2016 ([@CD009593-bbs2-0385]). The drugs used to treat MDR‐TB are less potent and more toxic than the drugs used to treat drug‐susceptible tuberculosis.

### Rifampicin resistance {#CD009593-sec3-0002}

Rifampicin inhibits bacterial DNA‐dependent RNA polymerase, encoded by the RNA polymerase gene (*rpoB*) ([@CD009593-bbs2-0349]). Resistance to this drug has mainly been associated with mutations in a limited region of the *rpoB* gene ([@CD009593-bbs2-0376]). Rifampicin resistance may occur alone or in association with resistance to isoniazid and other drugs. In high MDR‐TB settings, the presence of rifampicin resistance alone may serve as a proxy for MDR‐TB ([@CD009593-bbs2-0394]). People with drug‐resistant tuberculosis can transmit the infection to others.

Index test(s) {#CD009593-sec2-0002}
-------------

Xpert MTB/RIF is an automated polymerase chain reaction (PCR) test (molecular test) using the GeneXpert platform ([@CD009593-bbs2-0322]; [@CD009593-bbs2-0330]; [@CD009593-bbs2-0029]). Xpert MTB/RIF is a single test that can detect both *M tuberculosis* complex and rifampicin resistance within two hours after starting the test, with minimal hands‐on technical time. Unlike conventional NAA tests, Xpert MTB/RIF is unique because sample processing and PCR amplification and detection are integrated into a single self‐enclosed test unit, the GeneXpert cartridge. Following sample loading, all steps in the assay are completely automated and self‐contained. In addition, the assay's sample reagent, used to liquefy sputum, has potent tuberculocidal (the ability to kill tuberculosis bacteria) properties and so largely eliminates biosafety concerns during the test procedure ([@CD009593-bbs2-0319]). These features allow the technology to be taken out of a reference laboratory and used nearer to the patient ([@CD009593-bbs2-0370]). Xpert MTB/RIF requires an uninterrupted and stable electrical power supply, temperature control, and yearly calibration of the cartridge modules ([@CD009593-bbs2-0394]).

The test procedure may be used directly on clinical specimens, either raw sputum specimens or sputum pellets created after decontaminating and concentrating the sputum ([@CD009593-bbs2-0322]). In both cases, the test material is combined with the assay sample reagent (sodium hydroxide and isopropanol), mixed by hand or vortex, and incubated at room temperature for 15 minutes. After the incubation step, 2 mL of the treated specimen are transferred to the cartridge and the run is initiated ([@CD009593-bbs2-0029]). According to the manufacturer, Xpert MTB/RIF may be used with fresh sputum specimens, which may be either unprocessed sputum or processed sputum sediments. The sample reagent:sample volume ratio is 2:1 for unprocessed sputum and 3:1 for sputum pellets. The manufacturer does not specifically mention the use of Xpert MTB/RIF with frozen specimens ([@CD009593-bbs2-0330]).

Xpert MTB/RIF limit of detection, (the lowest number of colony forming units per sample that can be reproducibly distinguished from negative samples with 95% confidence) ([@CD009593-bbs2-0330]), is five genome copies of purified DNA per reaction or 131 colony forming units (CFUs) per mL in *M tuberculosis‐*spiked sputum ([@CD009593-bbs2-0029]). In comparison, identification of tuberculosis bacilli by microscopic examination requires at least 10,000 bacilli per mL of sputum ([@CD009593-bbs2-0378]). Xpert MTB/RIF detects both live and dead bacteria ([@CD009593-bbs2-0224]).

Xpert MTB/RIF uses molecular beacon technology to detect rifampicin resistance. Molecular beacons are nucleic acid probes that recognize and report the presence or absence of the normal, rifampicin‐susceptible, 'wild type\' sequence of the *rpoB* gene of tuberculosis. Five different‐coloured beacons are used, each covering a separate nucleic acid sequence within the amplified *rpoB* gene. When a beacon binds to the matching sequence, it fluoresces or 'lights up\', which indicates the presence of one of the gene sequences that is characteristic of rifampicin‐susceptible tuberculosis. Failure of the beacon to bind or delayed binding to the matching sequence indicates potential rifampicin resistance. The number and timing of detection (when the fluorescent signal rises above a predetermined baseline cycle threshold) of positive beacons as well as results of sample processing controls allow the test to distinguish among the following results: 'No tuberculosis\'; 'tuberculosis detected, rifampicin resistance detected\'; 'tuberculosis detected, no rifampicin resistance detected\'; and an 'invalid result\' ([Figure 1](#CD009593-fig-0001){ref-type="fig"}). A single Xpert MTB/RIF run will provide both detection of tuberculosis and detection of rifampicin resistance. One cannot deselect testing for rifampicin resistance and only run the assay for tuberculosis detection, although it is possible for the laboratory to omit results for rifampicin resistance when reporting to the healthcare provider.Figure 1Readout of Xpert MTB/RIF assay for a tuberculosis positive, rifampicin‐susceptible specimen. Courtesy: Karin Weyer, the WHO Global TB Programme.

Since Xpert MTB/RIF was released, there have been four generations (G1, G2, G3, and G4) of the test involving different software and cartridge combinations. G4 contains modifications that improved determination of rifampicin resistance detection as previous Xpert MTB/RIF versions had found that some rifampicin susceptibility results were falsely resistant. In order to improve on Xpert MTB/RIF sensitivity, Cepheid developed Xpert MTB/RIF Ultra (hereafter referred to as Xpert Ultra), a re‐engineered assay that uses a newly developed cartridge but may be run on the same device after a software upgrade. Xpert Ultra incorporates two different multi‐copy amplification targets and a larger DNA reaction chamber than Xpert MTB/RIF ([@CD009593-bbs2-0396]). A laboratory study reported that the limit of detection using Xpert Ultra improved to 15.6 CFU/mL of sputum compared to 112.6 CFU/mL for Xpert MTB/RIF ([@CD009593-bbs2-0146]). Of note, Xpert Ultra has added a new result category, 'trace call\', that corresponds to the lowest bacillary burden for *M tuberculosis* detection ([@CD009593-bbs2-0396]). Although no rifampicin resistance result will be available for people with trace results, a trace positive result is sufficient to initiate anti‐tuberculosis therapy in children or HIV‐positive people, according to the WHO report. Other people with a trace result should have a new sputum specimen collected for Xpert Ultra testing ([@CD009593-bbs2-0396]). Xpert Ultra is available for clinical use and several countries have moved from using Xpert MTB/RIF to using Xpert Ultra instead. In this Cochrane Review, we include studies that used any generation of the index tests.

Clinical pathway {#CD009593-sec2-0003}
----------------

Xpert MTB/RIF and Xpert Ultra are used for the diagnosis of tuberculosis and rifampicin resistance. [Figure 2](#CD009593-fig-0002){ref-type="fig"} shows the clinical pathway and presents the context in which the index tests might be used. The target condition is PTB. Persons to be evaluated for PTB are adults with signs or symptoms suggestive of tuberculosis, such as cough, fever, night sweats, weight loss, haemoptysis, and fatigue, or with an abnormal chest x‐ray suggestive of tuberculosis. Additionally, people who are known to have tuberculosis and are at risk for rifampicin‐resistant or MDR‐TB (e.g. those with a previous history of tuberculosis treatment or those who have an inadequate response to anti‐tuberculosis treatment) may undergo Xpert MTB/RIF and Xpert Ultra testing to evaluate for rifampicin resistance.Figure 2The clinical pathway describes how people might present and the point in the pathway at which they would be considered for testing with Xpert MTB/RIF or Xpert Ultra. A person with presumptive PTB may experience cough, chest pain, the coughing up of blood, fever, night sweats, fatigue, loss of appetite, and weight loss. When she presents to a health facility, she will undergo a health examination (history and physical examination) and usually a chest x‐ray. She will be tested with the index test, either Xpert MTB/RIF or Xpert Ultra, if available, as this test is recommended as the initial diagnostic test for all adults and children with signs and symptoms of tuberculosis.Abbreviations: DR‐TB: drug‐resistant tuberculosis; MDR‐TB: multidrug‐resistant tuberculosis; PTB: pulmonary tuberculosis; RIF: rifampicin; SL‐LPA: second‐line line probe assay; Xpert: either Xpert MTB/RIF of Xpert Ultra.Figure adapted from [@CD009593-bbs2-0342].

The index test is performed as an initial test for adults with presumptive PTB or MDR‐TB.

The downstream consequences of testing include the following.

True‐positive (TP): patients would benefit from rapid diagnosis and appropriate treatment.True‐negative (TN): patients would be spared unnecessary treatment and would benefit from reassurance and pursuit of an alternative diagnosis.False‐positive (FP): patients would probably experience anxiety and morbidity caused by additional testing, unnecessary treatment, and possible adverse events; possible stigma associated with a tuberculosis or MDR‐TB diagnosis; and the chance that a false‐positive result may halt further diagnostic evaluation.False‐negative (FN): increased risk of morbidity and mortality and delayed treatment initiation; risk of ongoing tuberculosis transmission.

### Settings of interest {#CD009593-sec3-0003}

We were interested in how the index test performed in people with presumptive PTB, who were evaluated as they would be in routine practice, most often in local hospitals or primary care centres. The index test may have the greatest impact on health when used in a setting such as a primary healthcare facility, where treatment can be started the same day as testing or as soon as possible.

It should be noted that in the original Cochrane Review, we described the setting of interest as peripheral‐level laboratories based on a classification system previously in use ([@CD009593-bbs2-0391]).

### Role of index test(s) {#CD009593-sec3-0004}

We were interested in the following roles for testing.

#### I. Xpert MTB/RIF and Xpert Ultra for detection of PTB {#CD009593-sec4-0001}

Index test used as an initial test for the diagnosis of PTB.

#### II. Xpert MTB/RIF and Xpert Ultra for detection of rifampicin resistance {#CD009593-sec4-0002}

Index test used as an initial test for the diagnosis of rifampicin‐resistant tuberculosis or MDR‐TB.

As mentioned, in high MDR‐TB settings the presence of rifampicin resistance alone may serve as a proxy for MDR‐TB. Xpert MTB/RIF and Xpert Ultra do not eliminate the need for subsequent culture and phenotypic drug susceptibility testing (DST), which are required to monitor treatment progress and to detect resistance to drugs other than rifampicin.

### Alternative test(s) {#CD009593-sec3-0005}

In this section, we describe selected alternative tests for detection of PTB and rifampicin resistance. For a comprehensive review of alternative tests, we refer the reader to several excellent resources ([@CD009593-bbs2-0353]; [@CD009593-bbs2-0381]).

Smear microscopy is the examination of smears for acid‐fast bacilli (tuberculosis bacteria) under a microscope. The examination may be performed by light microscopy (Ziehl‐Neelsen), fluorescence microscopy, or light‐emitting diode (LED) fluorescence microscopy. Advantages of smear microscopy include its simplicity, low cost, speed, and high specificity in high tuberculosis burden areas. In addition, smear microscopy identifies the most infectious people with tuberculosis. Smear microscopy can be performed in basic laboratories. Drawbacks of smear microscopy include the need for specialized training and its relatively low sensitivity, 50% to 60% on average for a direct smear ([@CD009593-bbs2-0373]). Around 5000 to 10,000 organisms per mL must be present in the specimen for tuberculosis bacteria to be visible by microscopy ([@CD009593-bbs2-0316]). Although the sensitivity of microscopy can be improved by approximately 10% with fluorescence ([@CD009593-bbs2-0372]), a large number of tuberculosis cases still go undiagnosed. Smear‐negative tuberculosis is disproportionately higher in HIV‐positive than in HIV‐negative individuals, accounting for 24% to 61% of all pulmonary cases in people living with HIV ([@CD009593-bbs2-0339]; [@CD009593-bbs2-0361]). Microscopy cannot distinguish between drug‐susceptible tuberculosis and drug‐resistant tuberculosis. The WHO recommends that microscopy as the initial diagnostic test should be replaced with WHO‐recommended rapid tests that can simultaneously detect tuberculosis and tuberculosis drug resistance ([@CD009593-bbs2-0386]).

Mycobacterial culture is a method used to grow bacteria on nutrient‐rich media. In comparison with microscopy, a positive culture requires only around 100 organisms per mL and therefore can detect lower numbers of tuberculosis bacteria ([@CD009593-bbs2-0316]). Additionally, culture is essential for species identification and DST. However, culture may take up to six to eight weeks and requires a highly equipped laboratory.

NAA tests are molecular systems that can detect small quantities of genetic material (DNA or RNA) from micro‐organisms, such as *M tuberculosis*. The key advantage of NAA tests is that they are rapid diagnostic tests, potentially providing results in a few hours. A variety of molecular amplification methods are available, of which PCR is the most common. NAA tests are available as commercial kits and in‐house tests (based on a protocol developed in a laboratory) and are used routinely in high‐income countries for tuberculosis detection. In‐house PCR is widely used in low‐income countries because these tests are less expensive than commercial kits. However, in‐house PCR is known to produce highly inconsistent results ([@CD009593-bbs2-0337]).

Alternative molecular methods for DST include the commercial line probe assays, GenoType MTBDR*plus* assay (MTBDR*plus,* Hain LifeScience, Nehren, Germany), and the Nipro NTM+MDRTB detection kit 2 (Nipro, Tokyo, Japan), which detect the presence of mutations associated with drug resistance to isoniazid and rifampicin ([@CD009593-bbs2-0358]). MTBDR*plus* is the most widely studied line probe assay. Advantages of line probe assays are that they can provide a result for detection of tuberculosis and drug resistance in one to two days. Drawbacks are that line probe assays are expensive and need to be used in intermediate and central laboratories ([@CD009593-bbs2-0381]). The WHO recommends that for persons with a sputum smear‐positive specimen or a cultured tuberculosis isolate, commercial molecular line probe assays may be used as the initial test instead of phenotypic culture‐based DST to detect resistance to rifampicin and isoniazid (conditional recommendation, moderate certainty in the evidence for the test's accuracy) ([@CD009593-bbs2-0389]). Other molecular assays for detection of tuberculosis and resistance to rifampicin and isoniazid along with instruments are in development ([@CD009593-bbs2-0382]).

Alere Determine™ TB LAM Ag (AlereLAM) Alere Inc, (Waltham, USA) is a commercially available point‐of‐care test for tuberculosis disease (PTB and extrapulmonary tuberculosis). The test detects lipoarabinomannan (LAM), a component of the bacterial cell wall, which is present in the urine of some people with tuberculosis. AlereLAM is performed by placing urine on one end of a test strip, with results appearing as a band on the strip if tuberculosis is present. The test is simple, requires no special equipment, and shows results in 25 minutes ([@CD009593-bbs2-0369]). Of note, the presence of LAM in the urine of HIV‐positive adults undergoing treatment for tuberculosis has been found to be associated with increased risk of mortality ([@CD009593-bbs2-0345]). In randomized trials, use of Alere LAM in HIV‐positive inpatients has been shown to reduce mortality ([@CD009593-bbs2-0345]; [@CD009593-bbs2-0362]). Based in part on evidence from a Cochrane Review, [@CD009593-bbs2-0369], the WHO recommends that AlereLAM should be used to assist in the diagnosis of tuberculosis in adult inpatients, specifically \"people living with HIV who have signs or symptoms of tuberculosis and a CD4 cell count less than or equal to 100 cells/μL, and people living with HIV who are 'seriously ill\' regardless of CD4 count or if the CD4 count is unknown. This recommendation also applies to HIV‐positive children with signs and symptoms of tuberculosis (pulmonary or extrapulmonary, or both) based on the generalisation of data from adults while acknowledging very limited data and concern regarding low specificity of the AlereLAM assay in children\" ([@CD009593-bbs2-0388]). The WHO does not recommend AlereLAM for tuberculosis screening or diagnosis of active tuberculosis disease in most population groups ([@CD009593-bbs2-0388]).

Fujifilm SILVAMP TB LAM (FuijiLAM, co‐developed by FIND, Geneva, Switzerland and Fujifilm, Tokyo, Japan) is a new, urine‐based, point‐of‐care test for tuberculosis diagnosis in people living with HIV. Using stored (biobanked) urine specimens from hospitalized people in South Africa, FujiLAM was found to have superior sensitivity, 70.4% (95% CI 53.0% to 83.1%) compared to AlereLAM sensitivity of 42.3% (31.7% to 51.8%) ([@CD009593-bbs2-0327]). At the time of this writing, a call was open for prospective clinical trials of FuijiLAM to generate data for an updated WHO policy review.

Rationale {#CD009593-sec2-0004}
---------

Xpert MTB/RIF and Xpert Ultra provide obvious benefits for patients (earlier diagnosis and the opportunity to begin earlier, appropriate treatment) and for public health (opportunities to interrupt tuberculosis transmission), especially in high tuberculosis burden countries.

Since 2010, the WHO has recommended the use of Xpert MTB/RIF as the preferred initial diagnostic test for people thought to have MDR‐TB or HIV‐associated tuberculosis (strong recommendation, moderate‐certainty evidence) ([@CD009593-bbs2-0393]). In 2013, the WHO expanded the recommendations, stating that Xpert MTB/RIF may be used rather than conventional microscopy and culture as the initial diagnostic test in all adults suspected of having tuberculosis (conditional recommendation acknowledging resource implications, high‐quality evidence) ([@CD009593-bbs2-0395]). In addition, the WHO recommended that following an Xpert MTB/RIF test that demonstrates rifampicin resistance, subsequent drug susceptibility testing (e.g. using a line probe assay to second‐line drugs) remains essential to detect resistance to drugs other than rifampicin ([@CD009593-bbs2-0395]). In 2017, based on a non‐inferiority analysis of Xpert Ultra compared with Xpert MTB/RIF, the WHO stated that recommendations on the use of Xpert MTB/RIF also apply to the use of Xpert Ultra as the initial diagnostic test for all adults and children with signs and symptoms of tuberculosis ([@CD009593-bbs2-0396]). We performed this Cochrane Review to inform an updated WHO policy review on the use of Xpert MTB/RIF and Xpert Ultra.

Objectives {#CD009593-sec1-0003}
==========

Primary objectives {#CD009593-sec2-0005}
------------------

To determine the diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra for tuberculosis in adults with presumptive PTB, and for rifampicin resistance in adults with presumptive rifampicin‐resistant tuberculosis or MDR‐TB.

Secondary objectives {#CD009593-sec2-0006}
--------------------

To compare the diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra.To investigate potential sources of heterogeneity in test accuracy. For detection of PTB, covariates were smear status; HIV status; history of tuberculosis; the setting that ran the test; tuberculosis burden; TB/HIV burden; and prevalence of PTB in the studies. For detection of rifampicin resistance, covariates were MDR‐TB burden and prevalence of rifampicin resistance in the studies.

Methods {#CD009593-sec1-0004}
=======

Criteria for considering studies for this review {#CD009593-sec2-0007}
------------------------------------------------

### Types of studies {#CD009593-sec3-0006}

We include cross‐sectional studies and cohort studies that assessed the diagnostic accuracy of the index test(s) for both PTB and rifampicin resistance, PTB alone, or rifampicin resistance alone. We also include randomized controlled trials (RCTs) that evaluated the use of the index(s) test on patient health outcomes, but that also reported sensitivity and specificity. Although the study design was a randomized trial for the purpose of determining the impact of the test on participant outcomes, the study design was a cross‐sectional study for the purpose of determining the diagnostic accuracy of the index tests in this review. We used abstracts to identify published studies and included these publications when they met our inclusion criteria. We only included studies that reported data comparing the index test(s) to an acceptable reference standard from which we could extract true positive (TP), true negative (TN), false positive (FP), and false negative (FN) values. The index tests could be assessed alone or together with other tests.

We included studies that evaluated the index tests in HIV‐positive people irrespective of tuberculosis symptoms, for instance HIV‐positive people being assessed for antiretroviral therapy, as in the study by [@CD009593-bbs2-0041]. We included these studies for the following reasons: the risk of developing tuberculosis is much higher in people living with HIV, estimated to be 20 to 37 times higher in HIV‐positive individuals than in HIV‐negative individuals ([@CD009593-bbs2-0340]); signs and symptoms of tuberculosis in people living with HIV vary, which makes it challenging to determine when to consider a diagnosis of tuberculosis; and many HIV‐positive people in low‐income countries develop tuberculosis as the first manifestation of AIDS.

We excluded case reports and studies with a case‐control design, the latter because these types of studies are prone to bias, in particular, studies enrolling participants with severe disease and healthy participants without disease. We excluded studies of the index tests in people with diabetes but without tuberculosis symptoms, and studies designed to find people with active tuberculosis in community settings. We excluded drug resistance surveys.

### Participants {#CD009593-sec3-0007}

We included studies that enrolled adults, aged 15 years or older, with presumptive PTB, rifampicin‐resistant tuberculosis, or MDR‐TB. For tuberculosis detection, we were interested in people who were not currently on tuberculosis treatment or those on treatment for less than seven days. Tuberculosis treatment might interfere with the confirmation of tuberculosis on culture (the reference standard for this review). If we could not tell the treatment status of the participants, we contacted primary study authors for this information. For rifampicin resistance detection, we were interested in people at high risk for MDR‐TB and we therefore included participants who had received previous treatment, participants who were receiving tuberculosis treatment because they had not converted their sputum from positive to negative, and contacts with participants with known drug‐resistant disease, as described in [@CD009593-bbs2-0011].

We included studies that assessed the diagnostic accuracy of Xpert MTB/RIF (Xpert MTB/RIF) and Xpert MTB/RIF Ultra (Xpert Ultra) using sputum and other respiratory specimens, such as fluid obtained from bronchial alveolar lavage and tracheal aspiration, consistent with the intended use of the manufacturer ([@CD009593-bbs2-0330]), and studies from all types of health facilities and all laboratory levels (peripheral, intermediate, and central) from all countries. Unlike the original Cochrane Reviews, for this review update if a study included both adults and children and we could not disaggregate results for adults alone, we excluded the study. We also excluded studies where the age of participants was unknown.

### Index tests {#CD009593-sec3-0008}

The index tests were Xpert MTB/RIF and Xpert Ultra.

Index test results are automatically generated (i.e. there is a single threshold), and the user is provided with a printable test result as follows.

MTB (*M tuberculosis*) DETECTED; Rif (rifampicin) resistance DETECTED.MTB DETECTED; Rif resistance NOT DETECTED.MTB detected; Rif resistance INDETERMINATE.MTB NOT DETECTED.INVALID (the presence or absence of MTB cannot be determined).ERROR (the presence or absence of MTB cannot be determined).NO RESULT (the presence or absence of MTB cannot be determined).

Xpert Ultra incorporates a semi‐quantitative classification for results: trace, very low, low, moderate, and high. 'Trace\' corresponds to the lowest bacterial burden for detection of *M tuberculosis* ([@CD009593-bbs2-0146]). We considered a trace result to mean MTB (*M tuberculosis*) DETECTED. However, no rifampicin‐resistance result was available for participants with trace results ([@CD009593-bbs2-0396]).

### Target conditions {#CD009593-sec3-0009}

The target conditions were active PTB and rifampicin resistance.

### Reference standards {#CD009593-sec3-0010}

For tuberculosis, acceptable reference standards used solid media (Löwenstein‐Jensen, Middlebrook 7H10 or 7H11, or Ogawa media) or a commercial liquid culture system, (such as BACTEC™ 460TB System or BACTEC™ MGIT™ 960 Mycobacterial Detection System, BD, USA; BacT/ALERT System, bioMérieux, France; or VersaTREK Mycobacteria Detection & Susceptibility, Thermo Fisher Scientific, USA).

For rifampicin resistance, the reference standards were phenotypic culture‐based DST methods recommended by the WHO ([@CD009593-bbs2-0390]). Acceptable methods were the proportion method performed on solid media (such as Löwenstein‐Jensen, Middlebrook 7H10 or 7H11, or Ogawa media), use of a commercial liquid culture system, such as MGIT™ 960 Mycobacterial Detection System, BD, USA, or both. For this review update, we also included MTBDR*plus,* a WHO‐recommended test ([@CD009593-bbs2-0389]).

Search methods for identification of studies {#CD009593-sec2-0008}
--------------------------------------------

We tried to identify all relevant studies regardless of language or publication status (published, unpublished, in press, and ongoing).

### Electronic searches {#CD009593-sec3-0011}

We searched the following databases up to 18 January 2018, using the search terms and strategy described in [Appendix 1](#CD009593-sec2-0016){ref-type="app"}:

Cochrane Infectious Diseases Group Specialized Register;MEDLINE (OVID, from 1966);Embase (OVID, from 1974);Science Citation Index ‐ Expanded (from 1900), Conference Proceedings Citation Index ‐ Science (CPCI‐S, from 1990), and BIOSIS Previews (from 1926); all three from the Web of Science;Scopus (Elsevier, from 1970);Latin American Caribbean Health Sciences Literature (LILACS) (BIREME, from 1982).

We also searched [ClinicalTrials.gov](ClinicalTrials.gov), the WHO International Clinical Trials Registry Platform (ICTRP; [www.who.int/trialsearch](www.who.int/trialsearch)), and the International Standard Randomized Controlled Trials Number (ISRCTN) registry ([www.isrctn.com/](www.isrctn.com/)) for trials in progress, and ProQuest Dissertations & Theses A&I (1990 to 7 August 2017) for dissertations. On 11 October 2018, we performed an additional search, specifically for studies that evaluated Xpert Ultra.

To identify other systematic reviews and meta‐analyses, we performed an additional search on 26 March 2018 in MEDLINE (PubMed), Embase (OVID) and the Cochrane Library, Issue 7 2018, applying filters for systematic reviews ([www.sign.ac.uk/search‐filters.html](www.sign.ac.uk/search‐filters.html)) to search terms for Xpert and tuberculosis.

### Searching other resources {#CD009593-sec3-0012}

We reviewed reference lists of included articles and any relevant review articles identified through the above methods. We also contacted researchers at FIND, the WHO Global TB Programme, and other experts in the field of tuberculosis diagnostics for information on ongoing and unpublished studies.

Data collection and analysis {#CD009593-sec2-0009}
----------------------------

### Selection of studies {#CD009593-sec3-0013}

We used Covidence to manage the selection of studies ([@CD009593-bbs2-0335]). Working in pairs, four review authors independently scrutinized titles and abstracts identified from literature searching to identify potentially eligible studies. We retrieved the article of any citation identified by any review author for full‐text review. Then, again working in pairs, four review authors independently assessed articles for inclusion using predefined inclusion and exclusion criteria, and resolved any discrepancies by discussion among all review authors. We recorded all studies excluded after full‐text assessment and their reasons for exclusion in the [Characteristics of excluded studies](#CD009593-sec2-0026){ref-type="sec"} table. We illustrated the study selection process in a PRISMA diagram. We included search results from the original review and re‐evaluated previously included studies to determine if the studies met the refined inclusion criteria.

In the 2014 Cochrane Review ([@CD009593-bbs2-0401]), for the multicentre studies [@CD009593-bbs2-0011] (five study centres) and [@CD009593-bbs2-0012] (six study centres), we entered data separately for each study centre. We did not repeat this for this updated review and hence we count [@CD009593-bbs2-0011] and [@CD009593-bbs2-0012] each as one study and present the two‐by‐two data for the total population in each study. [Appendix 2](#CD009593-sec2-0017){ref-type="app"} presents the data by individual study centre.

### Data extraction and management {#CD009593-sec3-0014}

We extracted data on the following characteristics. 

Author, publication year, study design, country where study was located, level of laboratory services, setting (outpatient, inpatient, or both outpatient and inpatient) and whether the test was run at point of care.Population characteristics: age, gender, smear status, HIV status.Index test(s), Xpert MTB/RIF or Xpert Ultra.Reference standard.Condition of the specimen (fresh or frozen).Quality Assessment of Studies of Diagnostic Accuracy ‐ Revised (QUADAS‐2) items ([@CD009593-bbs2-0383]).Number of TP, FP, FN, and TN (i.e. true positives, false positives, false negatives, and true negatives, with respect to culture).Number of uninterpretable results for detection of PTB.Number of indeterminate results for detection of rifampicin resistance.

We classified country income status as either low‐ and middle‐income or high‐income, according to the World Bank List of Economies ([@CD009593-bbs2-0397]). In addition, we classified 'country\' as being high burden or not high burden for tuberculosis, TB/HIV, or MDR‐TB, according to the post‐2015 era classification by the WHO ([@CD009593-bbs2-0387]). A country could be classified as high burden for one, two, or all three of the high burden categories.

We classified the level of laboratory that ran the index tests as being one of three service levels: peripheral, intermediate, or central ([@CD009593-bbs2-0341]). Peripheral laboratories may perform Xpert MTB/RIF or Xpert Ultra testing, but typically perform only smear microscopy, and will refer specimens or people in need of further tests, such as rapid molecular testing, culture, or DST, to a higher‐level laboratory. Intermediate laboratories typically perform tests such as microscopy, rapid molecular tests, culture on solid media and line probe assays on sputum. Central laboratories run intermediate laboratory tests, as well as culture on liquid media and DST on solid or liquid media to detect resistance to first‐ and second‐line anti‐tuberculosis drugs, line probe assays on positive cultures, and rapid speciation tests ([@CD009593-bbs2-0341]).

Whenever possible, we extracted TP, FP, FN, and TN values based on one Xpert MTB/RIF or Xpert Ultra result for one specimen provided by one participant. However, in some of the studies, the number of specimens (and index test results) exceeded the number of participants, suggesting that a single participant may have provided multiple specimens. We therefore compared pooled sensitivity and specificity for tuberculosis detection in all studies with pooled sensitivity and specificity in the subset of studies that provided one index test result based on one specimen provided by one participant (see [Sensitivity analyses](#CD009593-sec3-0018){ref-type="sec"}).

Concerning the condition of the specimen, although the manufacturer recommends use of fresh specimens, we were aware that several studies had been conducted using frozen specimens so we extracted this information as well. We investigated the influence of condition of specimen in a sensitivity analysis.

Concerning the definition of smear positivity, as most included studies performed the index tests in intermediate‐level or central‐level laboratories, we assumed these studies adhered to the revised definition of a new sputum smear‐positive PTB case based on the presence of at least one acid‐fast bacillus in at least one sputum sample in countries with a well‐functioning external quality assurance system ([@CD009593-bbs2-0392]). 

We developed a standardized data extraction form and piloted the form with 10 studies. Based upon the pilot, we finalized the form. Four review authors working in pairs independently extracted data from each study using the final form. We contacted study authors for missing data and clarifications and managed all data with REDCap ([@CD009593-bbs2-0348]). The final data extraction form is in [Appendix 3](#CD009593-sec2-0018){ref-type="app"}. With regard to the use of REDCap, the content in this review is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

We followed Cochrane policy, which states that \"authors of primary studies will not extract data from their own study or studies. Instead, another author will extract these data, and check the interpretation against the study report and any available study registration details or protocol\".

### Assessment of methodological quality {#CD009593-sec3-0015}

We used the QUADAS‐2 tool, tailored to this review, to assess the quality of the included studies ([Appendix 4](#CD009593-sec2-0019){ref-type="app"}) ([@CD009593-bbs2-0383]). QUADAS‐2 consists of four domains: patient selection, index test, reference standard, and flow and timing. We assessed all domains for the potential for risks of bias and the first three domains for concerns regarding applicability. Four review authors, working independently in pairs, completed QUADAS‐2 and resolved disagreements through discussion. We present the results of this quality assessment in text, tables, and graphs.

### Statistical analysis and data synthesis {#CD009593-sec3-0016}

We performed descriptive analyses for the results of the included studies using Stata 15 ([@CD009593-bbs2-0371]). We determined sensitivity and specificity estimates and 95% confidence intervals (CIs) for individual studies and generated forest plots using [@CD009593-bbs2-0365]. Whenever possible, we included nontuberculous mycobacteria (NTM) as non‐tuberculosis for specificity determinations. We chose to use data that were not subject to discrepant analyses (unresolved data), since resolved data after discrepant analyses are a potential for risk of bias ([@CD009593-bbs2-0346]).

We carried out meta‐analyses to estimate the pooled sensitivity and specificity of the index tests separately for tuberculosis detection and rifampicin resistance detection. When possible, we determined pooled estimates using an adaptation of the bivariate random‐effects model of [@CD009593-bbs2-0364], which uses the exact binomial likelihood for the observed proportions ([@CD009593-bbs2-0332]). We accounted for the hierarchical structure of two multicentre studies for which individual centre data were available by adding a random effect for each centre ([@CD009593-bbs2-0011]; [@CD009593-bbs2-0012]). The bivariate random‐effects approach allowed us to calculate the pooled estimates of sensitivity and specificity while dealing with potential sources of variation caused by (1) imprecision of sensitivity and specificity estimates within individual studies; (2) correlation between sensitivity and specificity across studies; and (3) variation in sensitivity and specificity between studies. For Xpert MTB/RIF and Xpert Ultra for PTB detection among smear‐positive individuals (described below), we performed a univariate analysis.

For the primary analysis for Xpert MTB/RIF or Xpert Ultra for tuberculosis detection, we first estimated accuracy using all studies meeting our inclusion criteria and then using only the subset of studies where participants were unselected. In the latter analysis, we excluded studies that preselected participants based on prior microscopy testing or primarily included participants with a history of previous tuberculosis treatment.

#### Rifampicin resistance detection {#CD009593-sec4-0003}

For analysis of Xpert MTB/RIF or Xpert Ultra accuracy for detection of rifampicin resistance, we included participants who (1) were culture‐positive; (2) had a valid phenotypic DST (or MTBDR*plus)* result; (3) were Xpert MTB/RIF (or Xpert Ultra) tuberculosis‐positive; and (4) had a valid Xpert MTB/RIF (or Xpert Ultra) Rif result.

Sensitivity = Xpert MTB/RIF (or Xpert Ultra) Rif resistant/DST Rif resistant.Specificity = Xpert MTB/RIF (or Xpert Ultra) Rif susceptible/DST Rif susceptible.

For rifampicin resistance detection, we performed bivariate meta‐analyses to determine sensitivity and specificity estimates.

#### Comparison of Xpert MTB/RIF and Xpert Ultra {#CD009593-sec4-0004}

We intended to perform meta‐analyses of the accuracy of Xpert MTB/RIF and Xpert Ultra by first including all studies with relevant data, i.e. indirect comparisons, and then by restricting the analyses to studies that made comparisons between Xpert MTB/RIF and Xpert Ultra in the same participants, i.e. direct comparisons ([@CD009593-bbs2-0375]). However, we identified only one study using Xpert Ultra and this study compared Xpert MTB/RIF and Xpert Ultra on the same participant specimens ([@CD009593-bbs2-0023]). As in the primary analysis in [@CD009593-bbs2-0023], Xpert Ultra trace calls in this review were considered to be positive for the detection of *M tuberculosis*.

We estimated all models using a Bayesian approach with low‐information prior distributions using OpenBUGS software (Version 3.2.3) ([@CD009593-bbs2-0354]), along with R (Version 3.3.2) ([@CD009593-bbs2-0363]). Under the Bayesian approach, all unknown parameters must be provided a prior distribution that defines the range of possible values of the parameter and the likelihood of each of those values based on information external to the data. In order to let the observed data determine the final results, we chose to use low‐information prior distributions over the pooled sensitivity and specificity parameters and their between‐study standard deviation parameters. We summarize the model we used in the Statistical Appendix together with the OpenBUGS programme used to implement it ([Appendix 5](#CD009593-sec2-0020){ref-type="app"}). It is known that meta‐analysis models can be sensitive to the choice of prior distributions over between‐study standard deviation parameters. We therefore carried out sensitivity analyses and considered alternative prior distributions that are less informative, allowing a wider range of possible values. To study the sensitivity of all results to the choice of prior distributions, we considered alternative prior distributions that were less informative, allowing a wider range of possible values. We noted no appreciable change in pooled accuracy parameters but, as expected, found that the posterior credible intervals and prediction intervals were slightly wider. Information from the prior distribution is combined with the likelihood of the observed data in accordance with Bayes theorem to obtain a posterior distribution for each unknown parameter ([Appendix 6](#CD009593-sec2-0021){ref-type="app"}).

Using a sample from the posterior distribution, we can obtain various descriptive statistics of interest. We estimated the median pooled sensitivity and specificity and their 95% credible intervals (CrIs). The median or the 50% quantile is the value below which lies 50% of the posterior sample. We reported the median because the posterior distributions of some parameters may be skewed and the median would be considered a better point estimate of the unknown parameter than the mean in such cases. The 95% CrI is the Bayesian equivalent of the classical (frequentist) 95% CI. (We have indicated 95% CI for individual study estimates and 95% CrI for pooled study estimates, as appropriate). The 95% CrI may be interpreted as an interval that has a 95% probability of capturing the true value of the unknown parameter, given the observed data and the prior information.

We also estimated the 'predicted\' sensitivity and specificity in a future study together with their 95% CrIs. The predicted estimate is our best guess for the estimate in a future study and is the same as the pooled estimate. The CrIs, however, may be different. These values are derived from the predicted region typically reported in a bivariate meta‐analysis plot. If there is no heterogeneity at all between studies, the CI (or CrI) around the predicted estimate will be the same as the CI around the pooled estimate. On the other hand, if there is considerable heterogeneity between studies, the CI around the predicted estimate will be much wider than the CI around the pooled estimate. We generated the plots using R (version 3.3.2) ([@CD009593-bbs2-0363]).

#### Approach to uninterpretable index test results {#CD009593-sec4-0005}

The index tests report an uninterpretable test result for unexpected results with any of the internal control measures of the assay. The uninterpretable rate for detection of PTB was the number of tests classified as 'invalid\', 'error\', or 'no result\' divided by the total number of index tests performed. The uninterpretable rate for detection of rifampicin resistance (referred to as indeterminate rate) was the number of tests classified as 'MTB detected; Rif resistance INDETERMINATE\' divided by the total number of index test‐positive results. As we found very few uninterpretable results reported, we excluded these results from the quantitative analysis. We used a Bayesian hierarchical model for a single proportion to estimate the pooled proportion of uninterpretable index test results.

### Investigations of heterogeneity {#CD009593-sec3-0017}

#### Detection of PTB {#CD009593-sec4-0006}

##### Effect of smear status and HIV status {#CD009593-sec5-0001}

We investigated heterogeneity by performing subgroup analyses to determine sensitivity and specificity estimates for participants grouped by smear or HIV status. We analysed the data in two ways: 1) we performed meta‐analyses where we included all studies with available data, and 2) we performed meta‐analyses restricting the analysis to studies that provided data for both smear‐positive and smear‐negative individuals (or both HIV‐negative and HIV‐positive individuals) within the same study. In the latter comparison, we hoped to achieve a similar distribution of other participant characteristics and manner of test execution in the subgroups.

For smear‐positive tuberculosis, we performed a univariate analysis for sensitivity. We did this because in many studies the value for true negatives was zero (tuberculosis was not detected when defined by a positive culture), and we considered all participants to be true positives. It has been observed among individuals with presumptive tuberculosis that when a sputum specimen is found to be positive by smear microscopy, the probability of a culture being negative is low ([@CD009593-bbs2-0379]).

##### Effect of other covariates {#CD009593-sec5-0002}

To study the impact of additional covariates of interest, we performed subgroup analyses with the following covariates.

PTB detection

High tuberculosis burden, yes or no.High TB/HIV burden, yes or no.Percentage of participants with a history of tuberculosis, greater than the median value versus less than or equal to the median value.Setting that ran the test, point of care or peripheral setting versus intermediate or central laboratory.Prevalence of PTB in the studies, greater than the median value versus less than or equal to the median value.

All the aforementioned covariates were categorical, study‐level covariates. For these analyses, we restricted the studies to those that included unselected participants, i.e. we excluded studies that preselected participants on the basis of a prior smear microscopy result or primarily included participants with a history of previous tuberculosis treatment.

#### Detection of rifampicin resistance {#CD009593-sec4-0007}

For rifampicin resistance detection, we performed subgroup analyses with the following covariates.

High MDR‐TB burden, yes or no.Studies involving participants who had received previous tuberculosis treatment, yes or no.Prevalence of rifampicin resistance in the studies, greater than the median value versus less than or equal to the median value.

All the aforementioned covariates were categorical, study‐level covariates.

### Sensitivity analyses {#CD009593-sec3-0018}

For detection of PTB, we performed sensitivity analyses by limiting inclusion in the meta‐analysis based on the following criteria.

Studies that explicitly represented the use of the index tests for the diagnosis of individuals with signs and symptoms of tuberculosis (presumptive tuberculosis). We excluded studies that involved HIV‐positive participants irrespective of tuberculosis symptoms.Studies where a single specimen yielded a single Xpert MTB/RIF result for a given participant. We excluded studies that included more specimens than participants.Studies that included only untreated participants. We excluded studies that did not explicitly state they included only untreated participants.Studies that used liquid culture as the reference standard.Studies where a consecutive or random sample of participants were enrolled.Studies where the reference standard was blinded.Studies that only used fresh specimens.Studies that accounted for all participants in the analysis. We excluded studies where we answered 'no\' or 'unclear\' to the QUADAS‐2 Flow and Timing signalling question: *Were all patients included in the analysis?*

In addition, in order to assess the influence of two large multicentre manufacturer‐supported studies on the summary estimates, we performed an analysis excluding these studies ([@CD009593-bbs2-0011]; [@CD009593-bbs2-0012]).

For the sensitivity analyses, we restricted the studies to those that included unselected participants; i.e. we excluded studies that preselected participants on the basis of a prior smear microscopy result or previous tuberculosis treatment.

### Assessment of reporting bias {#CD009593-sec3-0019}

We chose not to carry out formal assessment of publication bias using methods such as funnel plots or regression tests, because such techniques have not been helpful for diagnostic test accuracy studies ([@CD009593-bbs2-0355]). However, Xpert MTB/RIF and Xpert Ultra are produced by only one manufacturer and, as tests for which there has been considerable attention and scrutiny, we believe reporting bias was minimal.

#### Other analyses {#CD009593-sec4-0008}

##### Nontuberculous mycobacteria (NTM) {#CD009593-sec5-0003}

NTM, such as *M avium* complex and *M intracellulare*, comprise a multi‐species group of human pathogens that are ubiquitous in water and soil. NTMs can cause severe pulmonary and other diseases that share clinical signs with tuberculosis but are treated differently. People living with HIV with severe immunosuppression are particularly vulnerable to infections caused by NTM ([@CD009593-bbs2-0343]). We summarized separately data for NTM by determining the percent of false‐positive Xpert MTB/RIF results (data were only reported for Xpert MTB/RIF) in samples that grew NTMs (see Results: Other analyses: NTM).

#### Assessment of certainty of the evidence {#CD009593-sec4-0009}

Four review authors assessed the certainty of the evidence (also called quality of the evidence) using the GRADE approach ([@CD009593-bbs2-0318]; [@CD009593-bbs2-0367]; [@CD009593-bbs2-0368]), and GRADEpro Guideline Development Tool (GDT) software ([@CD009593-bbs2-0344]). In the context of a systematic review, ratings of the certainty of the evidence reflect the extent of our confidence that the estimates of effect (including test accuracy and associations) are correct. As recommended, we rated the certainty of the evidence as either high (not downgraded), moderate (downgraded by one level), low (downgraded by two levels), or very low (downgraded by more than two levels) for five domains: risk of bias, indirectness, inconsistency, imprecision, and publication bias.

For each outcome, we considered the certainty of the evidence to begin as high when high‐quality observational studies (cross‐sectional or cohort studies) enrolled participants with diagnostic uncertainty. If we had a reason for downgrading, we used our judgement to classify the reason as serious (downgraded by one level) or very serious (downgraded by two levels). We summarized this information in the 'Summary of findings\' tables ([Table 1](#CD009593-tbl-0001){ref-type="table"}; [Table 2](#CD009593-tbl-0002){ref-type="table"}).

We applied GRADE in the following ways.

Risk of bias: we used QUADAS‐2 to assess risk of bias.Indirectness: we used QUADAS‐2 for concerns of applicability and looked for important differences between the populations studied (for example, the spectrum of disease), the setting, index test, and outcomes, and asked whether differences were sufficient to lower certainty in results.Inconsistency: GRADE recommends downgrading for unexplained inconsistency in sensitivity and specificity estimates. We carried out prespecified analyses to investigate potential sources of heterogeneity and did not downgrade when we believed we could explain inconsistency in the accuracy estimates.Imprecision: we considered a precise estimate to be one that would allow a clinically meaningful decision. We considered the width of the CrI and asked ourselves, 'Would we make a different decision if the lower or upper boundary of the CrI represented the truth?\'. In addition, we worked out projected ranges for TP, FN, TN, and FP for a given prevalence of tuberculosis and made judgements on imprecision from these calculations. We also considered whether the number of participants included in the analysis was less than the number generated by a conventional sample size calculation for a single adequately‐powered study.Publication bias: we rated publication bias as undetected (not serious) because of the comprehensiveness of the literature search and following extensive outreach to tuberculosis researchers to identify studies. As we included a large number of studies, we thought that had we missed several small studies, the results would probably not be different.

Results {#CD009593-sec1-0005}
=======

Results of the search {#CD009593-sec2-0010}
---------------------

We identified 95 unique studies, integrating 77 new studies since publication of the Cochrane Review ([@CD009593-bbs2-0401]). All studies but one ([@CD009593-bbs2-0031] in Chinese) were written in English. For PTB detection, rifampicin resistance detection, or both PTB and rifampicin resistance detection, all 95 studies evaluated Xpert MTB/RIF (Xpert MTB/RIF) and one study compared Xpert MTB/RIF and Xpert MTB/RIF Ultra (Xpert Ultra) ([@CD009593-bbs2-0023]). Of the total 86 studies for PTB detection, 48 studies evaluated the test for detection of both PTB and rifampicin resistance and 38 studies for PTB alone. Of the total 57 studies for rifampicin resistance detection, nine studies evaluated the test for rifampicin resistance alone. [Figure 3](#CD009593-fig-0003){ref-type="fig"} shows the flow of studies in the review. We recorded the excluded studies, including those listed in the previous Cochrane Review ([@CD009593-bbs2-0401]), and the reasons for their exclusion in the [Characteristics of excluded studies](#CD009593-sec2-0026){ref-type="sec"} table.Figure 3Flow diagram of studies in the review. To identify other systematic reviews, we performed an additional literature search on 26 March 2018 ([Table 8](#CD009593-tbl-0008){ref-type="table"}).

Methodological quality of included studies {#CD009593-sec2-0011}
------------------------------------------

### Studies evaluating Xpert MTB/RIF and Xpert Ultra for detection of PTB {#CD009593-sec3-0020}

[Figure 4](#CD009593-fig-0004){ref-type="fig"}, [Figure 5](#CD009593-fig-0005){ref-type="fig"}, and [Figure 6](#CD009593-fig-0006){ref-type="fig"} show risk of bias and applicability concerns for 86 studies evaluating Xpert MTB/RIF and Xpert Ultra for tuberculosis detection.Figure 4Risk of bias and applicability concerns graph for pulmonary tuberculosis detection: review authors\' judgements about each domain presented as percentages across included studies.Figure 5Risk of bias and applicability concerns summary for pulmonary tuberculosis detection: review authors\' judgements about each domain for each included study, studies A through K.Figure 6Risk of bias and applicability concerns summary for pulmonary tuberculosis detection: review authors\' judgements about each domain for each included study, studies L through Z.

In the Patient Selection domain, we considered 55 studies (64%) to have low risk of bias because the study enrolled a consecutive or random sample of eligible participants and avoided inappropriate exclusions. We considered 16 studies (19%) to have high risk of bias because the study did not avoid inappropriate exclusions: 13 studies enrolled participants whose sputum specimens were primarily or exclusively smear‐positive or smear‐negative ([@CD009593-bbs2-0008]; [@CD009593-bbs2-0024]; [@CD009593-bbs2-0033]; [@CD009593-bbs2-0042]; [@CD009593-bbs2-0043]; [@CD009593-bbs2-0053]; [@CD009593-bbs2-0054]; [@CD009593-bbs2-0057]; [@CD009593-bbs2-0083]; [@CD009593-bbs2-0086]; [@CD009593-bbs2-0089]; [@CD009593-bbs2-0090]; [@CD009593-bbs2-0091]) and three studies exclusively enrolled participants who had previously received tuberculosis treatment ([@CD009593-bbs2-0050]; [@CD009593-bbs2-0051]; [@CD009593-bbs2-0067]). In addition, we considered 15 studies (17%) to have unclear risk of bias because the manner of participant selection was not stated ([@CD009593-bbs2-0004]; [@CD009593-bbs2-0007]; [@CD009593-bbs2-0009]; [@CD009593-bbs2-0013]; [@CD009593-bbs2-0018]; [@CD009593-bbs2-0031]; [@CD009593-bbs2-0035]; [@CD009593-bbs2-0047]; [@CD009593-bbs2-0049]; [@CD009593-bbs2-0058]; [@CD009593-bbs2-0059]; [@CD009593-bbs2-0064]; [@CD009593-bbs2-0071]; [@CD009593-bbs2-0077]; [@CD009593-bbs2-0079]). With respect to applicability, we considered 46 studies (53%) to have low concern because participants in these studies were evaluated in primary care facilities, local hospitals, or both settings ([@CD009593-bbs2-0001]; [@CD009593-bbs2-0002]; [@CD009593-bbs2-0005]; [@CD009593-bbs2-0006]; [@CD009593-bbs2-0007]; [@CD009593-bbs2-0010]; [@CD009593-bbs2-0011]; [@CD009593-bbs2-0012]; [@CD009593-bbs2-0013]; [@CD009593-bbs2-0015]; [@CD009593-bbs2-0016]; [@CD009593-bbs2-0018]; [@CD009593-bbs2-0023]; [@CD009593-bbs2-0024]; [@CD009593-bbs2-0027]; [@CD009593-bbs2-0028]; [@CD009593-bbs2-0030]; [@CD009593-bbs2-0031]; [@CD009593-bbs2-0037]; [@CD009593-bbs2-0038]; [@CD009593-bbs2-0039]; [@CD009593-bbs2-0040]; [@CD009593-bbs2-0041]; [@CD009593-bbs2-0047]; [@CD009593-bbs2-0050]; [@CD009593-bbs2-0051]; [@CD009593-bbs2-0056]; [@CD009593-bbs2-0057]; [@CD009593-bbs2-0059]; [@CD009593-bbs2-0061]; [@CD009593-bbs2-0063]; [@CD009593-bbs2-0065]; [@CD009593-bbs2-0067]; [@CD009593-bbs2-0070]; [@CD009593-bbs2-0072]; [@CD009593-bbs2-0075]; [@CD009593-bbs2-0076]; [@CD009593-bbs2-0077]; [@CD009593-bbs2-0079]; [@CD009593-bbs2-0081]; [@CD009593-bbs2-0082]; [@CD009593-bbs2-0085]; [@CD009593-bbs2-0087]; [@CD009593-bbs2-0089]; [@CD009593-bbs2-0090]; [@CD009593-bbs2-0092]). We considered 10 studies (12%) to have high concern because participants were evaluated exclusively as inpatients in tertiary care centres ([@CD009593-bbs2-0009]; [@CD009593-bbs2-0014]; [@CD009593-bbs2-0017]; [@CD009593-bbs2-0019]; [@CD009593-bbs2-0021]; [@CD009593-bbs2-0022]; [@CD009593-bbs2-0035]; [@CD009593-bbs2-0044]; [@CD009593-bbs2-0053]; [@CD009593-bbs2-0054]). We considered 30 studies (35%) to have unclear concern because we could not tell.

In the Index Test domain, we considered all studies to have low risk of bias. With respect to applicability, we considered most studies to have low concern and eight studies to have unclear concern because the ratio of sample reagent to specimen volume differed from that recommended by the manufacturer or we could not tell ([@CD009593-bbs2-0005]; [@CD009593-bbs2-0024]; [@CD009593-bbs2-0054]; [@CD009593-bbs2-0057]; [@CD009593-bbs2-0059]; [@CD009593-bbs2-0064]; [@CD009593-bbs2-0071]; [@CD009593-bbs2-0075]).

In the Reference Standard domain, we considered 69 studies (80%) to have low risk of bias because the results of the reference standard were interpreted without knowledge of the results of the index test. We considered five studies (6%) to have high risk of bias because the results of the reference standard were not blinded ([@CD009593-bbs2-0017]; [@CD009593-bbs2-0026]; [@CD009593-bbs2-0073]; [@CD009593-bbs2-0093]; [@CD009593-bbs2-0095]) and the remaining 12 studies (14%) to have unclear risk of bias because information about blinding was not reported. With respect to applicability (Reference Standard domain), we considered most studies to have low concern; we considered one study to have high concern because this study did not speciate mycobacteria isolated in culture ([@CD009593-bbs2-0056]) and two studies (2%) to have unclear concern because we could not tell ([@CD009593-bbs2-0001]; [@CD009593-bbs2-0007]).

In the Flow and Timing domain, we considered 72 studies (84%) to have low risk of bias because all participants were included in the analysis. We considered eight studies (9%) to have high risk of bias: in seven studies, results for index or reference tests were not available for many participants ([@CD009593-bbs2-0007]; [@CD009593-bbs2-0008]; [@CD009593-bbs2-0013]; [@CD009593-bbs2-0022]; [@CD009593-bbs2-0059]; [@CD009593-bbs2-0077]; [@CD009593-bbs2-0089]); in one study, participants who were treated for tuberculosis on the basis of clinical and radiological findings (smear‐negative, culture‐negative) were not included in the analysis ([@CD009593-bbs2-0012]). We considered six studies (7%) to have unclear risk of bias because we could not tell if all participants were included in the analysis ([@CD009593-bbs2-0017]; [@CD009593-bbs2-0023]; [@CD009593-bbs2-0028]; [@CD009593-bbs2-0029]; [@CD009593-bbs2-0069]; [@CD009593-bbs2-0088]).

### Studies evaluating Xpert MTB/RIF and Xpert Ultra for detection of rifampicin resistance {#CD009593-sec3-0021}

[Figure 7](#CD009593-fig-0007){ref-type="fig"} and [Figure 8](#CD009593-fig-0008){ref-type="fig"} show risk of bias and applicability concerns for 57 studies evaluating Xpert MTB/RIF and Xpert Ultra for rifampicin resistance detection.Figure 7Risk of bias and applicability concerns graph for rifampicin resistance detection: review authors\' judgements about each domain presented as percentages across included studies.Figure 8Risk of bias and applicability concerns summary for rifampicin resistance detection: review authors\' judgements about each domain for each included study.

In the Patient Selection domain, we considered 36 studies (63%) to have low risk of bias because the study enrolled a consecutive or random sample of eligible participants and avoided inappropriate exclusions. We considered 10 studies (18% ) to have high risk of bias because the study did not avoid inappropriate exclusions and instead enrolled participants preselected on the basis of their sputum specimens being either smear‐positive or smear‐negative or the study exclusively enrolled retreatment participants ([@CD009593-bbs2-0003]; [@CD009593-bbs2-0024]; [@CD009593-bbs2-0042]; [@CD009593-bbs2-0043]; [@CD009593-bbs2-0048]; [@CD009593-bbs2-0060]; [@CD009593-bbs2-0083]; [@CD009593-bbs2-0086]; [@CD009593-bbs2-0089]; [@CD009593-bbs2-0091]). We considered 11 studies (19%) to have unclear risk of bias because the manner of participant selection was not reported ([@CD009593-bbs2-0007]; [@CD009593-bbs2-0008]; [@CD009593-bbs2-0009]; [@CD009593-bbs2-0031]; [@CD009593-bbs2-0035]; [@CD009593-bbs2-0047]; [@CD009593-bbs2-0050]; [@CD009593-bbs2-0058]; [@CD009593-bbs2-0064]; [@CD009593-bbs2-0067]; [@CD009593-bbs2-0080]). With respect to applicability, we considered 26 studies (46%) to have low concern because participants in these studies were evaluated in primary care facilities, local hospitals, or both settings ([@CD009593-bbs2-0002]; [@CD009593-bbs2-0005]; [@CD009593-bbs2-0007]; [@CD009593-bbs2-0011]; [@CD009593-bbs2-0012]; [@CD009593-bbs2-0016]; [@CD009593-bbs2-0020]; [@CD009593-bbs2-0023]; [@CD009593-bbs2-0024]; [@CD009593-bbs2-0031]; [@CD009593-bbs2-0037]; [@CD009593-bbs2-0038]; [@CD009593-bbs2-0039]; [@CD009593-bbs2-0041]; [@CD009593-bbs2-0046]; [@CD009593-bbs2-0047]; [@CD009593-bbs2-0050]; [@CD009593-bbs2-0052]; [@CD009593-bbs2-0065]; [@CD009593-bbs2-0067]; [@CD009593-bbs2-0072]; [@CD009593-bbs2-0075]; [@CD009593-bbs2-0081]; [@CD009593-bbs2-0082]; [@CD009593-bbs2-0085]; [@CD009593-bbs2-0089]). We considered four studies to have high concern (7%) because participants were evaluated exclusively as inpatients in tertiary care centres ([@CD009593-bbs2-0009]; [@CD009593-bbs2-0014]; [@CD009593-bbs2-0035]; [@CD009593-bbs2-0044]). We considered the remaining 27 studies (47%) to have unclear concern because we could not tell.

In the Index Test domain, we considered all studies to have low risk of bias. With respect to applicability, we considered 53 studies (93%) to have low concern and four studies (7%) to have unclear concern because the ratio of sample reagent to specimen volume differed from that recommended by the manufacturer ([@CD009593-bbs2-0024]; [@CD009593-bbs2-0064]; [@CD009593-bbs2-0075]; [@CD009593-bbs2-0080]).

In the Reference Standard domain, we considered 47 studies (82%) to have low risk of bias because the results of the reference standard were interpreted without knowledge of the results of the index test. We considered four studies (7%) to have high risk of bias because the result of the reference standard was not blinded ([@CD009593-bbs2-0046]; [@CD009593-bbs2-0073]; [@CD009593-bbs2-0093]; [@CD009593-bbs2-0095]) and the remaining six studies (11%) to have unclear risk of bias because information was not reported. With respect to applicability in the Reference Standard domain, we considered all studies to have low concern because in these studies all specimens had already been speciated and identified as *Mycobacterium tuberculosis*.

In the Flow and Timing domain, we considered 51 studies (90%) to have low risk of bias because all participants were included in the analysis. We considered three studies (5%) to have high risk of bias because index and reference test results were not available for many participants ([@CD009593-bbs2-0007]; [@CD009593-bbs2-0008]; [@CD009593-bbs2-0089]). We considered three studies (5%) to have unclear risk of bias because we could not tell if all participants were included in the analysis ([@CD009593-bbs2-0023]; [@CD009593-bbs2-0069]; [@CD009593-bbs2-0088]).

Findings {#CD009593-sec2-0012}
--------

### I. Detection of PTB {#CD009593-sec3-0022}

A total of 86 studies involving 42,091 participants evaluated the accuracy of Xpert MTB/RIF for PTB ([Figure 9](#CD009593-fig-0009){ref-type="fig"}). For two multicentre studies ([@CD009593-bbs2-0011]; [@CD009593-bbs2-0012]) we provide two‐by‐two data for the individual centres in [Appendix 2](#CD009593-sec2-0017){ref-type="app"}. The median number of participants in the studies was 256 (Interquartile range (IQR) 145 to 494). Key characteristics for the included studies are presented in [Characteristics of included studies](#CD009593-sec2-0025){ref-type="sec"}.Figure 9Forest plots of Xpert sensitivity and specificity for detection of pulmonary tuberculosis. The individual studies are ordered by decreasing sensitivity. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive.

#### A. Primary analysis, Xpert MTB/RIF and Xpert Ultra for detection of PTB {#CD009593-sec4-0010}

##### A.1. Xpert MTB/RIF {#CD009593-sec5-0004}

For the 86 studies, sensitivity estimates ranged from 43% to 100% ([Figure 9](#CD009593-fig-0009){ref-type="fig"}). Differences in enrolment criteria (different populations targeted), disease severity, and settings were notable in several studies with low sensitivity: [@CD009593-bbs2-0040] (sensitivity 43%) included HIV‐positive pregnant women accessing prevention of mother‐to‐child transmission services (no tuberculosis symptoms reported) and sensitivity was based on a small number of tuberculosis cases (seven tuberculosis cases). [@CD009593-bbs2-0081] (sensitivity 44%) evaluated induced sputum specimens from participants with presumptive PTB, most of whom were asymptomatic. [@CD009593-bbs2-0004] (sensitivity 48%) only included adults unable to produce sputum and frozen specimens. [@CD009593-bbs2-0001] and [@CD009593-bbs2-0002] included few tuberculosis cases. [@CD009593-bbs2-0092] enrolled HIV‐positive people initiating antiretroviral therapy. [@CD009593-bbs2-0041] included HIV‐positive participants irrespective of tuberculosis symptoms. Specificity varied less than sensitivity, with specificity estimates ranging from 52% to 100%, although most specificity estimates were greater than 90% ([Figure 9](#CD009593-fig-0009){ref-type="fig"}). [@CD009593-bbs2-0062] (specificity 52%) was an outlier, and although we corresponded with the study author we could not explain the low specificity in this study.

###### A.1.a. Xpert MTB/RIF accuracy, all studies meeting inclusion criteria {#CD009593-sec6-0001}

In this meta‐analysis, we included 85 studies involving 41,965 participants. We excluded one study that only reported sensitivity data ([@CD009593-bbs2-0024]). Xpert pooled sensitivity and specificity (95% credible interval (CrI)) were 85% (82% to 87%) and 98% (97% to 98%), respectively ([Table 4](#CD009593-tbl-0004){ref-type="table"}).Table 1Xpert MTB/RIF for detection of pulmonary tuberculosis and rifampicin resistance**Type of analysis (number of studies; participants)Median pooledsensitivity (95% CrI)Median pooledspecificity (95% CrI)Median predicted sensitivity (95% CrI)Median predicted specificity (95% CrI)**Xpert MTB/RIF sensitivity and specificity for detection of PTB, all studies^a^ (85; 41,965)85% (82 to 87)98% (97 to 98)85% (52 to 97)98% (76 to 100)Xpert MTB/RIF sensitivity and specificity for detection of PTB, studies with unselected participants (70; 37,237)85% (82 to 88)98% (97 to 98)85% (56 to 96)98% (78 to 100)Xpert MTB/RIF sensitivity and specificity for detection of rifampicin resistance (48; 8020)96% (94 to 97)98% (98 to 99)96% (86 to 99)98% (89 to 100)[^4]

###### A.1.b. Xpert MTB/RIF accuracy, limited to studies with unselected participants {#CD009593-sec6-0002}

We included 70 studies involving 37,237 unselected participants ([@CD009593-bbs2-0001]; [@CD009593-bbs2-0002]; [@CD009593-bbs2-0004]; [@CD009593-bbs2-0005]; [@CD009593-bbs2-0006]; [@CD009593-bbs2-0007]; [@CD009593-bbs2-0009]; [@CD009593-bbs2-0010]; [@CD009593-bbs2-0011]; [@CD009593-bbs2-0012]; [@CD009593-bbs2-0013]; [@CD009593-bbs2-0014]; [@CD009593-bbs2-0015]; [@CD009593-bbs2-0016]; [@CD009593-bbs2-0017]; [@CD009593-bbs2-0018]; [@CD009593-bbs2-0019]; [@CD009593-bbs2-0021]; [@CD009593-bbs2-0022]; [@CD009593-bbs2-0023]; [@CD009593-bbs2-0025]; [@CD009593-bbs2-0026]; [@CD009593-bbs2-0027]; [@CD009593-bbs2-0028]; [@CD009593-bbs2-0029]; [@CD009593-bbs2-0030]; [@CD009593-bbs2-0031]; [@CD009593-bbs2-0032]; [@CD009593-bbs2-0034]; [@CD009593-bbs2-0035]; [@CD009593-bbs2-0036]; [@CD009593-bbs2-0037]; [@CD009593-bbs2-0038]; [@CD009593-bbs2-0039]; [@CD009593-bbs2-0040]; [@CD009593-bbs2-0041]; [@CD009593-bbs2-0044]; [@CD009593-bbs2-0045]; [@CD009593-bbs2-0047]; [@CD009593-bbs2-0049]; [@CD009593-bbs2-0056]; [@CD009593-bbs2-0058]; [@CD009593-bbs2-0059]; [@CD009593-bbs2-0061]; [@CD009593-bbs2-0062]; [@CD009593-bbs2-0063]; [@CD009593-bbs2-0064]; [@CD009593-bbs2-0065]; [@CD009593-bbs2-0066]; [@CD009593-bbs2-0068]; [@CD009593-bbs2-0069]; [@CD009593-bbs2-0070]; [@CD009593-bbs2-0071]; [@CD009593-bbs2-0072]; [@CD009593-bbs2-0073]; [@CD009593-bbs2-0074]; [@CD009593-bbs2-0075]; [@CD009593-bbs2-0076]; [@CD009593-bbs2-0077]; [@CD009593-bbs2-0078]; [@CD009593-bbs2-0079]; [@CD009593-bbs2-0081]; [@CD009593-bbs2-0082]; [@CD009593-bbs2-0084]; [@CD009593-bbs2-0085]; [@CD009593-bbs2-0087]; [@CD009593-bbs2-0088]; [@CD009593-bbs2-0092]; [@CD009593-bbs2-0093]; [@CD009593-bbs2-0095]). We excluded 16 studies, i.e. 13 studies that preselected participants on the basis of a prior smear microscopy result (participants whose sputum specimens were primarily or exclusively smear‐positive or smear‐negative) ([@CD009593-bbs2-0008]; [@CD009593-bbs2-0024]; [@CD009593-bbs2-0033]; [@CD009593-bbs2-0042]; [@CD009593-bbs2-0043]; [@CD009593-bbs2-0053]; [@CD009593-bbs2-0054]; [@CD009593-bbs2-0057]; [@CD009593-bbs2-0083]; [@CD009593-bbs2-0086]; [@CD009593-bbs2-0089]; [@CD009593-bbs2-0090]; [@CD009593-bbs2-0091]) and three studies that preselected participants who had previously received tuberculosis treatment ([@CD009593-bbs2-0050]; [@CD009593-bbs2-0051]; [@CD009593-bbs2-0067]) ([Figure 10](#CD009593-fig-0010){ref-type="fig"}).Figure 10Forest plots of Xpert sensitivity and specificity for detection of pulmonary tuberculosis in studies with unselected participants. The individual studies are ordered by decreasing sensitivity. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive.

Xpert MTB/RIF pooled sensitivity and specificity (95% Crl) were 85% (82% to 88%) and 98% (97% to 98%), essentially the same as the estimates obtained when including all studies regardless of their selection criteria ([Table 4](#CD009593-tbl-0004){ref-type="table"}).

[Figure 11](#CD009593-fig-0011){ref-type="fig"} presents the pooled and predicted sensitivity and specificity estimates together with the credible and prediction regions for Xpert MTB/RIF for PTB. The summary point (pooled value) appears close to the upper left‐hand corner of the plot, suggesting high accuracy of Xpert MTB/RIF for detection of PTB. The 95% credible region around the summary point of sensitivity and specificity, the region that contains likely combinations of the pooled sensitivity and specificity, is relatively narrow. The 95% prediction region is wider, displaying more uncertainty as to where the likely values of sensitivity and specificity might occur in a future study.Figure 11Summary plots of Xpert MTB/RIF sensitivity and specificity for detection of pulmonary tuberculosis. Each individual study is represented by an empty square. The size of the square is proportional to the sample size of the study such that larger studies are represented by larger squares. The filled circle is the median pooled estimate for sensitivity and specificity. The solid curves represent the 95% credible region around the summary estimate; the dashed curves represent the 95% prediction region.

##### A.2. Xpert Ultra {#CD009593-sec5-0005}

We identified one study that evaluated Xpert Ultra for PTB ([@CD009593-bbs2-0023]). This multicentre study, which took place in Belarus, Brazil, China, Georgia, India, Kenya, South Africa, and Uganda, compared Xpert Ultra and Xpert MTB/RIF on the same participant specimens, (1439 participants). Based on a reference standard of multiple cultures, Xpert Ultra yielded higher sensitivity at 88% (95% CI 85% to 91%), compared to Xpert MTB/RIF sensitivity of 83% (79% to 86%), and lower specificity at 96% (94% to 97%), compared to Xpert MTB/RIF specificity of 98% (97% to 99%) ([Figure 12](#CD009593-fig-0012){ref-type="fig"}).Figure 12Summary ROC plots for sensitivity and specificity of Xpert MTB/RIF and Xpert Ultra for detection of pulmonary tuberculosis.

#### B. Investigations of heterogeneity {#CD009593-sec4-0011}

Unless otherwise noted, investigations of heterogeneity are limited to those studies that enrolled unselected participants.

##### B.1. Xpert MTB/RIF for detection of PTB by smear status {#CD009593-sec5-0006}

###### B.1.a. Xpert MTB/RIF accuracy in participants with smear‐positive sputum specimens {#CD009593-sec6-0003}

[Figure 13](#CD009593-fig-0013){ref-type="fig"} displays the forest plots for studies reporting data for participants with smear‐positive specimens. Sensitivity estimates ranged from 75% to 100% and specificity estimates from 0% to 100%. We thought some of the variability in specificity estimates could be explained by small numbers of participants included in the studies. In addition, in some studies, including the four largest, the value for true negatives was zero (tuberculosis was not present when measured against culture), and all participants were considered to be true positives (tuberculosis was present when measured against culture).Figure 13Forest plots of Xpert MTB/RIF sensitivity and specificity for detection of pulmonary tuberculosis, participants with smear‐positive (culture‐positive) specimens. The individual studies are ordered by decreasing sensitivity. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive.

For smear‐positive, culture‐positive PTB, using a univariate random‐effects model and including all studies for which sensitivity data were available, Xpert MTB/RIF pooled sensitivity (95% CrI) was 98% (97% to 99%) (53 studies, 4574 participants). We did not determine pooled specificity because in many studies the value for true negatives was zero.

###### B.1.b. Xpert MTB/RIF accuracy in participants with smear‐negative sputum specimens {#CD009593-sec6-0004}

[Figure 14](#CD009593-fig-0014){ref-type="fig"} displays the forest plots for studies reporting data for participants with smear‐negative specimens. Sensitivity estimates ranged from 28% to 100%. The lowest sensitivity was described by [@CD009593-bbs2-0081]; this study evaluated induced sputum specimens from participants with presumptive PTB, most of whom were asymptomatic. Specificity estimates ranged from 57% to 100%. The lowest specificity was described by [@CD009593-bbs2-0062], with the remaining 55 studies ranging in specificity from 83% to 100%.Figure 14Forest plots of Xpert MTB/RIF sensitivity and specificity for detection of pulmonary tuberculosis, participants with smear‐negative (culture‐positive) specimens. The individual studies are ordered by decreasing sensitivity. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive.

For smear‐negative, culture‐positive PTB, using a bivariate model and including all studies for which sensitivity and specificity data were available, Xpert MTB/RIF pooled sensitivity and specificity (95% CrI) were 67% (63% to 72%) and 98% (97% to 99%), (56 studies, 22,581 participants).

###### B.1.c. Xpert MTB/RIF accuracy by smear status, studies that provided data for both smear‐positive and smear‐negative participants {#CD009593-sec6-0005}

We limited this analysis to 45 studies that reported results for participants with smear‐positive specimens and smear‐negative specimens within the same study ([@CD009593-bbs2-0005]; [@CD009593-bbs2-0006]; [@CD009593-bbs2-0011]; [@CD009593-bbs2-0012]; [@CD009593-bbs2-0016]; [@CD009593-bbs2-0017]; [@CD009593-bbs2-0018]; [@CD009593-bbs2-0019]; [@CD009593-bbs2-0021]; [@CD009593-bbs2-0022]; [@CD009593-bbs2-0023]; [@CD009593-bbs2-0025]; [@CD009593-bbs2-0026]; [@CD009593-bbs2-0027]; [@CD009593-bbs2-0028]; [@CD009593-bbs2-0029]; [@CD009593-bbs2-0031]; [@CD009593-bbs2-0032]; [@CD009593-bbs2-0034]; [@CD009593-bbs2-0036]; [@CD009593-bbs2-0038]; [@CD009593-bbs2-0039]; [@CD009593-bbs2-0041]; [@CD009593-bbs2-0044]; [@CD009593-bbs2-0047]; [@CD009593-bbs2-0058][@CD009593-bbs2-0061]; [@CD009593-bbs2-0062]; [@CD009593-bbs2-0065]; [@CD009593-bbs2-0066]; [@CD009593-bbs2-0069]; [@CD009593-bbs2-0070]; [@CD009593-bbs2-0071]; [@CD009593-bbs2-0072]; [@CD009593-bbs2-0073]; [@CD009593-bbs2-0074]; [@CD009593-bbs2-0075]; [@CD009593-bbs2-0077]; [@CD009593-bbs2-0078]; [@CD009593-bbs2-0079]; [@CD009593-bbs2-0081]; [@CD009593-bbs2-0085]; [@CD009593-bbs2-0088]; [@CD009593-bbs2-0093]; [@CD009593-bbs2-0095]). For smear‐positive tuberculosis, Xpert MTB/RIF pooled sensitivity was 98% (97% to 98%), considerably higher than the sensitivity of 68% (63% to 73%) for smear‐negative tuberculosis ([Table 5](#CD009593-tbl-0005){ref-type="table"}).Table 2Xpert MTB/RIF for detection of pulmonary tuberculosis, investigations of heterogeneity**Type of analysis (number of studies; participants)Median pooled sensitivity (95% CrI)Median pooled specificity (95% CrI)Median predicted sensitivity (95% CrI)Median predicted specificity (95% CrI)Xpert MTB/RIF accuracy for tuberculosis detection in clinical subgroups**Smear positive (45; 4064)^a^98% (97 to 98)Could not determine98% (89 to 100)Could not determineSmear negative (45; 18,962)^a^67% (62 to 72)98% (98 to 99)67% (37 to 88)98% (80 to 100)HIV negative (14; 3866)^a^88% (83 to 92)98% (97 to 99)88% (71 to 96)98% (92 to 100)HIV positive (14; 4664)^a^81% (75 to 86)98% (97 to 99)81% (59 to 93)98% (92 to 100)**Xpert MTB/RIF accuracy for tuberculosis detection based on percentage of participants with a history of previous tuberculosis**Previous tuberculosis \> 25% (11; 4196)82% (74 to 88)96% (93 to 98)82% (48 to 96)96% (78 to 99)Previous tuberculosis ≤ 25% (16; 8205)81% (72 to 87)98% (97 to 99)81% (39 to 97)98% (90 to 100)**Xpert MTB/RIF accuracy for tuberculosis detection by tuberculosis burden**^a^High tuberculosis burden = Yes (39; 21,965)^b^86% (82 to 89)97% (95 to 98)86% (57 to 96)97% (71 to 100)High tuberculosis burden = No (33; 15,272)^b^85% (81 to 89)99% (98 to 99)85% (55 to 96)99% (89 to 100)**Xpert MTB/RIF accuracy for tuberculosis detection by TB/HIV burden**^a^High TB/HIV burden = Yes (42; 24,412)^b^83% (80 to 87)97% (95 to 98)84% (51 to 96)97% (74 to 100)High TB/HIV burden = No (30; 12,825)^b^88% (84 to 90)99% (98 to 99)88% (67 to 96)99% (86 to 100)**Xpert MTB/RIF accuracy for tuberculosis detection by setting that ran the test**Xpert run at point of care or in a peripheral setting (10; 5816)83% (75 to 89)97% (93 to 99)83% (52 to 96)97% (66 to 100)Central or intermediate laboratory (60; 31,421)85% (83 to 88)98% (97 to 98)85% (57 to 96)98% (80 to 100)**Xpert MTB/RIF accuracy for tuberculosis detection by median tuberculosis prevalence**Prevalence \> 26% (35; 17,983)89% (87 to 91)96% (94 to 97)89% (69 to 97)96% (72 to 100)Prevalence ≤ 26% (35; 19,254)79% (75 to 83)99% (98 to 99)79% (51 to 93)99% (89 to 100)[^5]

*B.1.d. Xpert MTB/RIF versus Xpert Ultra for detection of PTB by smear status, direct comparison*

One study compared Xpert Ultra and Xpert MTB/RIF for detection of PTB by smear status against a reference standard of multiple cultures ([@CD009593-bbs2-0023]). In smear‐positive participants, sensitivities (95% CI) of Xpert Ultra and Xpert MTB/RIF were identical at 99% (97% to 100%) (323 participants). In smear‐negative participants, Xpert Ultra yielded higher sensitivity at 63% (95% CI 54% to 71%), compared to Xpert MTB/RIF sensitivity of 46% (37% to 55%), and lower specificity at 96% (94% to 97%), compared to Xpert MTB/RIF specificity of 98% (97% to 99%) ([Figure 15](#CD009593-fig-0015){ref-type="fig"}).Figure 15Forest plots comparing Xpert MTB/RIF and Xpert Ultra sensitivity and specificity for detection of pulmonary tuberculosis in smear‐positive and smear‐negative participants. The individual studies are ordered by decreasing sensitivity. The squares represent the sensitivity and specificity of one study, the black line its CI. TP = true positive; FP = false positive; FN = false negative; TN = true negative.

##### B.2. Xpert MTB/RIF for detection of PTB by HIV status {#CD009593-sec5-0007}

###### B.2.a. Xpert MTB/RIF accuracy in HIV‐negative people {#CD009593-sec6-0006}

In HIV‐negative participants, Xpert MTB/RIF sensitivity estimates ranged from 56% to 100% and specificity estimates from 95% to 100% ([Figure 16](#CD009593-fig-0016){ref-type="fig"}). We included all studies that provided data in this analysis. In HIV‐negative participants, Xpert MTB/RIF pooled sensitivity and specificity (95% CrI) were 89% (85% to 92%) and 98% (97% to 99%), (18 studies, 5118 participants).Figure 16Forest plots of Xpert MTB/RIF sensitivity and specificity for detection of pulmonary tuberculosis in HIV‐negative participants. The individual studies are ordered by decreasing sensitivity. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive.

###### B.2.b. Xpert MTB/RIF accuracy in HIV‐positive people {#CD009593-sec6-0007}

In HIV‐positive participants, Xpert MTB/RIF sensitivity estimates ranged from 67% to 100% and specificity estimates from 92% to 100% ([Figure 17](#CD009593-fig-0017){ref-type="fig"}). We included all studies that provided data in this analysis. In HIV‐positive participants, Xpert MTB/RIF pooled sensitivity and specificity (95% CrI) were 77% (71% to 82%) and 98% (98% to 99%), (30 studies, 9589 participants).Figure 17Forest plots of Xpert MTB/RIF sensitivity and specificity for detection of pulmonary tuberculosis in HIV‐positive participants. The individual studies are ordered by decreasing sensitivity. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive.

###### B.2.c. Xpert MTB/RIF accuracy by HIV status, studies that provided data for both HIV‐negative and HIV‐positive individuals {#CD009593-sec6-0008}

We limited this analysis to 14 studies that reported results for HIV‐negative and HIV‐positive participants within the same study ([@CD009593-bbs2-0009]; [@CD009593-bbs2-0013]; [@CD009593-bbs2-0011]; [@CD009593-bbs2-0012]; [@CD009593-bbs2-0014]; [@CD009593-bbs2-0015]; [@CD009593-bbs2-0023]; [@CD009593-bbs2-0027]; [@CD009593-bbs2-0028]; [@CD009593-bbs2-0047]; [@CD009593-bbs2-0068]; [@CD009593-bbs2-0069]; [@CD009593-bbs2-0075]; [@CD009593-bbs2-0085]). In HIV‐negative participants, Xpert MTB/RIF pooled sensitivity was 88% (83% to 92%), higher than the sensitivity of 81% (75% to 86%) in HIV‐positive participants, although the 95% CrIs overlapped. In HIV‐negative participants, Xpert MTB/RIF pooled specificity was 98% (97% to 99%), the same as the pooled specificity of 98% (97% to 99%) in HIV‐positive participants ([Table 5](#CD009593-tbl-0005){ref-type="table"}; [Figure 18](#CD009593-fig-0018){ref-type="fig"}).Figure 18Forest plots of Xpert MTB/RIF sensitivity and specificity for detection of pulmonary tuberculosis, HIV‐negative and HIV‐positive participants compared within the same study. The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive.

[Figure 19](#CD009593-fig-0019){ref-type="fig"} displays the summary ROC plot comparing Xpert MTB/RIF accuracy in HIV‐negative and HIV‐positive people in studies that involved both subgroups. The test demonstrated higher accuracy in HIV‐negative people.Figure 19Summary plots of Xpert MTB/RIF sensitivity and specificity for detection of pulmonary tuberculosis in HIV‐negative people (red) and HIV‐positive people (black). Each individual study is represented by an empty square. The of the square is proportional to the sample size of the study such that larger studies are represented by larger squares. The filled circle is the pooled median estimate for sensitivity and specificity. The solid curve represents the 95% credible region around the summary estimate; the dashed curves represent the 95% prediction region.

*B.2.d. Xpert MTB/RIF versus Xpert Ultra for detection of PTB by HIV status, direct comparison*

One study compared Xpert Ultra and Xpert MTB/RIF for detection of PTB by HIV status against a reference standard of multiple cultures ([@CD009593-bbs2-0023]). In HIV‐negative participants, Xpert Ultra sensitivity (95% CI) was 91% (86% to 95%) compared to Xpert MTB/RIF sensitivity of 90% (84% to 94%). In HIV‐positive participants, Xpert Ultra yielded a higher sensitivity at 90% (82% to 94%), compared to Xpert MTB/RIF sensitivity of 77% (68% to 84%), and a lower specificity at 96% (93% to 98%) compared to Xpert MTB/RIF specificity of 99% (98% to 100%) ([Figure 20](#CD009593-fig-0020){ref-type="fig"}).Figure 20Forest plots comparing Xpert MTB/RIF and Xpert Ultra sensitivity and specificity for detection of pulmonary tuberculosis in HIV‐negative and HIV‐positive participants. The individual studies are ordered by decreasing sensitivity. The squares represent the sensitivity and specificity of one study, the black line its CI. TP = true positive; FP = false positive; FN = false negative; TN = true negative.

##### B.3. Xpert MTB/RIF accuracy for detection of PTB in participants with a history of tuberculosis or previous tuberculosis treatment {#CD009593-sec5-0008}

###### B.3.a. Xpert MTB/RIF accuracy in participants with a history of tuberculosis {#CD009593-sec6-0009}

Eleven studies (4196 participants) reported a higher percentage (\> 25%) of participants with a history of tuberculosis ([@CD009593-bbs2-0001]; [@CD009593-bbs2-0002]; [@CD009593-bbs2-0011]; [@CD009593-bbs2-0034]; [@CD009593-bbs2-0036]; [@CD009593-bbs2-0041]; [@CD009593-bbs2-0059]; [@CD009593-bbs2-0065]; [@CD009593-bbs2-0070]; [@CD009593-bbs2-0071]; [@CD009593-bbs2-0085]) and 16 studies (8205 participants) reported a lower percentage (≤ 25%) of participants with a history of tuberculosis ([@CD009593-bbs2-0006]; [@CD009593-bbs2-0007]; [@CD009593-bbs2-0009]; [@CD009593-bbs2-0010]; [@CD009593-bbs2-0011]; [@CD009593-bbs2-0013]; [@CD009593-bbs2-0016]; [@CD009593-bbs2-0023]; [@CD009593-bbs2-0027]; [@CD009593-bbs2-0029]; [@CD009593-bbs2-0040]; [@CD009593-bbs2-0047]; [@CD009593-bbs2-0049]; [@CD009593-bbs2-0076]; [@CD009593-bbs2-0081]; [@CD009593-bbs2-0092]). In studies with a higher percentage of participants with previous tuberculosis, Xpert MTB/RIF pooled sensitivity (95% CrI) was 86% (82% to 89%), similar to the pooled sensitivity of 85% (81% to 89%) in studies with a lower percentage of participants with previous tuberculosis. In studies with a higher percentage of participants with previous tuberculosis, Xpert MTB/RIF pooled specificity was 97% (95% to 98%), lower than the specificity of 99% (98% to 99%) in studies with a lower percentage of participants with previous tuberculosis ([Table 5](#CD009593-tbl-0005){ref-type="table"}).

###### B.3.b. Xpert MTB/RIF accuracy in participants who had received previous tuberculosis treatment {#CD009593-sec6-0010}

We identified three studies involving 999 participants that preferentially enrolled participants who had received previous tuberculosis treatment ([@CD009593-bbs2-0050]; [@CD009593-bbs2-0051]; [@CD009593-bbs2-0067]). Sensitivity estimates ranged from 92% to 98% and specificity estimates from 75% to 92%. Xpert MTB/RIF pooled sensitivity and specificity (95% CrI) were 94% (87% to 97%) and 89% (75% to 95%) respectively. Xpert MTB/RIF pooled specificity was considerably lower than the pooled specificity of 98% (97% to 98%) in the primary analysis (70 studies).

##### B.4. Xpert MTB/RIF accuracy by tuberculosis burden {#CD009593-sec5-0009}

There were 39 studies (21,965 participants) conducted in high tuberculosis burden countries and 33 studies (5272 participants) conducted in countries not considered to be high tuberculosis burden. In countries with high tuberculosis burden, Xpert MTB/RIF pooled sensitivity (95% CrI) was 86% (82% to 89%), similar to the pooled sensitivity of 85% (81% to 89%) in countries not considered to be high tuberculosis burden. In countries with high tuberculosis burden, Xpert MTB/RIF pooled specificity was 97% (95% to 98%), lower than the pooled specificity of 99% (98% to 99%) in countries not considered to be high tuberculosis burden ([Table 5](#CD009593-tbl-0005){ref-type="table"}).

##### B.5. Xpert MTB/RIF accuracy by TB/HIV burden {#CD009593-sec5-0010}

There were 42 studies (24,412 participants) conducted in high TB/HIV burden countries and 30 studies (12,825 participants) conducted in countries not considered to be high TB/HIV burden. In countries with high TB/HIV burden, Xpert MTB/RIF pooled sensitivity (95% CrI) was 83% (80% to 87%), lower than the pooled sensitivity of 88% (84% to 90%) in countries not considered to be high TB/HIV burden, although there was considerable overlap in the Crls around these estimates. In countries with high TB/HIV burden, Xpert MTB/RIF pooled specificity was 97% (95% to 98%), lower than the pooled specificity of 99% (98% to 99%) in countries not considered to be high TB/HIV burden ([Table 5](#CD009593-tbl-0005){ref-type="table"}).

##### B.6. Xpert MTB/RIF accuracy by setting that ran the test {#CD009593-sec5-0011}

There were 10 studies (5816 participants) that ran Xpert MTB/RIF at point of care or in a peripheral setting ([@CD009593-bbs2-0002]; [@CD009593-bbs2-0015]; [@CD009593-bbs2-0017]; [@CD009593-bbs2-0019]; [@CD009593-bbs2-0025]; [@CD009593-bbs2-0027]; [@CD009593-bbs2-0031]; [@CD009593-bbs2-0037]; [@CD009593-bbs2-0077]; [@CD009593-bbs2-0087]), and 60 studies (31,421 participants) that ran Xpert MTB/RIF in an intermediate or central‐level laboratory. In studies running Xpert MTB/RIF at point of care or in a peripheral setting, the pooled sensitivity (95% CrI) was 83% (75% to 89%), lower than the sensitivity of 85% (83% to 88%) in studies running Xpert MTB/RIF in an intermediate or central‐level laboratory. In peripheral settings, the pooled specificity was 97% (94% to 99%), lower than the pooled specificity of 98% (97% to 98%) in more advanced laboratories. However, there was considerable overlap in Crls around these accuracy estimates ([Table 5](#CD009593-tbl-0005){ref-type="table"}).

##### B.7. Xpert MTB/RIF accuracy by tuberculosis prevalence {#CD009593-sec5-0012}

The prevalence of PTB cases confirmed by culture in the studies ranged from 0.8% ([@CD009593-bbs2-0018]) to 100% ([@CD009593-bbs2-0024]). Based on a median tuberculosis prevalence of 26%, in settings with tuberculosis prevalence above 26%, Xpert MTB/RIF pooled sensitivity (95% CrI) was 89% (87% to 91%), higher than the pooled sensitivity of 79% (75% to 83%) in settings with tuberculosis prevalence at or below 26%. The corresponding pooled specificities were 96% (94% to 97%) and 99% (98% to 99%) ([Table 5](#CD009593-tbl-0005){ref-type="table"}).

#### Uninterpretable results, detection of PTB {#CD009593-sec4-0012}

Among 47 studies involving 31,979 tests, the pooled proportion of uninterpretable test results for Xpert MTB/RIF was very low, at 1.1% (0.7% to 1.5%). In the study comparing Xpert Ultra and Xpert MTB/RIF, of 2001 specimens initially tested, uninterpretable results were found for 79 specimens (4%) with Xpert Ultra and 39 specimens (2%) with Xpert MTB/RIF. After exclusion of errors related to instrumentation, uninterpretable results were found for 64 specimens (3%) with Xpert Ultra and 28 specimens (1%) with Xpert MTB/RIF ([@CD009593-bbs2-0023]).

### II. Detection of rifampicin resistance {#CD009593-sec3-0023}

#### A. Xpert MTB/RIF for detection of rifampicin resistance {#CD009593-sec4-0013}

##### 1.a. Primary analysis, Xpert MTB/RIF {#CD009593-sec5-0013}

The 57 studies involved 8287 specimens, of which 1775 were rifampicin‐resistant, median 88 specimens (range 1 to 250). Six studies accounted for most (63%, 1127/1775) of the rifampicin‐resistant specimens ([@CD009593-bbs2-0011]; [@CD009593-bbs2-0012]; [@CD009593-bbs2-0023]; [@CD009593-bbs2-0031]; [@CD009593-bbs2-0037]; [@CD009593-bbs2-0078]) ([Figure 21](#CD009593-fig-0021){ref-type="fig"}). Although there was heterogeneity in sensitivity estimates (ranging from 75% to 100%), in general there was less variability among studies with a higher number of rifampicin‐resistant specimens. Specificity showed less variability than sensitivity, ranging from 83% to 100%.Figure 21Forest plots of Xpert MTB/RIF sensitivity and specificity for detection of rifampicin resistance. The individual studies are ordered by decreasing sensitivity. The squares represent the sensitivity and specificity of one study, the black line its CI. TP = true positive; FP = false positive; FN = false negative; TN = true negative.

Xpert MTB/RIF pooled sensitivity and specificity (95% CrI) were 96% (94% to 97%) and 98% (98% to 99%) (48 studies, 8020 participants) ([Table 4](#CD009593-tbl-0004){ref-type="table"}).

##### 1.b. Primary analysis, Xpert Ultra {#CD009593-sec5-0014}

One study ([@CD009593-bbs2-0023]) evaluated Xpert Ultra and Xpert MTB/RIF in the same participants for detection of rifampicin resistance. The sensitivity and specificity estimates were similar. Xpert Ultra sensitivity and specificity (95% CI) were 95% (90% to 98%) and 98% (97% to 99%) respectively (551 specimens, including 175 rifampicin‐resistant specimens); while Xpert MTB/RIF sensitivity and specificity were 95% (91% to 98%) and 98% (96% to 99%) respectively (552 specimens, including 175 rifampicin‐resistant specimens).

#### B. Investigations of heterogeneity, rifampicin resistance {#CD009593-sec4-0014}

##### B.1. Xpert MTB/RIF accuracy for detection of rifampicin resistance by MDR‐TB burden {#CD009593-sec5-0015}

In settings with high MDR‐TB burden, Xpert MTB/RIF pooled sensitivity (95% Crl) was 95% (93% to 97%), lower than the pooled sensitivity of 97% (93% to 99%) for studies not in the high MDR‐TB category. The corresponding pooled specificities (95% Crl) were 98% (96% to 99%) and 99% (95% CrI 98% to 99%) ([Table 6](#CD009593-tbl-0006){ref-type="table"}). For both sensitivity and specificity, the 95% CrIs in the two groups overlapped, suggesting that MDR‐TB burden did not have an effect on the accuracy estimates.Table 3Xpert MTB/RIF for detection of rifampicin resistance, investigations of heterogeneity**Type of analysis (Number of studies; participants)Median pooled sensitivity (95% CrI)Median pooled specificity (95% CrI)Median predicted sensitivity (95% CrI)Median predicted specificity (95% CrI)Xpert MTB/RIF accuracy for rifampicin resistance detection by MDR‐TB burden**High MDR‐TB burden = Yes (24; 5553)95% (93 to 97)98% (96 to 99)95% (85 to 99)98% (85 to 100)High MDR‐TB burden = No (25; 2467)97% (93 to 99)99% (98 to 99)97% (76 to 100)99% (95 to 100)**Xpert MTB/RIF accuracy for rifampicin resistance detection by history of previous tuberculosis treatment**Previously‐treated tuberculosis^a^ = Yes (7; 1062)98% (94 to 99)97% (93 to 99)98% (87 to 100)97% (81 to 100)Previously‐treated tuberculosis = No (41, 6958)95% (93 to 97)99% (98 to 99)95% (86 to 99)98% (91 to 100)**Xpert MTB/RIF accuracy for detection of rifampicin resistance by median tuberculosis prevalence**Prevalence \> 11% (24; 5505)96% (94 to 97)97% (96 to 98)96% (87 to 99)97% (88 to 99)Prevalence ≤ 11% (24; 2515)94% (89 to 97)99% (99 to 100)94% (80 to 99)99% (96 to 100)[^6]

##### B.2. Xpert MTB/RIF accuracy for detection of rifampicin resistance by previous tuberculosis treatment {#CD009593-sec5-0016}

Several studies designed to enrol participants suspected of MDR‐TB had high percentages of participants previously treated for tuberculosis ([@CD009593-bbs2-0046]; [@CD009593-bbs2-0048]; [@CD009593-bbs2-0050]; [@CD009593-bbs2-0052]; [@CD009593-bbs2-0060]; [@CD009593-bbs2-0067]; [@CD009593-bbs2-0094]). In these studies (7 studies, 1062 participants), Xpert MTB/RIF pooled sensitivity at 98% (95% CrI 94% to 99%) was higher than the pooled sensitivity of 95% (93% to 97%) in studies that did not preferentially enrol previously treated participants (41 studies, 6958 participants); and conversely, pooled specificity was lower at 97% (93% to 99%) than the pooled specificity of 99% (95% CrI 98% to 99%) in studies that did not preferentially enrol previously treated participants. However, for both sensitivity and specificity estimates the CrIs overlapped, suggesting that previous tuberculosis treatment did not have an effect on Xpert MTB/RIF accuracy for detection of rifampicin resistance ([Table 6](#CD009593-tbl-0006){ref-type="table"}).

##### B.3. Xpert MTB/RIF accuracy for detection of rifampicin resistance by prevalence of rifampicin resistance {#CD009593-sec5-0017}

Based on a median prevalence of rifampicin resistance of 11%, in studies with prevalence of rifampicin resistance above 11%, Xpert MTB/RIF pooled sensitivity (95% CrI ) was 96% (94% to 97%), higher than the pooled sensitivity of 94% (95% CrI 89% to 97%) for studies with prevalence of rifampicin resistance at or below 11%, although the CrIs overlapped. The corresponding pooled specificities were 97% (96% to 98%) and 99% (99% to 100%) ([Table 6](#CD009593-tbl-0006){ref-type="table"}).

#### Indeterminate results, rifampicin resistance {#CD009593-sec4-0015}

Among 21 studies involving 3591 tests, the pooled proportion of Xpert MTB/RIF indeterminate test results was very low, at 0.9% (0.4% to 1.5%). In the study comparing Xpert Ultra and Xpert MTB/RIF, of 684 specimens tested, indeterminate results were found for 16 specimens (2%) with Xpert Ultra and four specimens (1%) with Xpert MTB/RIF ([@CD009593-bbs2-0023]).

### Sensitivity analyses {#CD009593-sec3-0024}

For Xpert MTB/RIF for detection of PTB, we undertook sensitivity analyses by limiting inclusion in the meta‐analysis to:

Studies that explicitly represented the use of the index test for the diagnosis of individuals thought to have tuberculosis. We excluded studies that involved HIV‐positive participants irrespective of tuberculosis symptoms;Studies where a single specimen yielded a single Xpert MTB/RIF result for a given participant. We excluded studies that included more specimens than participants;Studies that only included untreated participants;Studies that used liquid culture as the reference standard;Studies where a consecutive or random sample of participants were enrolled;Studies where the reference standard was blinded;Studies that only used fresh specimens;Studies that accounted for all participants in the analysis. We excluded studies where we answered 'no\' or 'unclear\' to the QUADAS‐2 Flow and Timing signalling question: *Were all patients included in the analysis?;*Studies with exclusion of two large multicentre studies ([@CD009593-bbs2-0011]; [@CD009593-bbs2-0012]).

These sensitivity analyses made little difference to any of the findings ([Table 7](#CD009593-tbl-0007){ref-type="table"}).Table 4Sensitivity analyses, Xpert MTB/RIF**Type of analysis (Number of studies; participants)Median pooled sensitivity (95% Crl)Median pooled specificity (95% Crl)Median predicted sensitivity (95% Crl)Median predicted specificity (95% Crl)**Xpert MTB/RIF sensitivity and specificity for tuberculosis detection in studies with unselected patients (70; 37,237)85% (82 to 88)98% (97 to 98)85% (56 to 96)98% (78 to 100)Studies that explicitly represented the use of the index test for the diagnosis of individuals with signs and symptoms of tuberculosis (presumptive tuberculosis) (62; 33,844)86% (84 to 89)98% (97 to 98)86% (54 to 97)98% (78 to 100)Studies where a single specimen yielded a single Xpert MTB/RIF result for a given participant (53; 27,306)85% (81 to 87)98% (97 to 98)85% (50 to 97)97% (80 to 100)Studies that included only untreated participants (36; 15,502)82% (79 to 86)98% (98 to 99)83% (52 to 96)98% (90 to 100)Studies that used liquid culture as the reference standard (24; 12,548)83% (78 to 88)97% (95 to 98)83% (48 to 97)97% (65 to 100)Studies where consecutive or random participants were selected (52; 28,633)84% (80 to 87)98% (97 to 98)84% (50 to 96)98% (78 to 100)Studies where the reference standard was blinded (56; 31,228)84% (81 to 87)97% (96 to 98)85% (50 to 97)97% (77 to 100)Studies using fresh specimens (56; 29,090)86% (83 to 88)98% (97 to 98)86% (50 to 97)98% (75 to 100)Studies that accounted for all participants in the analysis (59; 27,128)85% (82 to 88)98% (97 to 98)85% (49 to 97)98% (76 to 100)Excluding [@CD009593-bbs2-0011] and [@CD009593-bbs2-0012] (68; 31889)85% (82 to 87)98% (97 to 98)85% (55 to 96)98% (77 to 100)[^7]

### Other analyses {#CD009593-sec3-0025}

#### NTM {#CD009593-sec4-0016}

Twenty‐eight studies evaluating Xpert MTB/RIF and involving 8901 participants provided data on a variety of NTMs that grew from the specimens tested, to look for evidence of cross‐reactivity: one NTM ([@CD009593-bbs2-0002]); four NTMs ([@CD009593-bbs2-0005]); two NTMs ([@CD009593-bbs2-0008]); 50 NTMs ([@CD009593-bbs2-0010]); one NTM ([@CD009593-bbs2-0017]); 16 NTMs ([@CD009593-bbs2-0021]); three NTMs ([@CD009593-bbs2-0022]); 12 NTMs ([@CD009593-bbs2-0035]); one NTM ([@CD009593-bbs2-0038]); nine NTMs ([@CD009593-bbs2-0043]); 16 NTMs ([@CD009593-bbs2-0042]); 40 NTMs ([@CD009593-bbs2-0044]); 14 NTMs ([@CD009593-bbs2-0046]); 95 NTMs ([@CD009593-bbs2-0047]); 20 NTMs ([@CD009593-bbs2-0057]); four NTMs ([@CD009593-bbs2-0064]); 10 NTMs ([@CD009593-bbs2-0068]); 45 NTMs ([@CD009593-bbs2-0069]); 122 NTMs ([@CD009593-bbs2-0072]); seven NTMs ([@CD009593-bbs2-0073]); five NTMs ([@CD009593-bbs2-0075]); three NTMs ([@CD009593-bbs2-0081]); 19 NTMs ([@CD009593-bbs2-0082]); two NTMs ([@CD009593-bbs2-0084]); eight NTMs ([@CD009593-bbs2-0085]); three NTMs ([@CD009593-bbs2-0089]); 22 NTMs ([@CD009593-bbs2-0091]); and two NTMs ([@CD009593-bbs2-0095]). Among these 28 studies comprising 536 NTMs, Xpert MTB/RIF was positive in 16 specimens that grew NTMs, pooled proportion 2.0% (0.4% to 4.4%). NTM data for Xpert Ultra were not reported.

Discussion {#CD009593-sec1-0006}
==========

This updated Cochrane Review on the diagnostic accuracy of Xpert MTB/RIF (Xpert MTB/RIF) and Xpert MTB/RIF Ultra (Xpert Ultra) for detection of tuberculosis and rifampicin resistance in adults summarizes the current literature and integrates 77 new studies (81% of the total 95 included studies), identified since the previous Cochrane Review ([@CD009593-bbs2-0401]). The findings in this update are consistent with those reported previously.

Summary of main results {#CD009593-sec2-0013}
-----------------------

For detection of PTB, Xpert MTB/RIF sensitivity and specificity were 85% and 98%.Xpert MTB/RIF sensitivity was 98% for smear‐positive, culture‐positive tuberculosis, and 67% for smear‐negative, culture‐positive tuberculosis.Xpert MTB/RIF sensitivity for PTB was 88% in HIV‐negative people and 81% in HIV‐positive people.For detection of PTB, the pooled proportion of Xpert MTB/RIF uninterpretable test results was very low.For detection of rifampicin resistance, Xpert MTB/RIF sensitivity and specificity were 96% and 98%.For detection of rifampicin resistance, the pooled proportion of Xpert MTB/RIF indeterminate test results was very low.In the one study that directly compared Xpert Ultra and Xpert MTB/RIF, Xpert Ultra yielded a higher sensitivity (88%) than Xpert MTB/RIF (83%), and a lower specificity (96%) than Xpert MTB/RIF (98%).In the one study that directly compared Xpert Ultra and Xpert MTB/RIF, for detection of smear‐negative culture‐positive tuberculosis, Xpert Ultra yielded a higher sensitivity (63%) than Xpert MTB/RIF (46%), and a lower specificity (96%) than Xpert MTB/RIF (98%).In the one study that directly compared Xpert Ultra and Xpert MTB/RIF, for detection of PTB in HIV‐positive people, Xpert Ultra yielded a higher sensitivity (90%) than Xpert MTB/RIF (77%), and a lower specificity (96%) than Xpert MTB/RIF (99%).

### Xpert MTB/RIF for PTB {#CD009593-sec3-0026}

Results of these studies indicate that, in theory, for a population of 1000 people where 100 have tuberculosis on culture, 103 would be Xpert MTB/RIF‐positive and 18 (17%) would not have tuberculosis (false‐positives); 897 would be Xpert MTB/RIF‐negative and 15 (2%) would have tuberculosis (false‐negatives) ([Table 1](#CD009593-tbl-0001){ref-type="table"}).

### Xpert Ultra for PTB {#CD009593-sec3-0027}

Results of these studies indicate that, in theory, for a population of 1000 people where 100 have tuberculosis on culture, 124 would be Xpert Ultra‐positive; of these, 36 (29%) would not have tuberculosis (false‐positives); and 876 would be Xpert Ultra‐negative; of these, 12 (1%) would have tuberculosis (false‐negatives) ([Table 1](#CD009593-tbl-0001){ref-type="table"}).

### Xpert MTB/RIF for rifampicin resistance {#CD009593-sec3-0028}

Results of these studies indicate that, in theory, for a population of 1000 people where 100 have rifampicin‐resistant tuberculosis, 114 would be positive for rifampicin‐resistant tuberculosis; of these 18 (16%) would not have rifampicin resistance (false‐positives); and 886 would be would be negative for rifampicin‐resistant tuberculosis; of these, four (0.4%) would have rifampicin resistance (false‐negatives) ([Table 2](#CD009593-tbl-0002){ref-type="table"}).

### Xpert Ultra for rifampicin resistance {#CD009593-sec3-0029}

Results of these studies indicate that, in theory, for a population of 1000 people where 100 have rifampicin‐resistant tuberculosis, 113 would be positive for rifampicin‐resistant tuberculosis; of these, 18 (16%) would not have rifampicin resistance (false‐positives); and 887 would be negative for rifampicin‐resistant tuberculosis; of these, five (1%) would have rifampicin resistance (false‐negatives) ([Table 2](#CD009593-tbl-0002){ref-type="table"}).

### Xpert MTB/RIF performance in different subgroups and settings {#CD009593-sec3-0030}

Xpert MTB/RIF detects DNA sequences of *M tuberculosis* after amplification and has a lower limit of detection of 131 CFUs/mL ([@CD009593-bbs2-0029]). The cycle threshold value (C~T~) is the number of PCR cycles after which Xpert MTB/RIF probes successfully detect *M tuberculosis* DNA in a given sample. Xpert MTB/RIF C~T~ values are strongly correlated with AFB smear status ([@CD009593-bbs2-0203]). The lower sensitivity of Xpert MTB/RIF in individuals with AFB smear‐negative PTB is related to the lower bacillary burden and higher associated C~T~ value compared to individuals with AFB smear‐positive PTB. Individuals with PTB and HIV co‐infection are more likely to have smear‐negative tuberculosis, which implies a lower bacillary burden and higher mean C~T~ values on Xpert testing ([@CD009593-bbs2-0321]; [@CD009593-bbs2-0203]), and this is the likely mechanism for the lower sensitivity of Xpert MTB/RIF for the diagnosis of tuberculosis in people living with HIV.

In individuals with a history of treatment for tuberculosis, we found that Xpert MTB/RIF pooled specificity (89%) was lower than the pooled specificity in the primary analysis (98%). This is consistent with findings from the literature that Xpert MTB/RIF may be positive at the end of tuberculosis treatment despite cure ([@CD009593-bbs2-0338]; [@CD009593-bbs2-0289]; [@CD009593-bbs2-0290]), and may rarely remain positive for up to five years after tuberculosis treatment ([@CD009593-bbs2-0325]). Among individuals with a history of tuberculosis treatment, the included Xpert Ultra paper found that specificity improved as time since tuberculosis treatment increased, and approximated to that of participants without a history of tuberculosis treatment when elapsed time was seven years ([@CD009593-bbs2-0023]). Xpert MTB/RIF does not distinguish dead from living bacilli and it is not surprising at the end of treatment to have Xpert MTB/RIF‐positive results (false‐positives) and hence lower specificity. C~T~ values may help in differentiating between true‐positive and false‐positive Xpert MTB/RIF results in people with a prior history of tuberculosis, with lower values in those with tuberculosis recurrence compared to those with false‐positive Xpert MTB/RIF ([@CD009593-bbs2-0289]; [@CD009593-bbs2-0290]).

In countries with high TB/HIV burden, we found that Xpert MTB/RIF pooled specificity (97%) was lower than the pooled specificity (99%) in countries not considered to have a high TB/HIV burden. This difference in specificity may be due to other factors, such as the laboratory level of MTB/RIF testing rather than the presence of HIV infection, as specificity in HIV‐positive and HIV‐negative individuals was similar. Supporting the importance of laboratory setting, Xpert MTB/RIF specificity was lower at point of care and in peripheral laboratories compared to intermediate and central laboratories.

For prevalence of tuberculosis, in comparing settings with a higher or lower prevalence of tuberculosis, for both Xpert MTB/RIF sensitivity and specificity, we found that the 95% credible intervals (CrIs) in the two groups did not overlap, suggesting an association of prevalence of tuberculosis with the accuracy estimates. In comparing settings with a higher or lower prevalence of rifampicin resistance, we found that the Crls for specificity did not overlap, suggesting an association of prevalence of rifampicin resistance with the specificity estimates. Changes in disease prevalence have often been found to be associated with other important changes, such as changes in the disease spectrum, which may affect diagnostic accuracy estimates ([@CD009593-bbs2-0352]).

Sensitivity and specificity depend on the performance of a test in a particular situation, defined by the population, the setting, and prior testing. In a different population or setting or with a different testing strategy, the sensitivity and specificity are likely to change ([@CD009593-bbs2-0323]). However, our sensitivity analyses of different specimen numbers and conditions did not change Xpert MTB/RIF performance. We did find that among specimens that were culture‐positive for NTM, false‐positive Xpert MTB/RIF results occurred in 2.0% (0.4% to 4.4%). Although there have been suggestions that certain nontuberculous mycobacterial species (e.g. *M malmoense*) may give false‐positive Xpert MTB/RIF results due to weak cross hybridization ([@CD009593-bbs2-0099]), the false‐positive rate in specimens culture‐positive for NTM was similar to the overall frequency of false positives.

Our systematic review included only one study that evaluated Xpert Ultra ([@CD009593-bbs2-0023]). This multicentre study found that Xpert Ultra yielded higher sensitivity at 88% (95% CI 85% to 91%) compared to Xpert MTB/RIF sensitivity of 83% (79% to 86%), but lower specificity of 96% (94% to 97%) compared to Xpert MTB/RIF specificity of 98% (97% to 99%) ([@CD009593-bbs2-0023]). This study performed several post hoc analyses that evaluated the impact of changing the classification of Xpert Ultra trace calls, which in the primary analysis were considered positive for the identification of *M tuberculosis*. Reclassifying all trace calls as a negative result increased Xpert Ultra specificity and decreased its sensitivity. Reclassifying trace calls as negative in participants with a history of tuberculosis or repeating trace calls with the second result determining the ultimate classification, both resulted in sensitivity estimates close to those observed in the primary analysis with only slightly compromised specificity.

On 11 October 2018, we performed a literature search specifically for studies that evaluated Xpert Ultra, but did not identify any additional studies. Following this search and after the end date for data analysis, we identified one additional study ([@CD009593-bbs2-0320]). Although not included in the main sections of this review, we provide a brief summary of this study here. [@CD009593-bbs2-0320] compared Xpert MTB/RIF and Xpert Ultra in 237 participants with presumptive tuberculosis who were evaluated at three outpatient clinics in South Africa. Similar to the results in [@CD009593-bbs2-0023], this multicentre study found that Xpert Ultra yielded higher sensitivity at 89% (78% to 96%), compared to Xpert MTB/RIF sensitivity of 82% (70% to 91%), but lower specificity at 96% (92% to 98%) compared to Xpert MTB/RIF specificity of 100% (98% to 100%). Importantly, in both studies, Xpert Ultra had superior sensitivity for smear‐negative tuberculosis: in [@CD009593-bbs2-0023], Xpert Ultra sensitivity was 63% (54% to 71%) versus Xpert MTB/RIF 46% (37% to 55%); and in [@CD009593-bbs2-0320], Xpert Ultra sensitivity was 65% (38% to 86%) versus Xpert MTB/RIF 41% (18% to 67%). In both studies, Xpert Ultra\'s increased sensitivity for smear‐negative tuberculosis was accompanied by decreased specificity, 96% in both studies, versus Xpert MTB/RIF specificity of 98% in [@CD009593-bbs2-0023] and 100% in [@CD009593-bbs2-0320]. In addition, in [@CD009593-bbs2-0023], in HIV‐positive participants Xpert Ultra had higher sensitivity (90%) than Xpert MTB/RIF (77%), again accompanied by a decrease in specificity (Xpert Ultra specificity of 96% versus Xpert MTB/RIF specificity of 99%). Xpert Ultra and Xpert MTB/RIF had similar accuracy for rifampicin resistance. As Xpert Ultra is rolled out globally, these differences in accuracy may have important ramifications depending on tuberculosis prevalence ([@CD009593-bbs2-0350]).

Our prespecified subgroup analyses included an assessment of whether Xpert MTB/RIF accuracy differs by the setting in which the test was performed. i.e. point of care or peripheral settings compared with central and intermediate laboratories. [@CD009593-bbs2-0087] found no difference in Xpert MTB/RIF accuracy when it was performed by trained nurses in a primary care setting compared to performance by laboratory technicians at a centralised facility. When we compared findings from studies by test setting, we found the pooled point estimates of Xpert MTB/RIF sensitivity and specificity to be lower in peripheral settings than in central and intermediate laboratories. However, there was considerable overlap in the credible intervals of these estimates and there is insufficient evidence to suggest a difference in Xpert MTB/RIF accuracy by setting. One of the confounding factors may be participant spectrum, the direction of which we cannot predict with certainty.

We acknowledge that patient health outcomes are clearly important to patients, to decision‐makers, and the wider tuberculosis community. We could not, however, systematically address outcomes in addition to diagnostic accuracy, as they would have required a different methodology. Nonetheless, we are aware of seven trials that have examined the impact of Xpert MTB/RIF on mortality in relation to smear microscopy or diagnostic algorithms reflective of usual practice ([@CD009593-bbs2-0014]; [@CD009593-bbs2-0334]; [@CD009593-bbs2-0336]; [@CD009593-bbs2-0356]; [@CD009593-bbs2-0359]; [@CD009593-bbs2-0087]; [@CD009593-bbs2-0380]). All of these trials were conducted in routine healthcare settings. However, only two of these trials have shown a statistically significant impact on mortality ([@CD009593-bbs2-0359]; [@CD009593-bbs2-0380]). [@CD009593-bbs2-0359] reported a significant impact on all‐cause mortality in people with clinically advanced HIV when Xpert MTB/RIF testing at point of care was compared to LED microscopy among newly‐diagnosed HIV‐positive adults with presumptive tuberculosis in primary health clinics in Malawi, with an incidence rate ratio (RR) of 0.43% (95% CI 0.22% to 0.87%). [@CD009593-bbs2-0380] reported a lower tuberculosis‐attributed death rate in the Xpert arm compared to the smear microscopy arm (2.3% versus 3.8%) among adults with presumptive tuberculosis in primary health clinics in Brazil. In particular, this trial showed an association between HIV positivity and increased risk of tuberculosis‐attributed death: adjusted odds ratio (aOR) 14.1 (95% CI 9.1% to 26.5%), and a 35% reduction in tuberculosis‐attributed death by Xpert when adjusted for HIV status and age group; OR 0.65 (95% CI 0.44% to 0.97%) ([@CD009593-bbs2-0380]).

Reasons that have been proposed to explain the lack of evidence for Xpert MTB/RIF's impact on mortality include the following: low statistical power; a limited focus on populations most likely to benefit from Xpert MTB/RIF testing, such as people with rifampicin resistance; high rates of empirical treatment; loss of patients to follow‐up; and health system weaknesses ([@CD009593-bbs2-0317]; [@CD009593-bbs2-0326]; [@CD009593-bbs2-0366]; [@CD009593-bbs2-0377]). At the time of this writing, Haraka and colleagues are carrying out a Cochrane Review to assess the impact of Xpert MTB/RIF on health outcomes ([@CD009593-bbs2-0347]).

Early detection of tuberculosis and rifampicin resistance may not lead to improved patient outcomes if the test result is not linked to appropriate treatment and other healthcare services. In a recent editorial, [@CD009593-bbs2-0360] argues that introducing a new diagnostic tool such as Xpert MTB/RIF into a fragmented healthcare system and expecting to find improved impact on patient health is unrealistic. Rather, changes in many or all steps in the healthcare cascade are needed ([@CD009593-bbs2-0360]). They propose a patient‐centred approach to assessing the impact of an innovation in patient health by mapping the point in the healthcare cascade where the diagnostic tool is introduced and identifying barriers to its effectiveness. In addition, the use of well‐designed implementation research should make it possible to examine assumptions about how the new tool will work and its impact on endpoints throughout the healthcare cascade ([@CD009593-bbs2-0360]).

Regarding resource requirements, the WHO convened a Guideline Development Group meeting by webinar specifically to review economic analyses on the use of Xpert MTB/RIF as the initial diagnostic test for all persons with tuberculosis signs and symptoms globally, and as an initial test in the 30 high tuberculosis burden countries. A review identified 15 cost‐effectiveness studies, most of which took place in sub‐Saharan Africa. Twelve studies found the use of Xpert MTB/RIF to be cost‐effective in their setting and three studies (in India, Malawi, and South Africa) found the use of the test to be cost or cost‐effectiveness neutral. The Guideline Development Group judged the requirements to implement Xpert MTB/RIF as being large (moderate‐certainty evidence of resource requirements), and judged cost effectiveness probably to be in favour of the introduction of Xpert MTB/RIF. The group decided that there was insufficient evidence to change the strength of the recommendation for the use of Xpert MTB/RIF as the initial diagnostic test for all persons with signs and symptoms of tuberculosis from conditional to strong. With respect to the certainty of evidence, guideline members raised concerns about the lack of internationally recognized thresholds for cost effectiveness and affordability, limiting the interpretation of data about cost effectiveness or affordability at the country level, as well as the difficulty of making recommendations globally when evidence varies by setting ([@CD009593-bbs2-0384]).

Since the WHO recommended the use of Xpert MTB/RIF, country‐level policy‐makers have been making decisions about adoption and scale‐up. The uptake has been much faster than for any other tuberculosis technology recommended by the WHO over the last 10 years. A recent survey of market penetration of Xpert MTB/RIF in high tuberculosis burden countries found greater use of Xpert MTB/RIF compared to smear microscopy for tuberculosis diagnosis ([@CD009593-bbs2-0329]).

This review represents the most comprehensive review of the diagnostic accuracy of Xpert MTB/RIF and Xpert Ultra, and provides evidence that may help countries to make decisions about scaling up the tests for programmatic management of tuberculosis and drug‐resistant tuberculosis. Although the information in this review will help to inform such decisions, other factors such as resource requirements and feasibility (including stable electrical power supply, temperature control, and maintenance of the cartridge modules) will also be important considerations.

### Application of the meta‐analysis to a hypothetical cohort {#CD009593-sec3-0031}

[Table 1](#CD009593-tbl-0001){ref-type="table"} and [Table 2](#CD009593-tbl-0002){ref-type="table"} summarize the findings of the review by applying the results to a hypothetical cohort of 1000 individuals with presumptive PTB or rifampicin resistance. We present several different scenarios. For Xpert MTB/RIF and Xpert Ultra for detection of PTB, we used prevalences of tuberculosis of 1%, 10%, and 30%. For detection of rifampicin resistance, we used prevalences of rifampicin resistance of 5%, 10%, and 15% (5% is estimated to be equivalent to the upper limit for rifampicin resistance prevalence in new cases; 15% is estimated to be the lower limit for rifampicin resistance prevalence among previously‐treated cases). The consequences of false‐positive results are patient anxiety, morbidity from additional testing and unnecessary treatment, and possible delay in further diagnostic evaluation. The consequences of false‐negative results are increased risk of patient morbidity and mortality, and continued risk of community transmission of tuberculosis.

Strengths and weaknesses of the review {#CD009593-sec2-0014}
--------------------------------------

### Completeness of evidence {#CD009593-sec3-0032}

The findings in this review are based on comprehensive searching, strict inclusion criteria, and standardized data extraction. This review includes a total of 95 studies. For Xpert MTB/RIF for detection of PTB, we included 86 studies involving 42,091 participants. For Xpert MTB/RIF for detection of rifampicin resistance, we included 57 studies involving 8287 participants. For the diagnostic accuracy of Xpert Ultra, we identified only one study. We had repeated correspondence with study authors to obtain additional data and information that was missing from the papers. The search strategy included studies published in all languages. Although we may have missed some studies despite the comprehensive search, as this was a large review, it is unlikely that the findings would have changed.

### Accuracy of the reference standards used {#CD009593-sec3-0033}

Culture is regarded as the best available reference standard for active tuberculosis disease and was the reference standard for tuberculosis in this review. We considered the type of culture used in the included studies because liquid culture is more sensitive than solid culture ([@CD009593-bbs2-0316]). Most studies did use liquid culture or a combination of solid and liquid culture; only 13 of the 70 studies with unselected participants (19%) exclusively used solid culture. Phenotypic culture‐based DST methods using WHO‐recommended critical concentrations ([@CD009593-bbs2-0390]) and MTBDR*plus*, a WHO‐recommended test, were the reference standards for rifampicin resistance. Concerning the former, the WHO is currently reviewing the critical concentration to recommend for rifampicin resistance testing. Concerning the latter, only four of the 57 studies (7%) used MTBDR*plus* alone as the reference standard.

### Quality and quality of reporting of the included studies {#CD009593-sec3-0034}

Most studies used consecutive selection of participants and interpreted the reference standard results without knowledge of index test results. Xpert MTB/RIF and Xpert Ultra results are generated automatically, without requiring subjective interpretation. In general, studies were fairly well reported, although we corresponded with many authors for additional data and missing information. We encourage authors of future studies to follow the recommendations in the STARD statement to improve the quality of reporting ([@CD009593-bbs2-0324]).

### Interpretability of subgroup analyses {#CD009593-sec3-0035}

We investigated potential sources of heterogeneity in different subgroups and settings. For tuberculosis detection, the test had higher sensitivity in smear‐positive and HIV‐negative participants. Generally, we found increased sensitivity in settings with higher tuberculosis prevalence (culture‐confirmed tuberculosis cases in the study) and similar or slightly lower specificity.

### Comparison with other systematic reviews {#CD009593-sec3-0036}

We are aware of 10 systematic reviews previously published that estimated diagnostic accuracy of Xpert MTB/RIF for PTB and rifampicin resistance in adults ([Table 8](#CD009593-tbl-0008){ref-type="table"}). In these reviews, summary sensitivities ranged from 67% (limited to smear‐negative specimens) to 90% (in our review: 85%) and summary specificities 97% to 99% (in our review: 98%).Table 5Systematic reviews on the diagnostic accuracy of Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance**Author, yearDate searched up toNo. studies (participants)PTB, summary estimates (95% CI)No. studiesRifampicin resistance, summary estimates (95% CrI)SensitivitySpecificitySensitivitySpecificity**[@CD009593-bbs2-0331]October\
201115 (8117)90% (89 to 91)98% (98 to 99)7see notesee note[@CD009593-bbs2-0301]\
(smear‐negative)May 201215 (2046)67% (62 to 71)98% (97 to 99)NANANA[@CD009593-bbs2-0401]December 201327 (6026)89% (85 to 92)99% (98 to 99)sensitivity: 17 specificity: 2495% (90 to 97)98% (97 to 99)[@CD009593-bbs2-0308]not reported12 (8122)89% (87 to 90)98% (98 to 99)NANANA[@CD009593-bbs2-0214]June 201524 (2486)87% (83 to 90)97% (96 to 98)NANANA[@CD009593-bbs2-0110]December 2015NANANA8see notesee noteHorne 2019January 201885 (41,965)85% (82 to 87)98% (97 to 98)48 (8020)96% (94 to 97)98% (98 to 99)[^8]

Compared with previous systematic reviews, our review extended the date of the search for potential studies for inclusion. Our strict inclusion criteria, for example, including only studies that used culture as the reference standard and excluding case‐control studies, meant that some of the studies included in other reviews were excluded from our review.

### Completeness and relevance of the review {#CD009593-sec3-0037}

This review included studies using all four generations of Xpert (G1, G2, G3, G4 cartridges) and the newest version, Xpert Ultra, although we identified only one study with Xpert Ultra. A Cochrane Review on Xpert MTB/RIF for extrapulmonary tuberculosis (including one study with Xpert Ultra) was recently published ([@CD009593-bbs2-0351]). This review found that in people with presumptive extrapulmonary tuberculosis, Xpert MTB/RIF may be helpful in confirming the diagnosis. Xpert MTB/RIF sensitivity varied across different extrapulmonary specimens, while for most specimens specificity was high. In addition, Xpert MTB/RIF was accurate for detection of rifampicin resistance ([@CD009593-bbs2-0351]). A Cochrane Review on Xpert MTB/RIF and Xpert Ultra for active tuberculosis in children is underway.

Applicability of findings to the review question {#CD009593-sec2-0015}
------------------------------------------------

For detection of PTB, most studies evaluated sputum specimens submitted by participants with presumptive tuberculosis, and ran the test in primary care facilities and local hospitals. Hence, for most studies, the participant characteristics and settings matched our review question. For detection of rifampicin resistance, we had low concern in 46% of studies and high concern in only 7% of studies. However, in nearly half of the studies (47%) the clinical setting was not reported or there was insufficient information to make a decision.

Authors\' conclusions {#CD009593-sec1-0007}
=====================

We found Xpert MTB/RIF to be sensitive and specific for detection of PTB and rifampicin resistance, findings which are consistent with those reported previously. Xpert MTB/RIF was more sensitive for tuberculosis in smear‐positive than smear‐negative participants, and HIV‐negative than HIV‐positive participants. Compared with Xpert MTB/RIF, Xpert Ultra had higher sensitivity and lower specificity for tuberculosis detection and similar sensitivity and specificity for rifampicin resistance detection (one study). Xpert MTB/RIF and Xpert Ultra provide accurate results and can allow rapid initiation of treatment for multidrug‐resistant tuberculosis. The ongoing use of Xpert MTB/RIF or Xpert Ultra in tuberculosis programmes in high tuberculosis burden settings, as well as use in primary care clinics where the test provides the opportunity to begin treatment promptly, will contribute evidence on whether its use leads to improvements in patient health.Future studies should assess the diagnostic accuracy of Xpert Ultra compared with other rapid tests for tuberculosis and drug resistance, especially in difficult‐to‐diagnose groups, i.e. children, people living with HIV, and those with extrapulmonary tuberculosis. Understanding the impact of Xpert Ultra in settings with differing prevalences of tuberculosis, in previously‐treated individuals, with varying strategies for the classification of trace calls, and its impact on patient health outcomes will be important.

Feedback {#CD009593-sec1-0013}
========

Boyles, 7 October 2014 {#CD009593-sec2-0022}
----------------------

### Summary {#CD009593-sec3-0047}

Name: Tom Boyles

Affiliation: University of Cape Town

*I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of my feedback.*

In the initial version of Steingart et al\'s systematic review of the Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults ([@CD009593-bbs2-0400]) includes 15 studies where Xpert MTB/RIF was used as an initial test replacing smear microscopy, with the majority of patients being drawn from two major studies ([@CD009593-bbs2-0011], [@CD009593-bbs2-0012]). My comment relates to the appropriate reference standard for tuberculosis is these studies. The systematic review appraised the quality of included studies with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS‐2) ([@CD009593-bbs2-0383]) tool which states that estimates of test accuracy are based on the assumption that the reference standard is 100% sensitive and that specific disagreements between the reference standard and index test result from incorrect classification by the index test.

For each of the studies in question the reference standard for tuberculosis is listed as "Löwenstein‐Jensen culture and MGIT 960" and the review considers that the reference standard is likely to correctly classify the target condition. There is considered to be low risk of bias or applicability concerns relating to the reference test.

However, in Boehme et al 2010 there were 105 patients with 'clinical tuberculosis' who were excluded from the analysis. These patients were negative by the reference standard of Löwenstein‐Jensen culture and MGIT 960 and should have been included in the 'no tuberculosis' group. In Boehme et al 2011 there were 153 similar patients who were excluded from the analysis.

Neither paper gives justification for the exclusion of these patients who according to QUADAS‐2 were negative by the reference standard and should be included in the 'no tuberculosis' group. Ideally the systematic review should be amended to include these patients but if the data is unavailable the risk of bias should be acknowledged.

*Note from the Editors: In addition to the above feedback, Boyles et al. published a case study in The International Journal of Tuberculosis and Lung Disease which outlined the above arguments, and illustrates this with a case study* ([@CD009593-bbs2-0325]*); which the Cochrane authors respond to, in the same journal (see below).*

### Reply {#CD009593-sec3-0048}

The review authors thank Boyles et al. for this comment. They raise important points about the selective exclusion of culture negative clinical tuberculosis cases in the Boehme studies.

We considered the published case study ([@CD009593-bbs2-0325]) in detail, and in response we carried out additional analyses to determine whether the Boehme studies unduly influenced the overall findings of this Cochrane review. One way we did this was by repeating the meta‐analysis with studies for which we could extract data for all enrolled participants, including patients classified as 'clinical tuberculosis' with negative sputum culture. We considered these participants as not having tuberculosis. In the new analysis, we found pooled sensitivity and specificity estimates to be similar to those we previously reported.

We published our findings as a response to Boyles et al. in *The International Journal of Tuberculosis and Lung Disease* ([@CD009593-bbs2-0374]).

In the updated Cochrane Review, for [@CD009593-bbs2-0011], we included culture negative results (clinical tuberculosis cases) in determinations of Xpert MTB/RIF specificity. For [@CD009593-bbs2-0012], we did not have data for clinical tuberculosis, and therefore, in the Flow and Timing domain, we changed our judgement for risk of bias to 'high\'.

The Academic Editors are Professor Gerry Davies and Dr Mariska Leeflang.

The editorial base of the Cochrane Infectious Diseases Group (CIDG) is funded by UK aid from the UK government for the benefit of low‐ and middle‐income countries (project number 300342‐104). The views expressed do not necessarily reflect the UK government's official policies.

We thank all authors of the included studies for answering our questions and providing additional data. We are grateful to Vittoria Lutje, CIDG Information Specialist, for help with the search strategy. We thank Hojoon Sohn and Lorie Kloda who contributed to the original review version. We also acknowledge Edward Desmond, California State Department of Health, for his comments on alternative tuberculosis tests, and Ellen Jo Baron, Cepheid, for her comments on the index test. In addition, we thank Chris Gilpin for assisting with the laboratory classification scheme and Matteo Zignol for providing the prevalence rates for MDR‐TB; both experts are with the Global TB Programme, WHO, Geneva; and Selcan Alptekin, Rothamsted Research, for translation assistance. Study data were collected and managed using REDCap electronic data capture tools hosted at University of Washington (supported by UL1 TR002319, KL2 TR002317, and TL1 TR002318 from NCATS/NIH).

MEDLINE (OVID) and Embase (OVID) {#CD009593-sec3-0038}
================================

1\. (tuberculosis or TB).tw

limit 1 to yr=\"2007 ‐Current\"

2\. Mycobacterium tuberculosis/

limit 2 to yr=\"2007 ‐Current\"

3\. Tuberculosis, Multidrug‐Resistant/ or Tuberculosis/ or Tuberculosis, Pulmonary/

limit 3 to yr=\"2007 ‐Current\"

4.  1 or 2 or 3

5\. (Xpert or GeneXpert or cepheid or( near\* patient)). tw.

limit 4 to yr=\"2007 ‐Current\"

4 and 5

Web of Knowledge (SCI‐expanded, SSCI, Conference Proceedings science, BIOSIS previews) {#CD009593-sec3-0039}
======================================================================================

 (tuberculosis OR TB OR mycobacterium) (topic) AND (Xpert OR Genexpert OR cepheid) (topic)

LILACS {#CD009593-sec3-0040}
======

(tuberculosis OR TB OR mycobacterium) (Words) AND (xpert OR Genexpert OR Cepheid) (Words)

SCOPUS {#CD009593-sec3-0041}
======

(tuberculosis OR TB OR mycobacterium) (title, abstract, keywords) AND (xpert OR Genexpert OR Cepheid) (title, abstract, keywords)

A. [@CD009593-bbs2-0011] and [@CD009593-bbs2-0012], multicentre studies, Xpert MTB/RIF for detection of pulmonary tuberculosis

**StudySiteTrue positiveFalse positiveFalse negativeTrue negative**[@CD009593-bbs2-0011]**a**Azerbaijan12382491[@CD009593-bbs2-0011]**b**Peru20118105[@CD009593-bbs2-0011]**c**South Africa, Cape Town136910188[@CD009593-bbs2-0011]**d**South Africa, Durban3677257[@CD009593-bbs2-0011]**e**India1791840[@CD009593-bbs2-0012]**a**Azerbaijan203426303[@CD009593-bbs2-0012]**a,b**Peru17136825[@CD009593-bbs2-0012]**c**South Africa201232669[@CD009593-bbs2-0012]**d**Uganda121024144[@CD009593-bbs2-0012]**e**India101160671[@CD009593-bbs2-0012]**f**The Philippines136512234

B. [@CD009593-bbs2-0011] and [@CD009593-bbs2-0012], multicentre studies, Xpert MTB/RIF for detection of rifampicin resistance

**StudySiteTrue positiveFalse positiveFalse negativeTrue negative**[@CD009593-bbs2-0011]**a**Azerbaijan474290[@CD009593-bbs2-0011]**b**Peru1630190[@CD009593-bbs2-0011]**c**South Africa, Cape Town1501126[@CD009593-bbs2-0011]**d**South Africa, Durban30038[@CD009593-bbs2-0011]**e**India1193261[@CD009593-bbs2-0012]**a**Azerbaijan4713160[@CD009593-bbs2-0012]**b**Peru2211161[@CD009593-bbs2-0012]**c**South Africa931175[@CD009593-bbs2-0012]**d**Uganda112112[@CD009593-bbs2-0012]**e**India82291[@CD009593-bbs2-0012]**f**The Philippines1496597

Footnotes: In the 2014 Cochrane Review, for multicentre studies, the study‐naming scheme uniquely identified multiple study centres from within each study (for example, Boehme 2010a; Boehme 2010b), each of which reported data separately for a distinct population at a given study site.

**I. ID**ID substudy (for study centres: a, b, c, etc)First authorCorresponding author & emailWas author contacted?1 -- Yes\
2 -- No\
If yes, dates(s)TitleYear (of publication)Year (study start date)Language1 -- English\
2 -- Other\
If other, specify:**II. Study details**Country where study was conductedCountry World Bank Classification1 -- Low income\
2 ‐ Middle income\
3 -- High income\
4 ‐ Low and high income\
5 ‐ Low and middle income\
6 ‐ Low, middle, and high\
7 -- Other combination, describePurpose of testing as described in the study1 ‐ Diagnosis\
2 ‐ Screening in HIV‐positive people\
9 ‐ Could not tell\
Study states:Objective of study1 ‐ Detection of PTB only\
2 ‐ Detection of rifampicin resistance only\
3 ‐ Both, detection of PTB and rifampicin resistanceStudy design1 -- Randomized controlled trial\
2 -- Cross‐sectional\
3 -- Cohort\
4 -- Other, specify\
9 -- Could not tell\
If other, describe:**IIa. Questions about pre‐selection during enrolment**Were patients pre‐selected based upon microscopy results?1 ‐ Yes\
2 ‐ No\
9 ‐ Unknown/NRIf yes, what was the basis for pre‐selection?1‐ Primarily or exclusively smear positive\
2 ‐ Primarily or exclusively smear negative\
8 ‐ Not applicableDid study include exclusively retreatment patients\
upon enrolment? (for example, patients who previously received\
first‐line drugs and those with nonconverting\
pulmonary tuberculosis who were receiving therapy)1 ‐ Yes\
2 ‐ No\
9 ‐ Unknown/NRParticipant selection1 -- Consecutive\
2 -- Random\
3 -- Convenience\
7 -- Other\
9 -- Unknown/NRDirection of study data collection1 -- Prospective\
2 -- Retrospective\
9 -- Unknown/NRNumber included after recruitment by inclusion and exclusion criteria\_\_\_\_\_\
9 -- Unknown/NRNumber included in analysis (\# recruited ‐ \# withdrawals)\_\_\_\_\_\
9 -- Unknown/NRUnit of analysis1 -- Patient (with a single Xpert per patient)\
2 -- Specimen (there are more specimens than patients)\
9 -- Unknown/NR\
Describe as in paper, if unclear:Comments about study design**III. Patient characteristics and setting**Presenting signs and symptomsDid the study avoid inappropriate exclusions? Please list exclusions noted in\
study, if any (for example, study includes predominantly or exclusively\
smear‐positive or \"difficult‐to‐diagnose\" patients)1 ‐ Yes\
2 ‐ No\
9 ‐ Unknonwn/NR\
Describe exclusions as stated in study:Type of specimen (may include expectorated,\
induced, bronchial alveolar lavage (BAL), tracheal aspirates)(check all that\
apply). Assume expectorated sputum if not specifically stated.1 -- Expectorated sputum\
2 -- Induced sputum\
3 -- Bronchial alveolar lavage or bronchial aspirates\
4 -- Tracheal aspirates\
6 -- Other\
9 -- Unknown/NR\
If other, describe types and record numbers:Clinical setting; describe as written in the paper1 -- Outpatient\
2 ‐ Inpatient\
3 -- Both out‐ and in‐patient\
4 -- Other, specify\
5 -- Laboratory based\
9 -- Unknown/NR\
Describe as in paper:Was Xpert testing performed at point of care?\
*(POCT is diagnostic testing that will result in a*\
*clear and actionable management decision (e.g.*\
*start of treatment, referral, initiation of confirmatory*\
*test) within [the same clinical encounter]{.ul} (e.g. same*\
*day). POCT should be mentioned in the study as*\
*it is unlikely if testing takes place in a central*\
*level laboratory*.1 ‐ Yes\
2 ‐ No\
9 ‐ Could not tellLevel of the laboratory system where Xpert tests\
were performed *(Tests generally available at different laboratory*\
*levels, though tests may overlap)* *Central: Intermediate laboratory tests and culture*\
*on liquid media and DST (1st and 2nd line*\
*anti‐tuberculosis drugs) on solid or in liquid media and LPA*\
*on positive cultures and rapid speciation tests* *Intermediate: Peripheral laboratory tests and*\
*culture on solid media and line probe assay (LPA)*\
*from smear positive sputum* *Peripheral: AFB (Ziehl‐Neelsen, Auramine‐rhodamine,*\
*Auramine‐O staining) and Xpert MTB/RI*F1‐ Central 2 ‐ Intermediate 3 ‐ Peripheral 4‐ Other, specify Describe as in paper:**IV. Other demographics**Age (range, mean (SD), median (IQR))9 ‐ Unknown/NR\#\#/total and % female9 ‐ Unknown/NRHIV status of participants0 ‐ HIV ‐\
1 ‐ HIV +\
2 ‐ Both HIV+/‐\
9 ‐ Unknown/NRIf HIV‐positive participants included, what is the percentage?% (specify numerator/denominator)*Prior tuberculosis history:* Did the study include patients with prior tuberculosis history?1 ‐ Yes\
2 ‐ No\
9 ‐ Unknown/NRIf so, what is the percentage?% (specify numerator/denominator)\
9 ‐ Unknown/NR (for data entry write \"NR\")*Prior treatment:* Did the study include patients with prior tuberculosis treatment?1 ‐ Yes\
2 ‐ No\
9 ‐ Unknown/NRIf so, what is the percentage?% (specify numerator/denominator)\
9 ‐ Unknown/NR (for data entry write \"NR\")*Current treatment:* Were patients on treatment (defined as tuberculosis drugs for\
greater than 7 days) for the current tuberculosis episode?\
*(note: may impact culture results)*1 ‐ Yes\
2 ‐ No\
9 ‐ Unknown/NRIf so, what is the percentage?% (specify numerator/denominator)\
9 ‐ Unknown/NR (for data entry write \"NR\")**V. Index test**Xpert version(s) evaluated1 ‐ Xpert MTB/RIF only\
2 ‐ Xpert Ultra only\
3 ‐ Any combination Xpert MTB/RIF and Xpert UltraXpert platform: Was Omni used? Unless Omni explicitely described, assume\
standard platform1 -- Yes, only Omni used for Xpert tests 2 -- Yes, both Omni and standard platform used for Xpert tests 3 ‐ NoWas the index test result interpreted without knowledge of the result of\
the reference standard result?1‐Yes (Since Xpert is automated, we will answer 'Yes" for all\
studies)**VI. Reference standard**For tuberculosis detection, what reference standard(s) was used?1 -- Solid culture (specify 1a)\
2 -- Liquid culture (specify 2a)\
3 -- Both solid and liquid culture (specify 1a and 2a)\
9 -- Unknown/NR\
1a ‐ Solid culture\
LJ\
7H10\
7H11\
Other\
9‐ Unknown/NR\
2a -- Liquid culture\
MGIT 960\
Other (specify):\
9‐ Unknown/NRFor MGIT only, if *more than one specimen* was inoculated for\
culture, were these specimens obtained on *different days?*1 -- Yes 2 -- No 8 -- Not applicable 9 -- Unknown/NRFor rifampicin resistance detection, what reference standard(s)\
was used?1 -- Solid culture (specify 1a)\
2 -- Liquid culture (specify 2a)\
3 -- Both solid and liquid culture (specify 1a and 2a)\
4 ‐ MTBDR*plus*\
5 ‐ Other, specify\
9 -- Unknown/NR\
1a ‐ Solid culture\
LJ\
7H10\
7H11\
Other\
Specify method, e.g., proportion\
2a -- Liquid culture\
MGIT 960\
Other (specify)Tuberculosis detection: Was the reference standard result interpreted\
without knowledge of the index test result? Answer yes for MGIT and LJ with species confirmation1 -- Yes 2 -- No 9 -- Unknown/NRRifampicin resistance detection: Was the reference standard\
result interpreted without knowledge of the index test result? Answer yes for MGIT1 -- Yes 2 -- No 9 -- Unknown/NR**VII. Specimen flow**Were Xpert sample and culture obtained from same specimen?1 -- Yes 2 -- No 9 -- Unknown/NRWhat specimen processing procedure was used before testing\
with Xpert?1 -- None 2 -- NALC‐NaOH 3 -- NaOH (Petroff) 4 -- Other 9 -- Unknown/NRWas microscopy used?1 -- Yes 2 -- No 9 -- Unknown/NRType of microscopy used1 -- Ziehl‐Neelsen 2 -- Fluorescence microscopy 3 ‐ Both Ziehl‐Neelsen and fluorescence microscopy 9 -- Unknown/NRSmear type (if study used both direct and concentrated,\
select concentrated)1 -- Direct 2 -- Concentrated (processed) 9 -- Unknown/NRFor Xpert specimen, what was the condition of the\
specimen when tested?1 -- Fresh 2 -- Frozen 3 ‐ Both fresh and frozen 9 -- Unknown/NR**VIII. Results**Did the study report % contaminated cultures?\
(Enter percentage contaminated cultures, if\
provided): \# of contaminated cultures/Total \# cultures performed = %1 -- Yes ‐\> % contaminated cultures: 2 -- NoDid the study report the number of uninterpretable\
results for Xpert for tuberculosis detection? (invalid, error, no result) *The uninterpretable rate for detection of PTB is the*\
*number of tests classified as "invalid," "error," or "no result"*\
*divided by the total number of Xpert tests performed.*1 -- Yes ‐\> \# Uninterpretable results: Denominator is total number of Xpert tests performed\
(Add total from Table 1 plus \# of uninterpretable results): 2 -- NoDid the study report the number of indeterminate results for\
Xpert for rifampicin resistance detection? *The indeterminate rate for detection of rifampicin resistance*\
*was the number of tests classified as "MTB detected; Rif*\
*resistance INDETERMINATE" divided by the total number*\
*of Xpert‐MTB positive results*1 -- Yes ‐\>\# Indeterminate results: (Enter 0 indeterminate results if the total number in\
Table 6 = the number of TPs in Table1) Denominator is total number of Xpert tests performed\
(Total Xpert positive results from Table 1 first row): 2 -- NoDid the study report any Xpert rifampicin resistant positive\
results in culture negative specimens?1 -- Yes ‐\> Number reported: 2 -- NoDid the study report nontuberculous mycobacteria (NTM)?\
Record number NTM over the number of cultures performed1 -- Yes ‐\> Number reported: 2 -- NoIf NTMs were identified, record number of Xpert positive\
results among NTMs\#Xpert positive tests among total number NTMs: 9 -- Unknown/NR

Abbreviations: HIV: human immunodeficiency virus; LJ: Löwenstein--Jensen; MGIT: mycobacterial growth indicator tube; NR: Not reported; NTM: Nontuberculous mycobacteria; PTB: pulmonary tuberculosis.

**TABLES, examples**

Table 1.

**Tuberculosisdetection, all participantsConfirmed tuberculosisTotalYesNo**Xpert MTB/RIF resultPositive   Negative   Total   

 Table 2.

**Tuberculosis detection, smear positiveConfirmed tuberculosisTotalYesNo**Xpert MTB/RIF resultPositive   Negative   Total   

 Table 3.

**Tuberculosisdetection, smear negativeConfirmed tuberculosisTotalYesNo**Xpert MTB/RIF resultPositive   Negative   Total   

Table 4.

**Rifampicin resistance detectionRifampicin‐resistantTotalYesNo**Xpert MTB/RIF resultPositiveNegativeTotal

In QUADAS‐2, we assessed methodological quality separately for each of the objectives, Xpert for pulmonary tuberculosis (PTB) detection and Xpert for rifampicin resistance detection.

Domain 1: Patient selection {#CD009593-sec3-0042}
===========================

Xpert MTB/RIF or Xpert Ultra for PTB detection {#CD009593-sec4-0017}
----------------------------------------------

Risk of bias: Could the selection of patients have introduced bias?

*Signalling question 1: Was a consecutive or random sample of patients enrolled?* We answered 'yes\' if the study enrolled a consecutive or random sample of eligible patients; 'no\' if the study selected patients by convenience; and 'unclear\' if the study did not report the manner of patient selection or we could not tell.

*Signalling question 2: Was a case‐control design avoided?* Studies using a case‐control design were not included in the review because this study design, especially when used to compare results in severely ill patients with those in relatively healthy individuals, may lead to overestimation of accuracy in diagnostic studies. We answered 'yes\' for all studies.

*Signalling question 3: Did the study avoid inappropriate exclusions?* We answered 'yes\' if the study included both smear‐positive and smear‐negative individuals; 'no\' if the study included primarily or exclusively smear‐positive or smear‐negative patients; and 'unclear\' if we could not tell. We also answered 'no\' if the study included primarily or exclusively patients who had undergone previous treatment (retreatment patients).

Applicability: Are there concerns that the included patients and setting do not match the review question?

We were interested in how Xpert MTB/RIF or Xpert Ultra performed in patients who were evaluated as they would be in routine practice. We answered 'low concern\' if patients were evaluated in local hospitals or primary care centres. We answered 'high concern\' if patients were evaluated exclusively as inpatients in tertiary care centres. We answered 'unclear concern\' if the clinical setting was not reported or there was insufficient information to make a decision. We also answered 'unclear concern\' if Xpert MTB/RIF or Xpert Ultra testing was done at a central‐level laboratory and the clinical setting was not reported for the following reason. It was difficult to tell if a given reference laboratory provided services mainly to very sick patients.

Xpert MTB/RIF or Xpert ultra for rifampicin resistance detection {#CD009593-sec4-0018}
----------------------------------------------------------------

Domain 1: Patient selection is the same as for Xpert for PTB detection except for

*Signalling question 3: Did the study avoid inappropriate exclusions?* We answered 'yes\' if the study included both smear‐positive and smear‐negative individuals; 'no\' if the study included primarily or exclusively smear‐positive or smear‐negative patients; and 'unclear\' if we could not tell. We answered 'yes\' if the study included primarily or exclusively retreatment patients because the group at risk for rifampicin resistance includes patients who had undergone previous treatment.

Domain 2: Index test {#CD009593-sec3-0043}
====================

Xpert for PTB detection {#CD009593-sec4-0019}
-----------------------

Risk of bias: Could the conduct or interpretation of the index test have introduced bias?

Signalling*question 1: Were the index test results interpreted without knowledge of the results of the reference standard?* We answered this question 'yes\' for all studies because Xpert test results were automatically generated and the user was provided with printable test results. Thus, there is no room for subjective interpretation of test results.

Signalling*question 2: If a threshold was used, was it prespecified?* The threshold was prespecified in all versions of Xpert. We answered this question 'yes\' for all studies.

For risk of bias, we judged 'low concern\' for all studies.

Applicability: Are there concerns that the index test, its conduct, or its interpretation differ from the review question? Variations in test technology, execution, or interpretation may affect estimates of the diagnostic accuracy of a test. All steps in the Xpert MTB/RIF and Xpert Ultra assays are completely automated and self‐contained following sample loading. We answered 'low concern\' if the index test was performed as recommended by the manufacturer, which was true for most studies. We answered 'unclear concern\' if the ratio of the Xpert MTB/RIF or Xpert Ultra sample reagent: specimen volume was not 2:1 for a raw specimen or 3:1 for a sediment, as recommended by the manufacturer. Central‐level laboratories use more highly trained staff than peripheral and intermediate‐level laboratories. However, we did not consider this to be a concern about applicability because, in some studies, the reason Xpert MTB/RIF or Xpert Ultra was performed in a central‐level laboratory was the requirement for a sophisticated laboratory infrastructure to perform culture (reference standard) not to perform Xpert.

Xpert for rifampicin resistance detection {#CD009593-sec4-0020}
-----------------------------------------

Domain 2: Index test is the same as for Xpert for PTB detection.

Domain 3: Reference standard {#CD009593-sec3-0044}
============================

Xpert for PTB detection {#CD009593-sec4-0021}
-----------------------

Risk of bias: Could the reference standard, its conduct, or its interpretation have introduced bias?

Signalling*question 1: Is the reference standard likely to correctly classify the target condition?*

We answered 'yes\' for all studies, since culture as a reference standard was a criterion for inclusion in the review.

Signalling*question 2: Were the reference standard results interpreted without knowledge of the results of the index test?*

We answered 'yes\' if the reference test provided an automated result (for example, MGIT 960), blinding was explicitly stated, or it was clear that the reference standard was performed at a separate laboratory and/or performed by different people. We answered 'no\' if the study stated that the reference standard result was interpreted with knowledge of the Xpert MTB/RIF or Xpert Ultra test result. We answered 'unclear\' if we could not tell.

Applicability: Are there concerns that the target condition as defined by the reference standard does not match the question? We answered 'high concern\' if included studies did not speciate mycobacteria isolated in culture; 'low concern\' if speciation was performed; and 'unclear concern\' if we could not tell.

Xpert for rifampicin resistance detection {#CD009593-sec4-0022}
-----------------------------------------

Risk of bias: Could the selection of patients have introduced bias?

Signalling*question 1: Is the reference standard likely to correctly classify the target condition?*

We answered 'yes\' if either culture‐based drug susceptibility testing (DST) or MTBDR*plus* was used. These were criteria for inclusion for this objective of the review.

Signalling*question 2: Were the reference standard results interpreted without knowledge of the results of the index test?*

We answered 'yes\' if the reference test provided an automated result (for example, MGIT 960), blinding was explicitly stated, or it was clear that the reference standard was performed at a separate laboratory and/or performed by different people. We answered 'no\' if the study stated that the reference standard result was interpreted with knowledge of the Xpert MTB/RIF or Xpert Ultra test result. We answered 'unclear\' if we could not tell.

Applicability: Are there concerns that the target condition as defined by the reference standard does not match the question? We judged applicability to be of 'low concern\' for those studies evaluating Xpert for rifampicin resistance because these specimens had already been identified as *Mycobacterium tuberculosis* positive*.*

Domain 4: Flow and timing {#CD009593-sec3-0045}
=========================

Xpert for PTB detection {#CD009593-sec4-0023}
-----------------------

Risk of bias: Could the patient flow have introduced bias?

Signalling*question 1: Was there an appropriate interval between the index test and reference standard?* In most included studies, we expected that specimens for Xpert MTB/RIF or Xpert Ultra and culture would be obtained at the same time, when patients were evaluated for presumptive PTB. However, even if there were a delay of several days between index test and reference standard, tuberculosis is a chronic disease and we considered misclassification of disease status to be unlikely, as long as treatment was not initiated in the interim. We answered 'yes\' if the index test and reference standard were performed at the same time or if the time interval was less than or equal to seven days, 'no\' if the time interval is greater than seven days, and 'unclear\' if we could not tell.

Signalling*question 2: Did all patients receive the same reference standard?* We answered this question 'yes\' for all studies as an acceptable reference standard (either solid or liquid culture) was specified as a criterion for inclusion in the review. However, we acknowledge that it is possible that some specimens could undergo solid culture and others liquid culture. This could potentially result in variations in accuracy, but we thought the variation would be minimal.

Signalling*question 3: Were all patients included in the analysis?* We determined the answer to this question by comparing the number of patients enrolled with the number of patients included in the 2 x 2 tables. We answered 'yes\' if the numbers matched and 'no\' if there were patients enrolled in the study that were not included in the analysis. We answered 'unclear\' if we could not tell.

Xpert for rifampicin resistance detection {#CD009593-sec4-0024}
-----------------------------------------

Domain 4: Flow and timing is the same as for Xpert MTB/RIF or Xpert Ultra for PTB detection.

Judgements for 'risk of bias\' assessments for a given domain

If we answered all signalling questions for a domain 'yes\', then we judged risk of bias as 'low\'.If we answered all or most signalling questions for a domain 'no\', then we judged risk of bias as 'high\'.If we answered only one signalling question for a domain 'no\', we discussed further the 'Risk of bias\' judgement.If we answered all or most signalling questions for a domain 'unclear\', then we judged risk of bias as 'unclear\'.If we answered only one signalling question for a domain 'unclear\', we discussed further the 'Risk of bias\' judgement for the domain.

Bayesian bivariate hierarchical model {#CD009593-sec3-0046}
=====================================

The Bayesian bivariate hierarchical model used for the meta‐analyses is summarized below. The hierarchical framework took into account heterogeneity between studies and also between centres within two of the largest studies. The model was derived as an extension of previously described models ([@CD009593-bbs2-0333]; [@CD009593-bbs2-0364]). An OpenBUGS program to fit this model is provided below. Three independent, dispersed sets of starting values were used to run separate chains. The Gelman‐Rubin statistic within the OpenBUGS program was used to assess convergence. No convergence problems were observed. The first 10,000 iterations were treated as burn‐in iterations and dropped. Summary statistics were obtained based on a total of 150,000 iterations resulting from the three separate chains.

Notation: From the jth centre in the ith study we extracted the cross‐tabulation between the index and reference tests TPij, FPij, TNij, FNij. The sensitivity in ijth study is denoted by Sij and the specificity by SPij. We denote the Binomial probability distribution with sample size N and probability p as Binomial(p,N), the Bivariate Normal probability distribution with mean vector μ and variance‐covariance matrix Σ as BVN(μ, Σ), the univariate Normal distribution with mean m and variance s by N(m, s) and the Uniform probability distribution between a and b by Uniform(a,b).

Likelihood [Figure 22](#CD009593-fig-0022){ref-type="fig"}Figure 22Bayesian bivariate hierarchical model, likelihood.

The pooled sensitivity is given by 1/1+exp (‐μ~1~) and pooled specificity as 1/1+exp (μ~2~).

Prior distributions [Figure 23](#CD009593-fig-0023){ref-type="fig"}.Figure 23Bayesian bivariate hierarchical model, prior distributions.

Prior distributions were placed over the coefficients in the linear function: a1 and a2˜ N(0,4) and b1 and b2˜ N(0,1.39) ([@CD009593-bbs2-0328]). ‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐ \# BIVARIATE MODEL ASSUMING PERFECT CULTURE REFERENCE TEST \# ALLOWING FOR HETEROGENEITY BETWEEN CENTRES WITHIN TWO OF \# THE STUDIES (BOEHME 2010 and BOEHME 2011)

model { \#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\# BOEHME 2010 for(j in 1:5) { logit(TPR.q\[j\])\<‐ q1\[j,1\] logit(FPR.q\[j\])\<‐ ‐q1\[j,2\] pos1\[j\]\<‐TP1\[j\]+FN1\[j\] neg1\[j\]\<‐TN1\[j\]+FP1\[j\] TP1\[j\] ˜ dbin(TPR.q\[j\],pos1\[j\]) FP1\[j\] ˜ dbin(FPR.q\[j\],neg1\[j\]) se.q\[j\] \<‐ TPR.q\[j\] sp.q\[j\] \<‐ 1‐FPR.q\[j\] q1\[j,1:2\]˜ dmnorm(l\[1,1:2\], T1\[1:2,1:2\]) } T1\[1:2,1:2\]\<‐inverse(SIGMA1\[1:2,1:2\])

SIGMA1\[1,1\] \<‐ sigma1\[1\]\*sigma1\[1\] SIGMA1\[2,2\] \<‐ sigma1\[2\]\*sigma1\[2\] SIGMA1\[1,2\] \<‐ k1\*sigma1\[1\]\*sigma1\[2\] SIGMA1\[2,1\] \<‐ k1\*sigma1\[1\]\*sigma1\[2\] sigma1\[1\] \<‐ pow(prec1\[1\],‐0.5) \# replaced by sigma1\[1\] ˜ dunif(0,3) in sensitivity analysis to check impact of less informative prior sigma1\[2\] \<‐ pow(prec1\[2\],‐0.5) \# replaced by sigma1\[2\] ˜ dunif(0,3) in sensitivity analysis to check impact of less informative prior prec1\[1\] ˜ dgamma(2,0.5) \# replaced by prec1\[1\] \<‐ pow(sigma1\[1\],‐2) in sensitivity analysis to check impact of less informative prior prec1\[2\] ˜ dgamma(2,0.5) \# replaced by prec1\[2\] \<‐ pow(sigma1\[2\],‐2) in sensitivity analysis to check impact of less informative prior k1 ˜ dunif(‐1,1) se\[1\]\<‐1/(1+exp(‐l\[1,1\])) sp\[1\]\<‐1/(1+exp(l\[1,2\])) l\[1,1:2\] ˜ dmnorm(mu\[1:2\], T\[1:2,1:2\]) \#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\# BOEHME 2011 for(j in 1:6) {

logit(TPR.r\[j\])\<‐ r1\[j,1\] logit(FPR.r\[j\])\<‐ ‐r1\[j,2\] pos2\[j\]\<‐TP2\[j\]+FN2\[j\] neg2\[j\]\<‐TN2\[j\]+FP2\[j\] TP2\[j\] ˜ dbin(TPR.r\[j\],pos2\[j\]) FP2\[j\] ˜ dbin(FPR.r\[j\],neg2\[j\]) se.r\[j\] \<‐ TPR.r\[j\] sp.r\[j\] \<‐ 1‐FPR.r\[j\] r1\[j,1:2\]˜ dmnorm(l\[2,1:2\], T2\[1:2,1:2\]) } T2\[1:2,1:2\]\<‐inverse(SIGMA2\[1:2,1:2\]) SIGMA2\[1,1\] \<‐ sigma2\[1\]\*sigma2\[1\] SIGMA2\[2,2\] \<‐ sigma2\[2\]\*sigma2\[2\] SIGMA2\[1,2\] \<‐ k2\*sigma2\[1\]\*sigma2\[2\] SIGMA2\[2,1\] \<‐ k2\*sigma2\[1\]\*sigma2\[2\] sigma2\[1\] \<‐ pow(prec2\[1\],‐0.5) \# replaced by sigma2\[1\] ˜ dunif(0,3) in sensitivity analysis to check impact of less informative prior sigma2\[2\] \<‐ pow(prec2\[2\],‐0.5) \# replaced by sigma2\[2\] ˜ dunif(0,3) in sensitivity analysis to check impact of less informative prior prec2\[1\] ˜ dgamma(2,0.5) \# replaced by prec2\[1\] \<‐ pow(sigma2\[1\],‐2) in sensitivity analysis to check impact of less informative prior prec2\[2\] ˜ dgamma(2,0.5) \# replaced by prec2\[2\] \<‐ pow(sigma2\[2\],‐2) in sensitivity analysis to check impact of less informative prior k2 ˜ dunif(‐1,1) se\[2\]\<‐1/(1+exp(‐l\[2,1\])) sp\[2\]\<‐1/(1+exp(l\[2,2\])) l\[2,1:2\] ˜ dmnorm(mu\[1:2\], T\[1:2,1:2\]) \#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\# SINGLE CENTRE STUDIES for(i in 3:70) { \#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\# LIKELIHOOD logit(TPR\[i\]) \<‐ l\[i,1\] logit(FPR\[i\]) \<‐ ‐l\[i,2\] pos\[i\]\<‐TP\[i\]+FN\[i\] neg\[i\]\<‐TN\[i\]+FP\[i\] TP\[i\] ˜ dbin(TPR\[i\],pos\[i\]) FP\[i\] ˜ dbin(FPR\[i\],neg\[i\]) se\[i\] \<‐ TPR\[i\] sp\[i\] \<‐ 1‐FPR\[i\] l\[i,1:2\] ˜ dmnorm(mu\[1:2\], T\[1:2,1:2\]) } \#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\# HYPER PRIOR DISTRIBUTIONS mu\[1\] ˜ dnomr(0.0.25) \# replaced by mu\[1\] ˜ dnorm(0,0.01) in sensitivity analysis to check impact of less informative prior mu\[2\] ˜ dnomr(0.0.25) \# replaced by mu\[2\] ˜ dnorm(0,0.01) in sensitivity analysis to check impact of less informative prior T\[1:2,1:2\]\<‐inverse(TAU\[1:2,1:2\]) \#\#\#\# BETWEEN‐STUDY VARIANCE‐COVARIANCE MATRIX TAU\[1,1\] \<‐ tau\[1\]\*tau\[1\] TAU\[2,2\] \<‐ tau\[2\]\*tau\[2\] TAU\[1,2\] \<‐ rho\*tau\[1\]\*tau\[2\] TAU\[2,1\] \<‐ rho\*tau\[1\]\*tau\[2\] tau\[1\] \<‐ pow(prec\[1\],‐0.5) \# replaced by tau\[1\] ˜ dunif(0,3) in sensitivity analysis to check impact of less informative prior tau\[2\] \<‐ pow(prec\[2\],‐0.5) \# replaced by tau\[2\] ˜ dunif(0,3) in sensitivity analysis to check impact of less informative prior \#\#\#\# prec = between‐study precision in the logit(sensitivity)and logit(specificity) prec\[1\] ˜ dgamma(2,0.5) \# replaced by prec\[1\] \<‐ powtau\[1\],‐2) in sensitivity analysis to check impact of less informative prior prec\[2\] ˜ dgamma(2,0.5) \# replaced by prec\[2\] \<‐ powtau\[2\],‐2) in sensitivity analysis to check impact of less informative prior rho ˜ dunif(‐1,1) \#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\# OTHER PARAMETERS OF INTEREST \#\#\#\# POOLED SENSITIVITY AND SPECIFICITY Pooled_S\<‐1/(1+exp(‐mu\[1\])) Pooled_C\<‐1/(1+exp(‐mu\[2\])) \#\#\#\# PREDICTED SENSITIVITY AND SPECIFICITY IN A FUTURE STUDY l.new\[1:2\] ˜ dmnorm(mu\[\],T\[,\]) sens.new \<‐ 1/(1+exp(‐l.new\[1\])) spec.new \<‐ 1/(1+exp(‐l.new\[2\])) } \#\#\#\# END OF PROGRAM \#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#

\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\# DATA \#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\# \# DATA WAS READ FROM THREE SEPARATE FILES \# DATA 1 ‐ BOEHME 2010 TP1\[\] FP1\[\] FN1\[\] TN1\[\] 123 8 24 91 201 1 8 105 136 9 10 188 36 7 7 257 179 1 8 40 END \#row 1 : Azerbaijan \#row 2 : Peru \#row 3 : South Africa, Cape Town \#row 4 : South Africa, Durban \#row 5 : India \#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\# \# DATA 2 ‐ FROM BOEHME 2011 TP2\[\] FP2\[\] FN2\[\] TN2\[\] 203 4 26 303 171 3 6 825 201 2 32 669 121 0 24 144 101 16 0 671 136 5 12 234 END \#row 1 : Azerbaijan \#row 2 : Peru \#row 3 : South Africa \#row 4 : Uganda \#row 5 : India \#row 6 : The Philippines \#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\#\# \# DATA 3 ‐ OTHER STUDIES TP\[\] FP\[\] FN\[\] TN\[\] NA NA NA NA NA NA NA NA 3 2 3 204 8 0 7 110 16 1 17 70 11 1 1 147 81 13 41 677 191 1 44 55 21 2 5 66 27 5 8 155 \# \... \# DATA HAVE BEEN TRUNCATED FOR EASE OF PRESENTATION IN THIS APPENDIX \# THE COMPLETE DATA CAN BE FOUND IN [Figure 10](#CD009593-fig-0010){ref-type="fig"} \# \... 89 5 8 234 11 1 14 475 94 10 29 291 68 15 13 129 111 19 30 320 154 27 31 517 197 6 30 180 84 8 79 1006 31 0 4 68 6 0 1 110 END \# row 1 Boheme 2010 \# row 2 Boheme 2011 \# row 3 Adelman 2015 \# row 4 Al‐darraji 2013 \# row 5 Atwebembeire 2016 \# row 6 Balcells 2012 \# row 7 Balcha 2014 \# row 8 Barmankulova 2015 \# row 9 Bates 2013 \# row 10 Bjerrum 2016 \# \... \# DATA HAVE BEEN TRUNCATED FOR EASE OF PRESENTATION IN THIS APPENDIX \# THE COMPLETE DATA CAN BE FOUND IN [Figure 10](#CD009593-fig-0010){ref-type="fig"} \# \... \# row 60 Sharma 2015 \# row 61 Shenai 2016 \# row 62 Sohn 2014 \# row 63 Ssengooba 2014 \# row 64 Tang 2017 \# row 65 Theron 2011 \# row 66 Theron 2014 \# row 67 Tsuyuguchi 2017 \# row 68 Yoon 2017 \# row 69 Zeka 2011 \# row 70 Zmak 2013

[Figure 22](#CD009593-fig-0022){ref-type="fig"} Bayesian bivariate hierarchical model, likelihood

[Figure 23](#CD009593-fig-0023){ref-type="fig"} Bayesian bivariate hierarchical model, prior distributions

Presented below are all the data for all of the tests entered into the review.

TestsData tables by testTestNo. of studiesNo. of participants[1 Xpert MTB/RIF for detection of pulmonary tuberculosis (PTB)](#CD009593-fig-00101){ref-type="fig"}Test 1Xpert MTB/RIF for detection of pulmonary tuberculosis (PTB).8642091[2 Xpert Ultra for detection of PTB](#CD009593-fig-00102){ref-type="fig"}Test 2Xpert Ultra for detection of PTB.11439[3 Smear‐positive, Xpert MTB/RIF](#CD009593-fig-00103){ref-type="fig"}Test 3Smear‐positive, Xpert MTB/RIF.534943[4 Smear‐positive, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra](#CD009593-fig-00104){ref-type="fig"}Test 4Smear‐positive, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra.1323[5 Smear‐positive, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra](#CD009593-fig-00105){ref-type="fig"}Test 5Smear‐positive, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra.1323[6 Smear‐negative, Xpert MTB/RIF](#CD009593-fig-00106){ref-type="fig"}Test 6Smear‐negative, Xpert MTB/RIF.5622581[7 Smear‐negative, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra](#CD009593-fig-00107){ref-type="fig"}Test 7Smear‐negative, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra.11111[8 Smear‐negative, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra](#CD009593-fig-00108){ref-type="fig"}Test 8Smear‐negative, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra.11111[9 HIV‐negative, Xpert MTB/RIF](#CD009593-fig-00109){ref-type="fig"}Test 9HIV‐negative, Xpert MTB/RIF.185118[10 HIV‐positive, Xpert MTB/RIF](#CD009593-fig-00110){ref-type="fig"}Test 10HIV‐positive, Xpert MTB/RIF.309593[11 HIV‐negative, within study comparisons](#CD009593-fig-00111){ref-type="fig"}Test 11HIV‐negative, within study comparisons.144681[12 HIV‐positive, within study comparisons](#CD009593-fig-00112){ref-type="fig"}Test 12HIV‐positive, within study comparisons.144663[13 HIV‐negative, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra](#CD009593-fig-00113){ref-type="fig"}Test 13HIV‐negative, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra.1483[14 HIV‐negative, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra](#CD009593-fig-00114){ref-type="fig"}Test 14HIV‐negative, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra.1483[15 HIV‐positive, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra](#CD009593-fig-00115){ref-type="fig"}Test 15HIV‐positive, Xpert MTB/RIF, direct comparison Xpert MTB/RIF vs Xpert Ultra.1432[16 HIV‐positive, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra](#CD009593-fig-00116){ref-type="fig"}Test 16HIV‐positive, Xpert Ultra, direct comparison Xpert MTB/RIF vs Xpert Ultra.1432[17 Xpert MTB/RIF for detection of rifampicin resistance](#CD009593-fig-00117){ref-type="fig"}Test 17Xpert MTB/RIF for detection of rifampicin resistance.578287[18 Xpert Ultra for detection of rifampicin resistance](#CD009593-fig-00118){ref-type="fig"}Test 18Xpert Ultra for detection of rifampicin resistance.1551

**DateEventDescription**5 June 2019New citation required but conclusions have not changedThe findings in this update are consistent with those reported previously ([@CD009593-bbs2-0401]).5 June 2019New search has been performedThe review authors identified 95 unique studies, integrating 77 new studies since publication of the Cochrane Review ([@CD009593-bbs2-0401]).

Protocol first published: Issue 1, 2012 Review first published: Issue 1, 2013

**DateEventDescription**30 June 2015AmendedAdded revised data including (smear positive culture negatives) for Boehme 2010 and Rachow. Added corrected data for Hanrahan. Added test and analysis for Hx of TB. Amended patient selection for Boehme 2011 to high risk of bias.16 March 2015Feedback has been incorporatedFeedback from Dr Tom Boyles at University of Cape Town has been incorporated and responded to.6 May 2014AmendedFollowing information from one of the trial authors, details of the version of Xpert MTB/RIF used in [@CD009593-bbs2-0005] have been corrected.13 February 2014AmendedSentence moved in abstract; corrected \'pooled median sensitivity\' to \'median pooled sensitivity\' throughout.30 November 2013New search has been performed1. We performed an updated literature search on 7 February 2013. 2. For smear microscopy as a comparator test, we added a descriptive plot showing the estimates of sensitivity and specificity of Xpert compared with those of smear microscopy in studies that reported on both tests. 3. We included studies using Xpert version G4 (two studies) and studies evaluating Xpert in primary care clinics (two studies). These studies did not change the overall findings. 4. We improved the QUADAS‐2 assessment concerning applicability. 5. For TB detection, we repeated our earlier meta‐regression analyses within subgroups defined by smear status. 6. For rifampicin resistance detection, we performed univariate meta‐analyses for sensitivity and specificity separately in order to include studies in which no rifampicin resistance was detected. We also performed a sensitivity analysis using the bivariate random‐effects model for the subset of studies that provided data for both sensitivity and specificity. 7. We revised the summary of findings table to include clinical scenarios with prevalence levels recommended by the World Health Organization. 8. In the Background, we shortened the section on alternative tests to include only those tests most relevant to the review. 9. We added health economic considerations to the Discussion. 10. We added updated TB surveillance information.30 November 2013New citation required but conclusions have not changedWe conducted a new search and revised the review as described.17 January 2013AmendedWe made some minor edits to the text to correct typographical errors. In addition, we replaced Figures 6, 8, 11, and 13 with new figures with minor modifications to the prediction regions.

In the protocol we stated that we would extract data on industry sponsorship. However, we became aware that FIND had negotiated a special price for the assay for tuberculosis‐endemic countries. As most of the included studies were located in tuberculosis‐endemic countries, we assumed Xpert had been purchased at the negotiated price. We therefore did not consider the included studies to be sponsored by industry.

We stated we would discuss the consequences when an uninterpretable test result was considered to be a (false) true negative result (may lead to missed or delayed diagnosis, with potential for increased morbidity, mortality, and tuberculosis transmission), or considered to be a (false) true positive result (may lead to unnecessary treatment with adverse events and increased anxiety). Since the rate of uninterpretable results was very low, we did not discuss these consequences.

Characteristics of included studies \[ordered by study ID\] {#CD009593-sec2-0025}
===========================================================

Adelman 2015**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: people with at least one of the following: cough, fever, night sweats, and weight loss\
Age: 18 years and older\
Sex, female: not reported\
HIV infection: 100%\
History of TB: 36%\
Sample size: 212\
Clinical setting: outpatient\
Laboratory level: intermediate\
Country: Ethiopia\
World Bank Income Classification: low income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 2.8%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?UnclearWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**UnclearUnclearDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Al‐Darraji 2013**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: not reported; HIV‐positive prisoners were screened\
Age: mean 37 years (standard deviation (SD) 6.6)\
Sex, female: 10%\
HIV infection: 100%\
History of TB: 29%\
Sample size: 125\
Clinical setting: outpatient, point of care\
Laboratory level: other, prison\
Country: Malaysia\
World Bank Income Classification: middle income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 12.0%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960, MTBDR*plus* for confirmationFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Ali 2017**Study characteristics**Patient samplingCross‐sectional design, unclear manner of enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: people with pulmonary TB, recently found to have smear‐positive sputum\
Age:\
≤ 15 years 1 (0.8% ) 16 to 30 81 (64.3%) 31 to 45 23 (18.2%) 46 to 60 15 (11.9%) ≥ 60 6 (4.8%)\
Sex, female: 33%\
HIV infection: not reported\
History of TB: 57%\
Sample size: 126\
Clinical setting: laboratory‐based\
Laboratory level: central\
Country: Sudan\
World Bank Income Classification: middle income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: noIndex testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: LJFlow and timing Comparative NotesParticipants were recruited from random geographical clusters during a one‐year period**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?No**HighUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?UnclearWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Unclear**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Atwebembeire 2016**Study characteristics**Patient samplingCross‐sectional design, unclear manner of enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: people who were unable to produce sputum with a clinical suspicion of TB (presence of at least 1 of the following signs: cough of at least 2 weeks, chronic unexplained weight loss, fever, or recent chest x‐ray showing radiological features compatible with TB); specimens were frozen\
Age: adults, mean or median age not reported\
Sex, female: 46%\
HIV infection: 31%\
History of TB: not reported\
Sample size: 104\
Clinical setting: laboratory‐based\
Laboratory level: central\
Country: Uganda\
World Bank Income Classification: low income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 31.7%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960Flow and timing Comparative NotesFrozen sediments of sputum specimens previously evaluated using MGIT and LJ were used in this study.**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**UnclearUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?UnclearWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Balcells 2012**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: people who fulfilled at least 1 of the following criteria: cough (\> 10 days), bloody sputum, pneumonia unresponsive to previous antibiotics, fever (\> 10 days), abnormal CXR or weight loss\
Age: mean 37.4 years, range 19 ‐ 65 years\
Sex, female: 20.6%\
HIV infection: 100%\
History of TB: 11.8%\
Sample size: 160\
Clinical setting: 5 hospitals and their respective HIV clinics\
Laboratory level: central\
Country: Chile\
World Bank Income Classification: middle income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
TB incidence rate: 18 per 100,000\
MDR‐TB prevalence: percentage MDR‐TB among new TB cases = 0.7% (Source: nationwide survey 2001) and among retreatment cases = 3.2% (Source: nationwide surveillance 2011)\
Prevalence of TB cases in the study: 7.5%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: proportion method on LJ mediaFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Balcha 2014**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: HIV‐positive people screened for TB irrespective of symptoms\
Age: 18 years and older, median 32 years (IQR 28 to 40)\
Sex, female: 59%\
HIV infection: 100%\
History of TB: 6%\
Sample size: 810\
Clinical setting: outpatient\
Laboratory level: intermediate\
Country: Ethiopia\
World Bank Income Classification: low income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 15.0%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960Flow and timing Comparative Notes2% of participants were on anti‐TB treatment for up to 2 weeks**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowUnclearDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Barmankulova 2015**Study characteristics**Patient samplingCross‐sectional design, unknown manner of enrolment, direction of data collection unclearPatient characteristics and settingPresenting signs and symptoms: at least 2 weeks of cough, accompanied with loss of weight, night sweats and fever in labour migrants\
Age: median 34 years (IQR 25 to 45) Sex, female: 43%\
HIV infection: not reported\
History of TB: 25%\
Sample size: 291\
Clinical setting: outpatient\
Laboratory level: intermediate and central\
Country: Kyrgyzstan\
World Bank Income Classification: middle income\
High TB burden country: no\
High MDR‐TB burden country: yes\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 80.8%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance LJ and MGIT 960Flow and timing43 participants without microscopy results and 3415 participants without culture results were not includedComparative Notes\"Migrants in the TB REACH project are defined as labour migrants who registered in one region but are working and living permanently in another region without registration and any access to primary healthcare facilities.\"**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**UnclearLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowUnclearDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?No**High**Barnard 2015**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed pulmonary TB defined as 2 of the following: HIV infection, persistent cough lasting \> 3 weeks, haemoptysis, weight loss \> 4 kg, intermittent fever \> 3 weeks or drenching night sweats \> 2 weeks. In addition, at least 1 of the following radiological criteria had to be present: cavitation, diffuse infiltrates, hilar or mediastinal adenopathy, primarily smear‐negative\
Age: 44 years (SD 16)\
Sex, female: 52%\
HIV infection: not reported\
History of TB: yes, % not reported\
Sample size: 112\
Clinical setting: not reported\
Laboratory level: central\
Country: South Africa\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 34.8%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MTBDR*plus*Flow and timing72 participants were excluded due to incomplete dataComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?No**HighUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Unclear**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?No**High**Bates 2013a**Study characteristics**Patient samplingCross‐sectional design, unknown manner of enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: people with cough and ability to produce a sputum sample who presented to obstetrics or gynaecology wards\
Age: median 28 years (IQR 24 to 32)\
Sex, female: 100%\
HIV infection: 66%\
History of TB: 12%\
Sample size: 94\
Clinical setting: inpatient\
Laboratory level: central\
Country: Zambia\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: no\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 27.7%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**UnclearHighDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Bjerrum 2016**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: HIV‐infected adults screened for pulmonary TB irrespective of symptoms\
Age: 18 years and older, median 38 years (IQR 31 to 45)\
Sex, female: 64%\
HIV infection: 100%\
History of TB: 6%\
Sample size: 195\
Clinical setting: both outpatient and inpatient\
Laboratory level: central\
Country: Ghana\
World Bank Income Classification: middle income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 17.9%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960Flow and timing Comparative NotesScreening study**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Boehme 2010**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collection, site in a multicentre studyPatient characteristics and settingPresenting signs and symptoms: persistent productive cough for ≥ 2 weeks\
Age: median 34 years, range 17 to 88 years\
Sex, female: 37%\
HIV infection: 40%\
History of TB: 46%\
Sample size: 1730\
Clinical setting: special facility for prisoners (Azerbaijan); primary health care DOTS (directly observed treatment, short‐course) centres in shanty towns (Peru); clinic (South Africa, Cape Town); TB clinics (South Africa, Durban); tertiary hospital (India)\
Laboratory level: central\
Country: Azerbaijan, India, Peru, South Africa\
World Bank Income Classification: middle income\
High TB burden country: yes (India, South Africa)\
High MDR‐TB burden country: yes (Azerbaijan, India, Peru, South Africa)\
High TB/HIV burden country: yes (India, South Africa)\
Prevalence of TB cases in study: 50.9%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ culture. 7H11 culture, and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: proportion method on LJ media, MGIT, MTBDR*plus*Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Boehme 2011**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collection, site in a multicentre studyPatient characteristics and settingPresenting signs and symptoms: cough lasting at least 2 weeks\
Age: median 38 years (IQR 29 to 50)\
Sex, female: 39%\
HIV infection: 19%\
History of TB: not reported\
Sample size: 6648\
Clinical setting: special facility for prisoners (Azerbaijan); 2 health centres and 1 district hospital (Peru); 1 health centre and 1 provincial hospital (South Africa, Cape Town); emergency unit of referral hospital (Uganda); health centre (India); MDR‐TB evaluation facility (Philippines)\
Laboratory level: central (Azerbaijan, Peru, Philippines, South Africa, Uganda); intermediate (India)\
Country: Azerbaijan, India, Peru, Philippines, South Africa, Uganda\
World Bank Income Classification: middle income (Azerbaijan, India, South Africa, Philippines); low income (Uganda)\
High TB burden country: yes (India, Philippines, South Africa)\
High MDR‐TB burden country: yes (Azerbaijan, India, Peru, Philippines, South Africa)\
High TB/HIV burden country: yes (India, South Africa, Uganda)\
Prevalence of TB cases in the study: 26.4%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ, Ogawa, MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: LJ proportion method; MGIT 960; MTBDR*plus*Flow and timingParticipants who were smear‐negative and culture‐negative but treated for TB on the basis of clinical and radiological findings (clinical tuberculosis) were not included in determination of specificityComparative NotesFollow‐up reported for all sites combined: 24/153 participants with culture‐negative, clinically‐diagnosed TB had positive results on MTB/RIF testing. 20/24 participants had follow‐up, and all 20 improved on TB treatment**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?No**High**Boum 2016**Study characteristics**Patient samplingCross‐sectional design, unknown manner of enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed pulmonary TB with cough for 2 weeks and at least 1 additional TB symptom (fever, weight loss, or night sweats)\
Age: 18 years and older, median 35 years (IQR 29 to 43) for HIV‐positive participants; median 46 years (IQR 30 to 60) for HIV‐negative participants\
Sex, female: 50%\
HIV infection: 70%\
History of TB: 12%\
Sample size: 887\
Clinical setting: both outpatient and inpatient\
Laboratory level: biosafety level 3 laboratory of Epicentre/Médecins sans Frontières Mbarara Research Centre\
Country: Uganda\
World Bank Income Classification: low income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 23.8%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960Flow and timingCould not account for all patientsComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**UnclearLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?No**High**Calligaro 2015**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed pulmonary TB (based on suggestive pulmonary infiltrates, a history of constitutional symptoms preceding the ICU admission, or people known or suspected to be infected with HIV, irrespective of the reason for admission to the ICU)\
Age: 18 years and older, median 38 (IQR 28 to 51)\
Sex, female: 40%\
HIV infection: 27 %\
History of TB: yes, % not reported\
Sample size: 91\
Clinical setting: inpatient\
Laboratory level: central\
Country: South Africa\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 12.1%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowHighDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Calligaro 2017**Study characteristics**Patient samplingRandomized trial, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: HIV‐positive patients with at least one TB symptom according to predefined WHO criteria and HIV‐positive patients irrespective of symptoms (in line with the WHO recommendation to screen all HIV‐positive individuals for TB)\
Age: 18 years or older, median 38 (IQR 32 to 47)\
Sex, female: 55%\
HIV infection: 58%\
History of TB: yes, per cent not reported\
Sample size: 403\
Clinical setting: outpatient\
Laboratory level: in South Africa, diagnostic tests were done at the point‐of‐contact at the mobile van, whereas in Zimbabwe, screened and eligible participants were transported to Mabvuku Clinic and the investigations were done there\
Country: Zimbabwe, South Africa\
World Bank Income Classification: low and middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 10.4%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Carriquiry 2012**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: cough for \> 10 days with abnormal chest x‐ray and at least 1 of the following symptoms: fever, fatigue, night sweats, haemoptysis, chest pain, or weight loss\
Age: 18 years or older, median 35 years (IQR 29 to 42)\
Sex, female: 27.5%\
HIV infection: 100%\
History of TB: 25%\
Sample size: 131\
Clinical setting: both inpatient and outpatient\
Laboratory level: central\
Country: Peru\
World Bank Income Classification: middle income\
High TB burden country: no\
High MDR‐TB burden country: yes\
High TB/HIV burden country: no\
TB incidence rate: 101 per 100,000\
MDR‐TB prevalence: percentage MDR‐TB among new TB cases = 5.3% (Source: nationwide survey 2006) and among retreatment cases = 24% (Source: nationwide survey 2006)\
Prevalence of TB cases in the study: 34.4%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ culture and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: proportion method on LJ mediaFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Chaisson 2014**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed pulmonary TB\
Age: adults, median 54 years (IQR 43 to 60)\
Sex, female: 23%\
HIV infection: 30%\
History of TB: not reported\
Sample size: 142\
Clinical setting: inpatient\
Laboratory level: central\
Country: USA\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 6.3%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: 7H11 and BacT/Alert MPFlow and timing59 participants (25% of eligible patients) were not tested, 46 owing to insufficient quantity and 13 for the following reasons: 6 samples rejected for culture because \> 3 days had elapsed since collection, 4 samples that were not tested for reasons that were not documented, 2 specimens that arrived when the Xpert machine was not operating because it was undergoing routine maintenance, and 1 specimen that was not 1 of the first 2 samples collectedComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowHighDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?NoWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**HighLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?No**Unclear**Chen 2017**Study characteristics**Patient samplingCross‐sectional design, unknown manner of enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: TB symptoms\
Age: 15 years and older, median 64 years (IQR 58 to 71)\
Sex, female: 42%\
HIV infection: not reported\
History of TB: not reported\
Sample size: 733\
Clinical setting: outpatient, health workers went door‐to‐door to identify individuals with TB symptoms and send them to the clinic\
Laboratory level: intermediate\
Country: China\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 0.8%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**UnclearLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Chew 2016**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed pulmonary TB\
Age: adults\
Sex, female: not reported\
HIV infection: not reported\
History of TB: not reported\
Sample size: 238\
Clinical setting: inpatient\
Laboratory level: central\
Country: Singapore\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 16.8%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowHighDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Chikaonda 2017**Study characteristics**Patient samplingCross‐sectional design, random enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: people with microbiologically or clinically diagnosed TB for detection of rifampicin resistance\
Age: 18 years and older\
Sex, female: not reported\
HIV infection: 57%\
History of TB: not reported\
Sample size: 188\
Clinical setting: outpatient\
Laboratory level: central\
Country: Malawi\
World Bank Income Classification: low income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: yesIndex testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MTBDR*plus*Flow and timing Comparative NotesXpert run especially in sputum smear‐negative and HIV‐positive people. Study used frozen specimens**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?UnclearWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Unclear**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Cowan 2017**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, both prospective and retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed TB\
Age: mean 50 years, range 18 ‐ 88 years\
Sex, female: 22%\
HIV infection: 24%\
History of TB: not reported\
Sample size: 318\
Clinical setting: inpatient\
Laboratory level: central\
Country: USA\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 6.3%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: 7H11 and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: 7H11 and MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowHighDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Davis 2014**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed pulmonary TB\
Age: adults, median 52 years (IQR 39 to 60)\
Sex, female: 35%\
HIV infection: 8%\
History of TB: yes, % not reported\
Sample size: 156\
Clinical setting: inpatient\
Laboratory level: central\
Country: USA\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 8.3%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ, 7H11, and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: LJ and 7H11 by proportion method and MGIT 960Flow and timingOf 227 eligible patients, 71 (31%) were excluded because they were not testedComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowHighDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?No**High**Dorman 2018**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collection, multicentre studyPatient characteristics and settingPresenting signs and symptoms: presumed pulmonary TB\
Age: adults, median 28 years (IQR 28 to 50)\
Sex, female: 40%\
HIV infection: 44%\
History of TB: 21%\
Sample size: 1439 for detection of MTB, 551 for rifampicin resistance\
Clinical setting: both outpatient and inpatient\
Laboratory level: central (reference)\
Country: Belarus, Brazil, China, Georgia, India, Kenya, South Africa, Uganda\
World Bank Income Classification: low and middle income\
High TB burden country: yes (Brazil, China, India, Kenya, South Africa)\
High MDR‐TB burden country: yes (Belarus, China, India, Kenya, South Africa)\
High TB/HIV burden country: yes (Brazil, China, India, Kenya, South Africa, Uganda)\
Prevalence of TB cases in the study: 32.1%Index testsIndex: Xpert MTB/RIF and Xpert UltraTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative Notes25 participants (3%) who were smear‐positive but in whom all cultures were negative were excluded from the analysis**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?No**Unclear**Friedrich 2011**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: people recently diagnosed with smear‐positive first time TB, untreated\
Age: 18 to 65 years\
Sex, female: not reported\
HIV infection: not reported\
History of TB: not reported\
Sample size: 126\
Clinical setting: smear examination at TB clinic and referred to inpatient settings\
Laboratory level: central\
Country: South Africa, Cape Town\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
TB incidence rate: 993 per 100,000\
MDR‐TB prevalence: % MDR‐TB among new TB cases = 0.9% (Source: survey in Western Cape Province, 2002) and among retreatment cases = 4.0% (Source: survey in Western Cape Province, 2002)\
Prevalence of TB cases in the study: 100.0%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative NotesThe aim of this study was to assess NAATs for selecting participants for clinical trials of anti‐TB medication. People with severe co‐morbidities were excluded. This study was used only for determination of sensitivity because all enrolled participants were predetermined to have TB disease**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?No**HighLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowUnclearDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Geleta 2015**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, direction of data collection unclearPatient characteristics and settingPresenting signs and symptoms: signs, symptoms, or chest x‐ray suggestive of TB\
Age: median 35 years, range 18 to 82 years\
Sex, female: 37%\
HIV infection: not reported\
History of TB: not reported\
Sample size: 220\
Clinical setting: not reported\
Laboratory level: central\
Country: Ethiopia\
World Bank Income Classification: low income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 26.4%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Hanif 2011**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed TB based on presence of cough and radiographic findings\
Age: range 20 to 57 years\
Sex, female: not reported\
HIV infection: not reported\
History of TB: not reported\
Sample size: 206\
Clinical setting: laboratory‐based\
Laboratory level: central\
Country: Kuwait\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
TB incidence rate: 36 per 100,000\
MDR‐TB prevalence: % MDR‐TB among new TB cases = 0% and among retreatment cases = 12% (Source: nationwide surveillance, 2011)\
Prevalence of TB cases in the study: 29.1%Index testsIndex: Xpert MTB/RIF assayTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ culture and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: BACTEC 460Flow and timing Comparative NotesNo participants were found to have rifampicin resistance**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?NoWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**HighLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?NoWere all patients included in the analysis?Yes**Low**Hanrahan 2013**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: prolonged (\> 2 weeks) cough and/or other TB symptoms\
Age: 18 years and older, median 35 years (IQR 29 to 44)\
Sex, female: 65%\
HIV infection: 69%\
History of TB: 10%\
Sample size: 553\
Clinical setting: outpatient\
Laboratory level: peripheral\
Country: South Africa, Johannesburg\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
TB incidence rate: 993 per 100,000\
MDR‐TB prevalence: % MDR‐TB among new TB cases = 1.4% (Source: survey in Gauteng province, 2002) and among retreatment cases = 5.5% (Source: survey in Gauteng province, 2002)\
Prevalence of TB cases in the study: 11.6%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Hanrahan 2014**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed pulmonary TB\
Age:15 years and older, median 37 years (IQR 29 to 46)\
Sex, female: 62%\
HIV infection: 58%\
History of TB: not reported\
Sample size: 2082\
Clinical setting: outpatient\
Laboratory level: central\
Country: South Africa\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 19.5%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: Pulmonary TB\
Reference standard for pulmonary TB: MGIT 960Flow and timing Comparative NotesThis study focused on drug‐susceptible TB and therefore excluded 10 people found to have rifampicin resistance on Xpert**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Unclear**Unclear**Helb 2010**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: cough lasting at least 2 weeks\
Age: median 34 years, range 18 to 76 years\
Sex, female: 30.8%\
HIV infection: 0.9%\
History of TB: 1.9%\
Sample size: 107\
Clinical setting: TB hospital, unclear whether inpatient or outpatient or both\
Laboratory level: central\
Country: Vietnam\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: no\
TB incidence rate: 199 per 100,000\
MDR‐TB prevalence: Percent MDR‐TB among new TB cases = 2.7% (Source: nationwide survey, 2006) and among retreatment cases = 19% (Source: nationwide survey, 2006)\
Proportion of TB cases in the study: 76.6%Index testsIndex: Xpert MTB/RIF assayTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard: LJ culture and MGIT 960Flow and timing Comparative NotesRifampicin resistance data were not reported**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Unclear**Unclear**Henostroza 2016**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: ART‐naïve people presenting for initiation of HIV care\
Age: 16 years and older, median 34 years (IQR 29 to 40)\
Sex, female: 49%\
HIV infection: 100%\
History of TB: not reported\
Sample size: 332\
Clinical setting: outpatient\
Laboratory level: central\
Country: Zambia\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: no\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 18.6%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960Flow and timing Comparative NotesThe paper states that outpatients in this cohort were likely to have been less ill than hospitalized patients**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Huang 2015**Study characteristics**Patient samplingCross‐sectional design, manner of enrolment unclear, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: not reported\
Age: mean 42 years, range 15 to 55 years\
Sex, female: 44%\
HIV infection: not reported\
History of TB: not reported\
Sample size: 378\
Clinical setting: laboratory‐based\
Laboratory level: peripheral\
Country: China\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 49.7%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960\
Target condition: Rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**UnclearLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Huh 2014**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive pulmonary TB as defined by the presence of the clinical symptoms (cough, fever, night sweats, or weight loss) and radiologic findings compatible with TB, in either a chest x‐ray or a computed tomography scan\
Age: median 58 years, range 18 to 93 years\
Sex, female: 34%\
HIV infection: 0.3%\
History of TB: not reported\
Sample size: 271\
Clinical setting: tertiary care hospital, unclear if outpatient, inpatient, or both\
Laboratory level: central\
Country: Republic of Korea\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 38.4%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960, Ogawa culture\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960, LJ‐DSTFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Jo 2016**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: not reported, included patients from bronchoscopy registry, primarily smear‐negative.\
Age: adults, mean 63 years (SD 17)\
Sex, female: 34%\
HIV infection: 0.3%\
History of TB: 15%\
Sample size: 320\
Clinical setting: not reported\
Laboratory level: central\
Country: Republic of Korea\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 20.0%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: Ogawa and MGIT 960Flow and timing Comparative NotesOnly 10 bronchoscopically obtained specimens (7.69%) were smear‐positive**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?No**HighUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Kawkitinarong 2017**Study characteristics**Patient samplingCross‐sectional design, random enrolment for 2 sites, consecutive enrolment for 1 site, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed pulmonary TB\
Age: adults, median 41 years (IQR 30.8 to 54.3)\
Sex, female: 42.5%\
HIV infection: 25.9%\
History of TB: not reported\
Sample size: 389\
Clinical setting: not reported\
Laboratory level: central\
Country: Thailand\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 64.3%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: Pulmonary TB\
Reference standard for pulmonary TB: Ogawa and MGIT 960\
Target condition: Rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Kim CH 2015**Study characteristics**Patient samplingCross‐sectional design, manner of participant selection unknown, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed TB\
Age: mean 56 years (SD 18)\
Sex, female: 43%\
HIV infection: 0.1%\
History of TB: not reported\
Sample size: 405\
Clinical setting: inpatient\
Laboratory level: central\
Country: Republic of Korea\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 12.8%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: Ogawa and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: LJ, concentration methodFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**UnclearHighDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Unclear**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Ko 2016**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed pulmonary TB\
Age: adults (range 17 ‐ 87 years), median 58 years (IQR 43 to 71)\
Sex, female: 42%\
HIV infection: 0.4%\
History of TB: not reported\
Sample size: 249\
Clinical setting: not reported\
Laboratory level: central\
Country: Republic of Korea\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 42.2%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: Pulmonary TB\
Reference standard for pulmonary TB: Ogawa and MGITFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?UnclearWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Kurbaniyazova 2017**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: people with cough of 2 weeks, fever, night sweats and weight loss; TB patients with positive smear results or a sputum smear‐negative result but radiographic abnormalities suggestive of TB; retreatment cases; contacts of TB or MDR‐TB patients; patients with severe clinical condition; and HIV‐positive patients or those with unknown HIV status in high‐risk settings such as migrants or prisoners; according to the diagnostic algorithm of Kyrgyzstan's National Tuberculosis Programme's clinical protocol\
Age: adults \> 18\
Sex, female: not reported\
HIV infection: not reported\
History of TB: not reported\
Sample size: 2734\
Clinical setting: outpatient\
Laboratory level: central\
Country: Kyrgyzstan\
World Bank Income Classification: middle income\
High TB burden country: no\
High MDR‐TB burden country: yes\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 62.2%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT\
Target condition: Rifampicin resistance\
Reference standard for rifampicin resistance: LJ and MGITFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Kurbatova 2013**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive or recently diagnosed TB\
Age: 18 years and older\
Sex, female: not reported\
HIV infection: estimated \< 5 %\
History of TB: not reported\
Sample size: 228\
Clinical setting: outpatient and inpatient\
Laboratory level: central\
Country: Russia\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: no\
High TB/HIV burden country: yes\
TB incidence rate: 97 per 100,000\
MDR‐TB prevalence: Percent MDR‐TB among new TB cases = 20% (Source: Surveillance in 20 Oblasts 2010) and among retreatment cases = 46% (Source: Surveillance in 20 Oblasts 2008)\
Prevalence of TB cases in the study: 46.9%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative NotesFresh, unconcentrated sputum was initially homogenized using a vortex with glass beads**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Kwak 2013**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: people presumed to have pulmonary TB\
Age: adults \> 15 years, median 61 years (IQR 47.5 to 73)\
Sex, female: 37%\
HIV infection: 0.7%\
History of TB: not reported\
Sample size: 681\
Clinical setting: both outpatient and inpatient\
Laboratory level: central\
Country: Republic of Korea\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 22.9%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: Ogawa and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: LJ by method of absolute concentrationFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**LaCourse 2016**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: none reported. HIV‐infected women accessing prevention of mother‐to‐child transmission services as part of antenatal care were eligible\
Age: 16 years and older, median 25 years (IQR 22 to 30)\
Sex, female: 100%\
HIV infection: 100%\
History of TB: 9%\
Sample size: 288\
Clinical setting: outpatient\
Laboratory level: central\
Country: Kenya\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 2.4%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Lawn 2011**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: HIV‐infected people with advanced immunodeficiency; most had 1 or more of the following TB symptoms: current cough, fever, night sweats, or weight loss\
Age: median 34 years (IQR 28 to 41)\
Sex, female: 65.4%\
HIV infection: 100%\
History of TB: 26.5%\
Sample size: 394\
Clinical setting: HIV anti‐retroviral clinic; all participants were screened for TB\
Laboratory level: central\
Country: South Africa, Cape Town\
World Bank Income Classification: middle income\
High TB burden country: yes High MDR‐TB burden country: yes High TB/HIV burden country: yes\
TB incidence rate: 993 per 100,000\
MDR‐TB prevalence: % MDR‐TB among new TB cases = 0.9% (Source: survey in Western Cape Province, 2002) and among retreatment cases = 4.0% (Source: survey in Western Cape Province, 2002)\
Prevalence of TB cases in the study: 18.3%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative NotesThis study evaluated the use of Xpert to screen HIV‐infected people with advanced immunodeficiency enrolling in antiretroviral therapy services regardless of symptoms, although most participants in the study had TB symptoms. Of 3 participants with apparent false‐positive Xpert MTB/RIF results, on follow‐up 2 had overt pulmonary and systemic symptoms suggestive of TB and improved on anti‐TB treatment. The 3rd participant was lost to follow‐up.\
Median CD4 cell count, 171 cells/ml; IQR 102 to 236**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Le Palud 2014**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive pulmonary TB based on clinical features (e.g. cough, haemoptysis, fever, asthenia, loss of weight, and night sweats) or radiological features (e.g. nodule, pneumonia, cavitation, and pleurisy), smear‐negative\
Age: median 54 years (IQR 34 to 74)\
Sex, female: 37%\
HIV infection: 4%\
History of TB: not reported\
Sample size: 162\
Clinical setting: not reported\
Laboratory level: central\
Country: France\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 12.3%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: Colestos slant and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?No**HighUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Lee 2013**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed pulmonary TB, smear‐negative\
Age: median: 54 years, range 18 to 90 years\
Sex, female: 41%\
HIV infection: 1%\
History of TB: 21%\
Sample size: 132\
Clinical setting: not reported\
Laboratory level: central\
Country: Republic of Korea\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 28.8%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: Ogawa medium and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: Ogawa medium, proportion methodFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?No**HighUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?UnclearWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Unclear**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Lippincott 2014**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive pulmonary TB\
Age: median: 51 years (IQR 39 to 63)\
Sex, female: 36%\
HIV infection: 24%\
History of TB: not reported\
Sample size: 499\
Clinical setting: inpatient\
Laboratory level: central\
Country: USA\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 3.0%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowHighDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Liu 2017**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: people presumed to have pulmonary TB, who had cough, expectoration or haemoptysis for more than 2 weeks were enrolled\
Age: 15 years and older\
Sex, female: not reported\
HIV infection: not reported\
History of TB: not reported\
Sample size: 3096\
Clinical setting: not reported\
Laboratory level: intermediate\
Country: China\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 14.1%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: LJFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Lorent 2015**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive drug‐resistant TB, including previously treated people (failure, relapse, return after default); symptomatic close contacts of known MDR‐TB cases; new TB patients with delayed smear conversion at month 2 or 3 of first‐line treatment; and all HIV‐infected people, regardless of smear results\
Age: median: 43 years (IQR 34 to 52)\
Sex, female: 47%\
HIV infection: 65%\
History of TB: 46%\
Sample size: 274\
Clinical setting: outpatient\
Laboratory level: central\
Country: Cambodia\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: no\
High TB/HIV burden country: noIndex testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: LJ proportion methodFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?NoWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?No**HighLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Luetkemeyer 2016**Study characteristics**Patient samplingCross‐sectional design, unknown manner of enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: cough, fever, night sweats, or weight loss\
Age: 18 years and older, median 46 years (IQR 35 to 54)\
Sex, female: 38%\
HIV infection: 45%\
History of TB: 13%\
Sample size: 992\
Clinical setting: inpatient and outpatient\
Laboratory level: central\
Country: Brazil, South Africa and USA\
World Bank Income Classification: high and middle income\
High TB burden country: yes (South Africa), no (USA)\
High MDR‐TB burden country: yes (South Africa), no (USA)\
High TB/HIV burden country: yes (South Africa), no (USA)\
Prevalence of TB cases in the study: 22.4Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: solid media and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: Middlebrook agarFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**UnclearLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Makamure 2017**Study characteristics**Patient samplingCross‐sectional design, enrolment by convenience, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: MDR‐TB high‐risk patients (TB symptoms with at least 1 of the following: previously confirmed MDR‐TB, failure to convert after at least 2 months therapy, treatment failure, return after default, relapse after completion of treatment or contacts of known MDR‐TB cases)\
Age: 15 years and older, median: 38 years (IQR 30 to 47)\
Sex, female: 42%\
HIV infection: 63%\
History of TB: 78%\
Sample size: 210\
Clinical setting: not reported\
Laboratory level: central\
Country: Zimbabwe\
World Bank Income Classification: low income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yesIndex testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: LJFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?NoWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**HighUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?Were the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Mbelele 2017**Study characteristics**Patient samplingCross‐sectional design, unknown manner of enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed pulmonary TB\
Age: 18 years and older, mean 43 years (SD 15)\
Sex, female: 66%\
HIV infection: 15%\
History of TB: 14%\
Sample size: 262\
Clinical setting: not reported\
Laboratory level: central\
Country: Tanzania\
World Bank Income Classification: low income\
High TB burden country: yes\
High MDR‐TB burden country: no\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 32.4%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**UnclearUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Unclear**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Meawed 2016**Study characteristics**Patient samplingCross‐sectional design, unknown manner of enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: recurrence of general or local chest symptoms, suspected retreatment TB\
Age: mean 33 years (SD 19), age range 21 ‐ 67 years\
Sex, female: 33%\
HIV infection: not reported\
History of TB: 100%\
Sample size: 58\
Clinical setting: outpatient\
Laboratory level: central\
Country: Egypt\
World Bank Income Classification: middle income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 93.1%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?No**HighLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?UnclearWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Metcalfe 2015**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: recurrent TB (TB following cure or completion of treatment of a previous TB episode), or prevalent retreatment TB (treatment failure, i.e. sputum smear‐positivity at month 5 or later)\
Age: 15 years and older\
Sex, female: not reported\
HIV infection: 75%\
History of TB: 100%\
Sample size: 149\
Clinical setting: outpatient\
Laboratory level: central\
Country: Zimbabwe\
World Bank Income Classification: low income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 59.7Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ, MGIT 960 and MODSFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?No**HighLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Metcalfe 2016**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: cough (any duration), fever, night sweats, or weight loss, with a history of prior TB\
Age: 15 years and older\
Sex, female: not reported\
HIV infection: 68%\
History of TB: 100%\
Sample size: 352\
Clinical setting: outpatient\
Laboratory level: central\
Country: Zimbabwe\
World Bank Income Classification: low income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yesIndex testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: LJ and MODSFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?Were the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Meyer 2017**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive TB with cough ≥ 2 weeks but \< 6 months, smear‐negative\
Age: 18 years and older, median 34 years (IQR 28 to 44)\
Sex, female: 49%\
HIV infection: 66%\
History of TB: 12%\
Sample size: 1782\
Clinical setting: inpatient\
Laboratory level: central\
Country: Uganda\
World Bank Income Classification: low income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 22%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?No**HighHighDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Mok 2016**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive pulmonary TB, sputum scarce or sputum smear‐negative\
Age: 21 years and older, median 59 years (IQR 43 to 66)\
Sex, female: 29%\
HIV infection: not reported\
History of TB: not reported\
Sample size: 158\
Clinical setting: inpatient\
Laboratory level: central\
Country: Singapore\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 28%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?No**HighHighDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowUnclearDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Mokaddas 2015**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive TB\
Age: 14 years and older\
Sex, female: not reported\
HIV infection: not reported\
History of TB: not reported\
Sample size: 287\
Clinical setting: laboratory‐based\
Laboratory level: central\
Country: Kuwait\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 21.9%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?Were the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Mollel 2017**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: not reported\
Age: 16 years and older, mean 42 years\
Sex, female: 55%\
HIV infection: 100%\
History of TB: not reported\
Sample size: 69\
Clinical setting: outpatient\
Laboratory level: intermediate\
Country: Tanzania\
World Bank Income Classification: low income\
High TB burden country: yes\
High MDR‐TB burden country: no\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 13.0%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?UnclearWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**UnclearHighDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Moure 2011**Study characteristics**Patient samplingCross‐sectional design, enrolment by convenience, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: not reported; participants found to be smear‐negative on microscopy\
Age: older than 15 years; mean: 42 years\
Sex, female: not reported\
HIV infection: not reported\
History of TB: not reported\
Sample size: 107\
Clinical setting: laboratory‐based\
Laboratory level: central\
Country: Spain\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
TB incidence rate: 15 per 100,000\
MDR‐TB prevalence: percentage MDR‐TB among new TB cases = 0.2% (Source: Survey in Galicia region, 2005) and among retreatment cases = 1.5% (Source: Survey in Galicia region, 2005)\
Prevalence of TB cases in the study: 72.9%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ culture and MGIT 960Flow and timing Comparative NotesSample set included 1 pulmonary biopsy specimen\
Of 85 pulmonary and extrapulmonary specimens tested, 6 were positive by Xpert MTB/RIF for rifampicin resistance, and 7 specimens were positive by the reference standard**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?NoWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**HighLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowUnclearDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Moussa 2016**Study characteristics**Patient samplingCross‐sectional design, unknown manner of enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: clinical signs of pulmonary TB\
Age: 18 to 60 years\
Sex, female: not reported\
HIV infection: 0%\
History of TB: not reported\
Sample size: 218\
Clinical setting: laboratory‐based\
Laboratory level: central\
Country: Egypt\
World Bank Income Classification: middle income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 32.1%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: Middlebrook 7H11 agarFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**UnclearUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Mutingwende 2015**Study characteristics**Patient samplingCross‐sectional design, unknown manner of enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive TB in miners\
Age: median 46 years (IQR 39 to 51)\
Sex, female: 4%\
HIV infection: 74%\
History of TB: 57%\
Sample size: 306\
Clinical setting: outpatient\
Laboratory level: central\
Country: South Africa\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 75.7%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960Flow and timing242 test results were missing for Xpert, microscopy and MGITComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**UnclearLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowUnclearDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?No**High**N\'Guessan 2016**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed pulmonary TB, smear‐positive (failure, relapse, default)\
Age: mean 33 years (SD 11), range 15 to 73 years\
Sex, female: 32%\
HIV infection: 18%\
History of TB: 100%\
Sample size: 63\
Clinical setting: not reported\
Laboratory level: central\
Country: Cote d\'Ivoire\
World Bank Income Classification: middle income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: noIndex testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?No**HighUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?Were the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Ngabonziza 2016**Study characteristics**Patient samplingCross‐sectional design with consecutive enrolment of participants, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: people with presumptive TB\
Age: 15 years and older, median 37 years (IQR 28 to 50)\
Sex, female: 38%\
HIV infection: 27%\
History of TB: not reported\
Sample size: 600\
Clinical setting: outpatient\
Laboratory level: central\
Country: Rwanda\
World Bank Income Classification: low income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 16.0%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?UnclearWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Nikam 2014**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: symptoms of pulmonary TB\
Age: 15 years and older\
Sex, female: not reported\
HIV infection: not reported\
History of TB: not reported\
Sample size: 274\
Clinical setting: laboratory‐based\
Laboratory level: central\
Country: India\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 55.1%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960Flow and timing Comparative NotesThe authors thought that the study may have included participants on anti‐TB treatment**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Nliwasa 2016**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: cough for \> 2 weeks\
Age: 15 years and older, median: 32 years (IQR 25 to 41)\
Sex, female: 44%\
HIV infection: 44%\
History of TB: not reported\
Sample size: 273\
Clinical setting: outpatient\
Laboratory level: central\
Country: Malawi\
World Bank Income Classification: low income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 17.4%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Nosova 2013a**Study characteristics**Patient samplingCross‐sectional design, unknown manner of enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed pulmonary TB\
Age: adults\
Sex, female: not reported\
HIV infection: not reported\
History of TB: not reported\
Sample size: 278\
Clinical setting: laboratory‐based\
Laboratory level: central\
Country: Russia\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 37.2%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960\
Reference standard for rifampicin resistance detection: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**UnclearUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowUnclearDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**O\'Donnell 2015**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed pulmonary TB\
Age: median 33 years, range 18 to 63 years\
Sex, female: 47%\
HIV infection: 51%\
History of TB: 28%\
Sample size: 173\
Clinical setting: outpatient and inpatient\
Laboratory level: central\
Country: South Africa\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 76.8%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: 7H10 agar plates and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: 7H10Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Park 2013**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed pulmonary TB\
Age: 15 years and older\
Sex, female: not reported\
HIV infection: not reported\
History of TB: not reported\
Sample size: 320\
Clinical setting: not reported\
Laboratory level: central\
Country: Republic of Korea\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 7.2%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: LJ and MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Pimkina 2015**Study characteristics**Patient samplingCross‐sectional design, unknown manner of enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: people with known risk factors for MDR‐TB and all retreatment patients including those with extensive lung damage, e.g. cavities\
Age: 18 years and older; median 50 years\
Sex, female: 29%\
HIV infection: not reported\
History of TB: 100%\
Sample size: 792\
Clinical setting: laboratory‐based, specimens submitted from local general practitioners and hospitals\
Laboratory level: central\
Country: Lithuania\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 48.2%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 950\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: LJ and MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?No**HighLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?UnclearWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Unclear**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Pinyopornpanish 2015**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: 2 or more of the following symptoms: fever, chronic cough, weight loss, pleuritic chest pain, haemoptysis, and with or without abnormal chest radiograph compatible with pulmonary tuberculosis (e.g. cavitary lesion, infiltration, and miliary pattern)\
Age: 15 years and older, mean 56 years (SD 20)\
Sex, female: 40%\
HIV infection: 26%\
History of TB: not reported\
Sample size: 109\
Clinical setting: not reported\
Laboratory level: central\
Country: Thailand\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 39.4%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Rachow 2011**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive pulmonary TB based on clinical and radiographic findings\
Age: mean 39 years (SD 13.8)\
Sex, female: 51.7%\
HIV infection: 58.9%\
History of TB: not reported\
Sample size: 249\
Clinical setting: referral hospital\
Laboratory level: central\
Country: Tanzania\
World Bank Income Classification: low income\
High TB burden country: yes\
High MDR‐TB burden country: no\
High TB/HIV burden country: yes\
TB incidence rate: 169 per 100,000\
MDR‐TB prevalence: percentage MDR‐TB among new TB cases = 1.1% (Source: nationwide survey, 2007) and among retreatment cases = 0% (Source: Nationwide survey, 2007)\
Prevalence of TB cases in the study: 27.7%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ culture and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative NotesParticipants were followed for a period of 56 days. Among 77 participants classified as smear‐negative, culture‐negative \'clinical TB\', Xpert MTB/RIF was positive in 7 (9.1%) participants\
No participants were found to have rifampicin resistance**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Unclear**Unclear**Reddy 2017**Study characteristics**Patient samplingCross‐sectional design, random enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: TB symptoms\
Age: 18 to 60 years\
Sex, female: 47%\
HIV infection: not reported\
History of TB: 33%\
Sample size: 705\
Clinical setting: outpatient\
Laboratory level: central\
Country: South Africa\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 23.8%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Reechaipichitkul 2017**Study characteristics**Patient samplingCross‐sectional design, unknown manner of enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: clinical signs and symptoms of pulmonary TB, including cough and prolonged fever of \> 2 weeks\
Age: 15 years and older, mean 55 years (SD 18)\
Sex, female: 34%\
HIV infection: 5%\
History of TB: 38%\
Sample size: 125\
Clinical setting: not reported\
Laboratory level: intermediate\
Country: Thailand\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 50.4%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**UnclearUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowUnclearDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?UnclearWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Rice 2017**Study characteristics**Patient samplingCross‐sectional design consecutive enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: signs and symptoms of pulmonary TB\
Age: median 50 years (IQR 35 to 60)\
Sex, female: not reported\
HIV infection: not reported\
History of TB: not reported\
Sample size: 751\
Clinical setting: outpatient\
Laboratory level: central\
Country: USA\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 18.2%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: Middlebrook solid, MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative NotesParticipants were also tested with Xpert if the test result would alter case management or TB control activities**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?UnclearWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Safianowska 2012**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive TB\
Age: mean 61 years, range 20 to 97 years\
Sex, female: 36.6%\
HIV infection: 0%\
History of TB: not reported\
Sample size: 145\
Clinical setting: laboratory‐based\
Laboratory level: intermediate\
Country: Poland\
World Bank Income Classification: high income\
TB incidence rate: 23 per 100,000\
MDR‐TB prevalence: percentage MDR‐TB among new TB cases = 0.5% (Source: nationwide surveillance, 2011) and among retreatment cases = 3.5% (Source: nationwide surveillance, 2011)\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 11.8%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ culture\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: LJ media, method not specifiedFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?NoWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?No**HighLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Sah 2017**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive TB\
Age: 20 to 83 years\
Sex, female: not reported\
HIV infection: not reported\
History of TB: not reported\
Sample size: 105\
Clinical setting: not reported\
Laboratory level: central\
Country: Nepal\
World Bank Income Classification: low income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 37.1%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: LJFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Scott 2011**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive TB presenting with cough, fever, night sweats, and/or weight loss\
Age: mean 32 years, range 19 to 75 years\
Sex, female: 41.1%\
HIV infection: 69.0%\
History of TB: not reported\
Sample size: 177\
Clinical setting: primary care clinic\
Laboratory level: central\
Country: South Africa, Johannesburg\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
TB incidence rate: 993 per 100,000\
MDR‐TB prevalence: percentage MDR‐TB among new TB cases = 1.4% (Source: survey in Gauteng province, 2002) and among retreatment cases = 5.5% (Source: survey in Gauteng province, 2002)\
Prevalence of TB cases in the study: 37.9%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative Notes1 follow‐up visit was performed approximately 60 days after enrolment\
Xpert MTB/RIF was performed on frozen specimens while MGIT culture and smear microscopy were performed on fresh specimens**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowUnclearDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Scott 2017**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive TB, including presence of a cough for 2 weeks, weight loss, night sweats, fever, chest pain\
Age: mean 34 years, range 18 to 60 years\
Sex, female: 38%\
HIV infection: 73%\
History of TB: 15%\
Sample size: 206\
Clinical setting: outpatient\
Laboratory level: central\
Country: South Africa\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 32.1%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Shao 2017**Study characteristics**Patient samplingCross‐sectional design, unknown manner of enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive TB\
Age: mean 53 years (SD 19)\
Sex, female: 31%\
HIV infection: not reported\
History of TB: not reported\
Sample size: 225\
Clinical setting: outpatient\
Laboratory level: peripheral\
Country: China\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 38.1%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJFlow and timing129 presumed TB patients were excludedComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**UnclearLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?No**High**Sharma 2015**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: clinical suspicion of TB\
Age: adults, mean 37 years (SD 18)\
Sex, female: 35%\
HIV infection: not reported\
History of TB: not reported\
Sample size: 1437\
Clinical setting: laboratory‐based\
Laboratory level: central\
Country: India\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 31.2%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: LJFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Shenai 2016**Study characteristics**Patient samplingCross‐sectional design, unknown manner of enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: cough for 2 weeks and 1 or more of the following: fever, night sweats, or weight loss\
Age: 18 years or older; median 40 years (IQR 30 to 50)\
Sex, female: 40%\
HIV infection: 18%\
History of TB: not reported\
Sample size: 336\
Clinical setting: outpatient\
Laboratory level: central\
Country: Brazil, South Africa, Uganda\
World Bank Income Classification: low and middle income\
High TB burden country: yes (Brazil), yes (South Africa), no (Uganda)\
High MDR‐TB burden country: no (Brazil), yes (South Africa), no (Uganda)\
High TB/HIV burden country: yes (Brazil), yes (South Africa), yes (Uganda)\
Prevalence of TB cases in the study: 28.9%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**UnclearLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Singh 2016**Study characteristics**Patient samplingCross‐sectional design, unknown manner of enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive pulmonary TB\
Age: range 15 to 60 years\
Sex, female: not reported\
HIV infection: 0%\
History of TB: not reported\
Sample size: 72\
Clinical setting: not reported\
Laboratory level: central\
Country: India\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yesIndex testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**UnclearUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowUnclearDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Sohn 2014**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive active pulmonary TB, only 18% of participants were symptomatic\
Age: median 44 years (IQR 31 to 61), range 18 to \> 50 years\
Sex, female: 44%\
HIV infection: 2%\
History of TB: 22%\
Sample size: 501\
Clinical setting: outpatient\
Laboratory level: central\
Country: Canada\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 5.0%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative NotesOnly 18% of the included participants had symptoms suggestive of active TB (e.g. fever, cough, night sweats, weight loss)**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Ssengooba 2014**Study characteristics**Patient samplingCross‐sectional design, random enrolment, prospective study designPatient characteristics and settingPresenting signs and symptoms: clinical TB symptoms\
Age: 18 years and older, median 33 years (IQR 29 to 37)\
Sex, female: 63%\
HIV infection: 100%\
History of TB: not reported\
Sample size: 424\
Clinical setting: inpatient and outpatient\
Laboratory level: central\
Country: Uganda\
World Bank Income Classification: low income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 29.0%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative NotesSubstudy of [@CD009593-bbs2-0357]**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Tadesse 2016**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment of participants, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: clinical suspicion of TB, smear‐negative\
Age: 18 years and older, median 38 years (IQR 23 to 55)\
Sex, female: 38%\
HIV infection: 0%\
History of TB: not reported\
Sample size: 185\
Clinical setting: not reported\
Laboratory level: central\
Country: Ethiopia\
World Bank Income Classification: low income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 10.3%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: LJ and MGIT 960Flow and timing Comparative Notes\"One hundred twenty‐four patients were excluded from the study (56 were HIV‐positive/unknown, 30 were smear positive, 19 provided a sample with inadequate volume, 13 did not provide three sputa, and six had missing acid‐fast bacilli‐smear results).\"**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?No**HighUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Tang 2017**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: clinical suspicion of TB\
Age: median 36 years, range 16 to 78 years\
Sex, female: 47%\
HIV infection: not reported\
History of TB: not reported\
Sample size: 240\
Clinical setting: not reported\
Laboratory level: central\
Country: China\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 36.0%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative NotesStudy authors considered the quality of specimens, collection, transport, and testing times as possible explanations for low Xpert specificity in this study**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Theron 2011**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive TB based on compatible signs and symptoms\
Age: median 36 years, range 18 to 83 years\
Sex, female: 32.3%\
HIV infection: 31.3%\
History of TB: 34.3%\
Sample size: 480\
Clinical setting: 2 primary care clinics in a high HIV prevalence area\
Laboratory level: central\
Country: South Africa, Cape Town\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
TB incidence rate: 993 per 100,000\
MDR‐TB prevalence: percentage MDR‐TB among new TB cases = 0.9% (Source: survey in Western Cape Province, 2002) and among retreatment cases = 4.0% (Source: survey in Western Cape Province, 2002)\
Prevalence of TB cases in the study: 29.4%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative NotesShort‐term follow‐up cultures were obtained; 16 of 19 Xpert MTB/RIF‐positive culture‐negative participants were considered likely to be TB cases based on follow‐up cultures, gene sequencing, and the presence of characteristic radiographic features using a standardized scoring system**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Theron 2013**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumptive pulmonary TB, sputum scarce or smear‐negative\
Age: 18 years and older, median 46 years (IQR 33 to 56)\
Sex, female: 46%\
HIV infection: 30%\
History of TB: 34%\
Sample size: 154\
Clinical setting: not reported\
Laboratory level: central\
Country: South Africa\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 17.8%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?No**HighUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Theron 2014a**Study characteristics**Patient samplingRandomized, parallel‐group, multicentre trial, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: 1 or more symptoms of pulmonary TB according to predefined WHO criteria\
Age: 18 years or older, median 37 years (IQR 30 to 46)\
Sex, female: 43%\
HIV infection: 69%\
History of TB: not reported\
Sample size: 729\
Clinical setting: outpatient\
Laboratory level: peripheral\
Country: South Africa, Zimbabwe, Zambia, and Tanzania\
World Bank Income Classification: low and middle income\
High TB burden country: yes (South Africa), yes (Zimbabwe), yes (Zambia), yes (Tanzania)\
High MDR‐TB burden country: yes (South Africa), yes (Zimbabwe), no (Zambia), no (Tanzania)\
High TB/HIV burden country: yes (South Africa), yes (Zimbabwe), yes (Zambia), yes (Tanzania)\
Prevalence of TB cases in the study: 25.4%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Tsuyuguchi 2017**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed TB\
Age: mean 65 years (SD 17), range 23 to 94 years\
Sex, female: 38%\
HIV infection: not reported\
History of TB: not reported\
Sample size: 417\
Clinical setting: not reported\
Laboratory level: central\
Country: Japan\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 55.0%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: Ogawa and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timingA total of 515 sputum specimens were collected; however, 35 were ineligible due to over‐testingComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Unclear**Unclear**Van Rie 2013**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: prolonged (\> 2 weeks) cough or other TB symptoms, or both, and had 2 prior‐negative smear by fluorescence microscopy\
Age: median 36 years (IQR 30 to 34)\
Sex, female: 56.8%\
HIV infection: 72.4%\
History of TB: 17.6%\
Sample size: 161\
Clinical setting: primary care clinic\
Laboratory level: peripheral\
Country: South Africa, Johannesburg\
World Bank Income Classification: middle income\
High TB burden country: yes\
High MDR‐TB burden country: yes\
High TB/HIV burden country: yes\
TB incidence rate: 993 per 100,000\
MDR‐TB prevalence: percentage MDR‐TB among new TB cases = 1.4% (Source: survey in Gauteng province, 2002) and among retreatment cases = 5.5% (Source: survey in Gauteng province, 2002)\
Prevalence of TB cases in the study: 9.3%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timingOnly those participants presumed to have TB who returned for results of the initial smear microscopy examinations were enrolledComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?No**HighLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?No**High**Walusimbi 2013a**Study characteristics**Patient samplingCross‐sectional design, unknown manner of enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: cough for \> 2 weeks, with or without fever, night sweats, loss of weight, or blood‐stained sputum, smear‐negative\
Age: adults, median 34 years (IQR 29 to 40)\
Sex, female: 56%\
HIV infection: 100%\
History of TB: not reported\
Sample size: 601\
Clinical setting: inpatient and outpatient\
Laboratory level: central\
Country: Uganda\
World Bank Income Classification: low income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 11.7%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?No**HighLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Williamson 2012**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: not reported: smear‐positive specimens\
Age: 15 years and older\
Sex, female: not reported\
HIV infection: estimated \< 1%\
History of TB: not reported\
Sample size: 89\
Clinical setting: laboratory‐based\
Laboratory level: central\
Country: New Zealand\
World Bank Income Classification: high income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
TB incidence rate: 7.6 per 100,000\
MDR‐TB prevalence: percentage MDR‐TB among new TB cases = 2.5% (Source: nationwide surveillance 2009) and among retreatment cases = 13% (Source: nationwide surveillance 2009)\
Prevalence of TB cases in the study: 75.3%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?No**HighUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Yoon 2017**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: HIV‐positive people initiating antiretroviral therapy\
Age: 18 years and older, median 33 years (IQR 27 to 40)\
Sex, female: 53%\
HIV infection: 100%\
History of TB: 4%\
Sample size: 1177\
Clinical setting: outpatient HIV/AIDS clinics\
Laboratory level: central\
Country: Uganda\
World Bank Income Classification: middle income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: yes\
Prevalence of TB cases in the study: 13.8%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960Flow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?YesWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Zeka 2011**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: clinical findings of possible TB\
Age: median 48 years, range 25 to 70 years\
Sex, female: 42.4%\
HIV infection: not reported\
History of TB: not reported\
Sample size: 103\
Clinical setting: laboratory‐based\
Laboratory level: central\
Country: Turkey\
World Bank Income Classification: middle income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
TB incidence rate: 24 per 100,000\
MDR‐TB prevalence: percentage MDR‐TB among new TB cases = 0.9% (Source: survey in Ankara City 2011) and among retreatment cases = 38% (Source: survey in Ankara City 2011)\
Prevalence of TB cases in the study: 34.0%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ culture and MB/MBacT liquid medium\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: proportion method on 7H10 mediaFlow and timing Comparative NotesOnly one rifampicin resistant isolate was identified. Data for sputum specimens were provided by the study author**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?NoWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?No**HighLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Zetola 2014**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, retrospective data collectionPatient characteristics and settingPresenting signs and symptoms: (i) people with presumed pulmonary TB at high risk for MDR‐TB, (ii) people who had been treated with anti‐TB drugs and in whom TB had again been diagnosed, i.e. all retreatment categories (failure, default, and relapse), (iii) HIV‐positive people with signs or symptoms of TB, (iv) people who were seriously ill and suspected of having TB regardless of HIV status, and (v) people with unknown HIV status presenting with clinical evidence of HIV infection and signs or symptoms of PTB\
Age: 18 years or older, median 37 years (IQR 31 to 44)\
Sex, female: 40%\
HIV infection: 75%\
History of TB: 62%\
Sample size: 370\
Clinical setting: not reported\
Laboratory level: central\
Country: Botswana\
World Bank Income Classification: middle income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: yesIndex testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: LJFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?Were the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Zmak 2013**Study characteristics**Patient samplingCross‐sectional design, consecutive enrolment, prospective data collectionPatient characteristics and settingPresenting signs and symptoms: presumed pulmonary TB\
Age: adults\
Sex, female: not reported\
HIV infection: not reported\
History of TB: not reported\
Sample size: 120\
Clinical setting: laboratory‐based\
Laboratory level: central\
Country: Croatia\
World Bank Income Classification: middle income\
High TB burden country: no\
High MDR‐TB burden country: no\
High TB/HIV burden country: no\
Prevalence of TB cases in the study: 6.0%Index testsIndex: Xpert MTB/RIFTarget condition and reference standard(s)Target condition: pulmonary TB\
Reference standard for pulmonary TB: LJ and MGIT 960\
Target condition: rifampicin resistance\
Reference standard for rifampicin resistance: LJFlow and timing Comparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowUnclearDOMAIN 2: Index Test Xpert MTB/RIF**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results for TB detection interpreted without knowledge of the results of the index test?NoWere the reference standard results for rifampicin resistance detection interpreted without knowledge of the results of the index test?No**HighLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**[^9]

Characteristics of excluded studies \[ordered by study ID\] {#CD009593-sec2-0026}
===========================================================

StudyReason for exclusion[@CD009593-bbs2-0096]Duplicate data with additional analyses; [@CD009593-bbs2-0013] includes same data set[@CD009593-bbs2-0097]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0098]Abstract[@CD009593-bbs2-0099]Data insufficient for 2 x 2 table[@CD009593-bbs2-0100]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0102]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0104]Data insufficient for 2 x 2 table[@CD009593-bbs2-0101]Data insufficient for 2 x 2 table[@CD009593-bbs2-0103]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0105]Abstract[@CD009593-bbs2-0106]Abstract[@CD009593-bbs2-0107]Data insufficient for 2 x 2 table[@CD009593-bbs2-0108]Includes both adults and children or no information about age[@CD009593-bbs2-0109]Reference standard not satisfied[@CD009593-bbs2-0110]Systematic review[@CD009593-bbs2-0111]Abstract[@CD009593-bbs2-0112]Case‐control study[@CD009593-bbs2-0113]This was a case‐control study that compared Xpert MTB/RIF with an in‐house IS6110‐based real‐time PCR using TaqMan probes (IS6110‐TaqMan assay) for TB detection[@CD009593-bbs2-0114]Cost‐effectiveness study[@CD009593-bbs2-0115]Abstract[@CD009593-bbs2-0116]Data insufficient for 2 x 2 table[@CD009593-bbs2-0117]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0118]Abstract[@CD009593-bbs2-0119]Data insufficient for 2 x 2 table[@CD009593-bbs2-0120]Includes both adults and children[@CD009593-bbs2-0121]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0122]Reference standard not satisfied[@CD009593-bbs2-0123]Data insufficient for 2 x 2 table[@CD009593-bbs2-0124]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0125]Duplicate data with additional analyses; [@CD009593-bbs2-0047] includes same data set[@CD009593-bbs2-0126]Includes data for pulmonary and extrapulmonary TB combined[@CD009593-bbs2-0127]Xpert was not the index test[@CD009593-bbs2-0128]Data insufficient for 2 x 2 table[@CD009593-bbs2-0129]Abstract[@CD009593-bbs2-0130]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0131]This study evaluated Xpert MTB/RIF for the diagnosis of TB in children[@CD009593-bbs2-0132]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0133]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0134]Not a diagnostic accuracy study[@CD009593-bbs2-0135]Xpert was not the index test[@CD009593-bbs2-0136]Data insufficient for 2 x 2 table[@CD009593-bbs2-0137]Xpert was not the index test[@CD009593-bbs2-0138]Data insufficient for 2 x 2 table[@CD009593-bbs2-0139]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0140]Includes respiratory specimens and gastric aspirates[@CD009593-bbs2-0141]Abstract[@CD009593-bbs2-0142]This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB[@CD009593-bbs2-0143]Data insufficient for 2 x 2 table[@CD009593-bbs2-0144]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0145]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0146]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0147]Abstract[@CD009593-bbs2-0148]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0149]Study on patient impact[@CD009593-bbs2-0150]Reference standard not satisfied[@CD009593-bbs2-0151]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0152]Data insufficient for 2 x 2 table[@CD009593-bbs2-0153]Xpert not the index test[@CD009593-bbs2-0154]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0155]Data insufficient for 2 x 2 table[@CD009593-bbs2-0156]Case report[@CD009593-bbs2-0157]Prevalence survey[@CD009593-bbs2-0158]Cost‐effectiveness study[@CD009593-bbs2-0159]Data insufficient for 2 x 2 table[@CD009593-bbs2-0160]Abstract[@CD009593-bbs2-0161]This study compared Xpert MTB/RIF G3 and G4. We excluded it because of concern about duplicate data. In addition, the criteria for the reference standard for rifampicin resistance detection were not satisfied[@CD009593-bbs2-0162]Abstract[@CD009593-bbs2-0163]This study evaluated Xpert MTB/RIF for the diagnosis of pleural TB[@CD009593-bbs2-0164]Abstract[@CD009593-bbs2-0165]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0166]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0167]Abstract[@CD009593-bbs2-0168]Includes data for pulmonary and extrapulmonary TB combined[@CD009593-bbs2-0169]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0170]Abstract[@CD009593-bbs2-0171]Abstract[@CD009593-bbs2-0172]Includes data for pulmonary and extrapulmonary TB combined[@CD009593-bbs2-0173]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0174]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0175]Reference standard not satisfied[@CD009593-bbs2-0176]Data insufficient for 2 x 2 table[@CD009593-bbs2-0177]This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB[@CD009593-bbs2-0178]Not a diagnostic accuracy study[@CD009593-bbs2-0179]Community‐based screening[@CD009593-bbs2-0180]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0181]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0182]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0183]Xpert was not the index test[@CD009593-bbs2-0184]We could not obtain this article[@CD009593-bbs2-0185]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0186]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0187]Data insufficient for 2 x 2 table[@CD009593-bbs2-0188]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0189]Abstract[@CD009593-bbs2-0190]Xpert was not the index test[@CD009593-bbs2-0191]Abstract[@CD009593-bbs2-0192]Systematic review[@CD009593-bbs2-0193]Not a diagnostic accuracy study[@CD009593-bbs2-0194]Xpert was not the index test[@CD009593-bbs2-0195]Data insufficient for 2 x 2 table[@CD009593-bbs2-0196]Data insufficient for 2 x 2 table[@CD009593-bbs2-0197]includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0198]Data insufficient for 2 x 2 table[@CD009593-bbs2-0199]Case‐control study[@CD009593-bbs2-0200]Duplicate data; [@CD009593-bbs2-0035] includes the same data with more participants[@CD009593-bbs2-0201]Data insufficient for 2 x 2 table[@CD009593-bbs2-0202]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0203]Systematic review[@CD009593-bbs2-0204]Could not obtain full text[@CD009593-bbs2-0205]Study on patient impact[@CD009593-bbs2-0206]Data insufficient for 2 x 2 table[@CD009593-bbs2-0207]Primarily a lipoarabinomannan detection study[@CD009593-bbs2-0208]Data insufficient for 2 x 2 table[@CD009593-bbs2-0209]Reference standard not satisfied[@CD009593-bbs2-0210]Reference standard not satisfied[@CD009593-bbs2-0211]Community‐based screening[@CD009593-bbs2-0212]Impact study[@CD009593-bbs2-0213]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0214]Systematic review[@CD009593-bbs2-0215]This study evaluated Xpert MTB/RIF for the diagnosis of TB lymphadenitis[@CD009593-bbs2-0216]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0217]Abstract[@CD009593-bbs2-0218]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0219]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0220]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0221]Screening[@CD009593-bbs2-0222]Systematic review[@CD009593-bbs2-0223]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0224]Treatment monitoring[@CD009593-bbs2-0225]Data insufficient for 2 x 2 table[@CD009593-bbs2-0226]Xpert was not the index test[@CD009593-bbs2-0227]Abstract[@CD009593-bbs2-0228]Data insufficient for 2 x 2 table[@CD009593-bbs2-0229]Abstract[@CD009593-bbs2-0230]This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB[@CD009593-bbs2-0231]Reference standard not satisfied[@CD009593-bbs2-0232]Xpert was not the index test[@CD009593-bbs2-0233]Study on patient impact[@CD009593-bbs2-0234]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0235]Data insufficient for 2 x 2 table[@CD009593-bbs2-0236]Study on patient impact[@CD009593-bbs2-0237]Case‐control study[@CD009593-bbs2-0238]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0239]Abstract[@CD009593-bbs2-0240]This study evaluated Xpert MTB/RIF for the diagnosis of TB in children[@CD009593-bbs2-0241]This study evaluated Xpert for the diagnosis of TB in children[@CD009593-bbs2-0242]Xpert was not the index test[@CD009593-bbs2-0243]Duplicate data; same study as [@CD009593-bbs2-0064]. [@CD009593-bbs2-0243] is written in Russian[@CD009593-bbs2-0244]Active case finding, not a diagnostic test accuracy study[@CD009593-bbs2-0245]This study evaluated Xpert MTB/RIF in patients able to produce sputum, irrespective of admission diagnosis, not presumed TB patients[@CD009593-bbs2-0246]Not a diagnostic accuracy study[@CD009593-bbs2-0247]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0248]Case‐control study[@CD009593-bbs2-0249]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0250]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0251]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0252]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0253]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0254]Case report[@CD009593-bbs2-0255]Reference standard not satisfied[@CD009593-bbs2-0256]This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB[@CD009593-bbs2-0257]Data insufficient for 2 x 2 table[@CD009593-bbs2-0258]Duplicate data; study was nested in [@CD009593-bbs2-0087][@CD009593-bbs2-0259]This study evaluated Xpert for the diagnosis of TB in children[@CD009593-bbs2-0260]Not a diagnostic accuracy study[@CD009593-bbs2-0261]Not a diagnostic accuracy study[@CD009593-bbs2-0262]Data insufficient for 2 x 2 table[@CD009593-bbs2-0263]Not a diagnostic accuracy study[@CD009593-bbs2-0264]Duplicate data; more participants were included in [@CD009593-bbs2-0071][@CD009593-bbs2-0265]Xpert was not the index test[@CD009593-bbs2-0266]Impact study[@CD009593-bbs2-0267]Study design unclear, possibly case‐control[@CD009593-bbs2-0268]Data insufficient for 2 x 2 table[@CD009593-bbs2-0269]Xpert was not the index test[@CD009593-bbs2-0270]Not a diagnostic accuracy study[@CD009593-bbs2-0271]Data insufficient for 2 x 2 table[@CD009593-bbs2-0272]Not a diagnostic accuracy study[@CD009593-bbs2-0273]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0274]Case‐control study[@CD009593-bbs2-0275]Data insufficient for 2 x 2 table[@CD009593-bbs2-0276]Reference standard not satisfied[@CD009593-bbs2-0277]Not a diagnostic accuracy study[@CD009593-bbs2-0278]Reference standard not satisfied[@CD009593-bbs2-0279]Includes both pulmonary and extrapulmonary specimens combined[@CD009593-bbs2-0280]Case‐control study[@CD009593-bbs2-0281]Reference standard not satisfied[@CD009593-bbs2-0282]Abstract[@CD009593-bbs2-0283]Drug resistance survey[@CD009593-bbs2-0284]Xpert was not the index test[@CD009593-bbs2-0285]This study evaluated Xpert for the diagnosis of extrapulmonary TB[@CD009593-bbs2-0286]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0287]Treatment monitoring[@CD009593-bbs2-0288]Duplicate data set for [@CD009593-bbs2-0087] with a different aim[@CD009593-bbs2-0289]Duplicate data. Author reported that this study overlaps with the [@CD009593-bbs2-0087] and can be excluded[@CD009593-bbs2-0290]Screening study[@CD009593-bbs2-0291]Abstract[@CD009593-bbs2-0292]Xpert was not the index test[@CD009593-bbs2-0293]Abstract[@CD009593-bbs2-0294]This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB[@CD009593-bbs2-0295]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0296]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0297]This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB[@CD009593-bbs2-0298]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0299]Case report[@CD009593-bbs2-0300]This study evaluated Xpert MTB/RIF for the diagnosis of TB in children[@CD009593-bbs2-0301]Systematic review[@CD009593-bbs2-0302]Systematic review[@CD009593-bbs2-0303]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0304]Case‐control study[@CD009593-bbs2-0305]This study evaluated Xpert MTB/RIF for the diagnosis of extrapulmonary TB[@CD009593-bbs2-0306]Xpert was not the index test[@CD009593-bbs2-0307]Includes both adults and children or no information about age of enrolment[@CD009593-bbs2-0308]Systematic review[@CD009593-bbs2-0309]This study evaluated Xpert MTB/RIF for the diagnosis of TB in children[@CD009593-bbs2-0310]Includes both adults and children or no information about age of enrolment

Characteristics of ongoing studies \[ordered by study ID\] {#CD009593-sec2-0027}
==========================================================

[@CD009593-bbs2-0311]Trial name or titleA trial of same‐day testing and treatment to improve outcomes among symptomatic patients newly diagnosed with HIVTarget condition and reference standard(s)Tuberculosis, HIV/AIDSIndex and comparator testsSpot and early‐morning Xpert Ultra results and chest x‐ray, as single and as combined tests, with liquid culture as reference standardStarting date16 May 2017Contact informationSerena P Koenig, MD, skoenig\@bwh.harvard.eduNotes[ClinicalTrials.gov](ClinicalTrials.gov) Identifier: NCT03154320[@CD009593-bbs2-0312]Trial name or titleAchieving tuberculosis control In ZambiaTarget condition and reference standard(s)TuberculosisIndex and comparator testsComparison of two diagnostic tools (chest‐xray with computer‐assisted diagnosis versus C‐reactive protein) and Xpert Ultra for active community‐based tuberculosis case detectionStarting date13 April 2018Contact informationStewart Reid, MD, MPH, stewart.reid\@cidrz.orgNotes[ClinicalTrials.gov](ClinicalTrials.gov) Identifier: NCT03497195[@CD009593-bbs2-0313]Trial name or titleImproving tuberculosis diagnosis and treatment through Basic, Applied and health systems Research (BAR)Target condition and reference standard(s)TuberculosisIndex and comparator testsXpert Ultra point‐of‐care testing compared to the standard of care tuberculosis testing at a centralised facilityStarting date29 November 2017Contact informationGrant Theron, PhD. gtheron\@sun.ac.zaNotes[ClinicalTrials.gov](ClinicalTrials.gov) Identifier: NCT03356925[@CD009593-bbs2-0314]Trial name or titleXpert Ultra and Xpert HIV‐VL in people living with HIV (UltraHIV)Target condition and reference standard(s)Tuberculosis, HIV/AIDSIndex and comparator testsImpact studyStarting date15 June 2017Contact informationGrant Theron, PhD. gtheron\@sun.ac.zaNotes[ClinicalTrials.gov](ClinicalTrials.gov) Identifier: NCT03187964[@CD009593-bbs2-0315]Trial name or titleDiagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous bronchoalveolar lavage fluid in HIV‐infected adults: a prospective cohort studyTarget condition and reference standard(s)Tuberculosis and HIV/AIDS, MGITIndex and comparator testsXpert UltraStarting date12 February 2018Contact informationPeize Zhang, 516472422\@qq.comNotesWHO International Clinical Trials: Chi CTR1800014792
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[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: Abbreviations: CrI: credible interval; PTB: pulmonary tuberculosis.

    Prevalence estimates were suggested by the WHO Global TB Programme. For Xpert MTB/RIF, the median tuberculosis prevalence in the included studies was 26%. For Xpert Ultra, the tuberculosis prevalence in the study was 32%.

    Credible limits were estimated based on those around the point estimates for pooled sensitivity and specificity; 95% confidence intervals were estimated for the single study that evaluated Ultra.

    ^a^The median tuberculosis prevalence in the studies was 26% and thus the results tend to be more applicable to settings with a higher tuberculosis prevalence. For tuberculosis prevalence of 1% and 10%, whether or not to downgrade is unclear. It is possible the test will perform differently at lower tuberculosis prevalences. We did not downgrade for indirectness. ^b^For individual studies, sensitivity estimates ranged from 43% to 100%. We thought that differences in enrolment criteria (different populations targeted), disease severity, and setting could in part explain heterogeneity. We did not downgrade for inconsistency. ^c^There were a large number of studies and participants in this analysis. The 95% CrI around true positives and false negatives would probably not lead to different decisions depending on which credible limits are assumed. We did not downgrade for imprecision. ^d^The tuberculosis prevalence in the study was 32% and thus the results tend to be more applicable to settings with a higher tuberculosis prevalence. For tuberculosis prevalences of 1% and 10%, whether or not to downgrade is unclear. It is possible the test will perform differently at lower prevalences. We did not downgrade for indirectness. ^e^Although there was only one study on the accuracy of Xpert Ultra for PTB, this was a multicentre study conducted in eight countries (South Africa, Uganda, Kenya, India, China, Georgia, Belarus, and Brazil). We downgraded by one level for imprecision.

    **GRADE certainty of the evidence**

    **High:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

    The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure.

[^3]: Abbreviations: CrI: credible interval; DST: drug susceptibility testing; PTB: pulmonary tuberculosis.

    Prevalence estimates were suggested by the WHO Global TB Programme. The upper limit for the prevalence of rifampicin resistance in new cases was estimated to be 5% (50/1000 cases); the lower limit for the prevalence of rifampicin resistance in previously‐treated cases was estimated to be 15% (150/1000 cases). For Xpert MTB/RIF, the median prevalence of rifampicin resistance in the included studies was 11%. For Xpert Ultra, the prevalence of rifampicin resistance in the study was 32%.

    Credible limits were estimated based on those around the point estimates for pooled sensitivity and specificity; 95% confidence intervals were estimated for the single study that evaluated Xpert Ultra.

    ^a^In the Patient Selection domain, with respect to applicability, we had low concern in 46% of studies and high concern in only 7% of studies. In nearly half of the studies (47%) the clinical setting was not reported or there was insufficient information to make a decision. We did not downgrade for indirectness. ^b^The prevalence of rifampicin resistance in the study was 32% (higher than the three prevalence levels considered in the table). Although it is possible that the test will perform differently at lower prevalences, we think that this is unlikely. The magnitude of any effect (either direction) is probably small, given that in this study both Xpert MTB/RIF and Xpert Ultra sensitivity and specificity for rifampicin resistance were nearly identical to the pooled sensitivity and specificity in the review. We did not downgrade for indirectness. ^c^Although there was only one study on the accuracy of Xpert Ultra for rifampicin resistance, this was a multicentre study conducted in eight countries (South Africa, Uganda, Kenya, India, China, Georgia, Belarus, and Brazil). We downgraded by one level for imprecision.

    **GRADE certainty of the evidence**

    **High:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate:** we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low:** our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. **Very low:** we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

    The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure.

[^4]: Abbreviations: CrI: credible interval; PTB: pulmonary tuberculosis. ^a^This analysis included all studies, including those studies that preselected participants based on microcopy results and mainly involved participants who had received previous tuberculosis treatment.

[^5]: Abbreviations: CrI: credible interval; HIV: human immunodeficiency virus; TB: tuberculosis. ^a^Accuracy estimates were determined in studies providing data for both subgroups. ^b^Substudies from [@CD009593-bbs2-0011] and [@CD009593-bbs2-0012] contributed to both tuberculosis burden categories.

[^6]: Abbreviations: CrI: credible interval; MDR‐TB: multidrug‐resistant tuberculosis. ^a^Studies with high percentages of participants previously treated for tuberculosis.

[^7]: Abbreviations: Crl: credible interval.

[^8]: Abbreviations: CI: confidence interval; Crl: credible interval; NA: not applicable; PTB: pulmonary tuberculosis.

    [@CD009593-bbs2-0331] included adults and children; Xpert for detection of rifampicin resistance, sensitivity range 17% to 100%, specificity range 72% to 100%. [@CD009593-bbs2-0301] only included smear‐negative participants. [@CD009593-bbs2-0401] is the previous Cochrane Review. [@CD009593-bbs2-0308] only included studies that provided data by smear and HIV status. [@CD009593-bbs2-0214] 106 studies (52,410 specimens) for both PTB and extrapulmonary tuberculosis. [@CD009593-bbs2-0110] 2017 summarized accuracy of Xpert for detection of rifampicin resistance, sensitivity range 33% to 100%; specificity range 91% to 100%. Horne 2019 is this updated Cochrane Review.

    Systematic reviews not included in this table:

    [@CD009593-bbs2-0192] did not provide summary sensitivity and specificity estimates. [@CD009593-bbs2-0203] provided sensitivity and specificity with respect to Xpert cycle threshold (Ct) values. [@CD009593-bbs2-0222] provided accuracy estimates for PTB on gastric aspirates and stool. [@CD009593-bbs2-0302] only included children.

[^9]: Abbreviations: HIV: human immunodeficiency virus; ICU: intensive care unit; IQR: interquartile range; LJ: Löwenstein--Jensen; MDR‐TB: multidrug‐resistant TB; MGIT: mycobacterial growth indicator tube; MODS: microscopic observation drug susceptibility; SD: standard deviation; TB: tuberculosis
